https://www.astrazeneca.com/ 2026-08-03T08:41:30.493Z https://www.astrazeneca.com/publication.html 2024-10-21T10:30:31.775Z https://www.astrazeneca.com/r-d.html 2026-04-28T20:57:02.515Z https://www.astrazeneca.com/r-d/our-approach.html 2026-04-29T09:54:58.437Z https://www.astrazeneca.com/r-d/our-approach/stem-at-astrazeneca.html 2026-03-13T10:25:05Z https://www.astrazeneca.com/r-d/next-generation-therapeutics.html 2026-07-14T09:32:10.875Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/small-molecule.html 2026-07-14T09:29:02.522Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/protacs.html 2026-01-12T21:15:40.474Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/in-vivo-expressed-biologics.html 2024-07-08T04:50:50.185Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/sodium-zirconium-cyclosilicate.html 2024-07-08T04:49:40.697Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/monoclonal-antibodies.html 2022-08-10T11:48:24.606Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/antibody-drug-conjugate.html 2024-08-07T07:52:38.398Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/bispecific-antibody.html 2026-01-12T20:57:05.338Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/fragment-antibody.html 2022-08-10T11:44:50.807Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/therapeutic-proteins.html 2024-07-08T04:46:48.611Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/anticalin-proteins.html 2022-08-10T11:34:56.604Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/T-cell-engager.html 2026-01-12T21:13:25.860Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/gene-therapy.html 2025-06-13T08:33:41.331Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/cell-therapies.html 2026-06-11T08:53:11.786Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/multispecifics.html 2024-10-28T09:32:53.630Z https://www.astrazeneca.com/r-d/next-generation-therapeutics/radioconjugates.html 2024-10-24T11:24:05.307Z https://www.astrazeneca.com/r-d/transformative-science.html 2024-08-14T11:35:47.301Z https://www.astrazeneca.com/r-d/our-strategic-r-d-centres.html 2025-03-25T09:34:48.896Z https://www.astrazeneca.com/r-d/data-science-and-ai.html 2025-02-25T13:59:59.860Z https://www.astrazeneca.com/r-d/digital-health-revolutionising-healthcare-for-patients.html 2024-06-28T13:31:16.775Z https://www.astrazeneca.com/r-d/precision-medicine.html 2025-06-12T20:20:10.281Z https://www.astrazeneca.com/r-d/glossary.html 2024-09-11T13:34:47.032Z https://www.astrazeneca.com/r-d/clinical-innovation.html 2025-06-12T11:58:36.090Z https://www.astrazeneca.com/r-d/our-technologies.html 2025-02-21T15:08:30.449Z https://www.astrazeneca.com/r-d/our-technologies/acoustic-tube-sample-management.html 2024-07-08T04:55:08.359Z https://www.astrazeneca.com/r-d/our-technologies/advanced-molecular-imaging.html 2024-09-05T09:34:46.708Z https://www.astrazeneca.com/r-d/our-technologies/cryo-em.html 2024-07-08T04:53:46.263Z https://www.astrazeneca.com/r-d/our-technologies/functional-genomics.html 2024-09-03T12:24:39.703Z https://www.astrazeneca.com/r-d/our-technologies/multi-omics.html 2024-07-08T04:52:08.767Z https://www.astrazeneca.com/r-d/our-technologies/ilab.html 2024-07-08T04:56:31.074Z https://www.astrazeneca.com/r-d/our-technologies/machine-learning-drug-discovery.html 2025-05-28T08:19:20.211Z https://www.astrazeneca.com/r-d/our-technologies/genomics.html 2026-06-22T09:14:01.153Z https://www.astrazeneca.com/our-therapy-areas.html 2026-07-26T09:35:58.880Z https://www.astrazeneca.com/our-therapy-areas/oncology.html 2026-05-04T19:12:57.090Z https://www.astrazeneca.com/our-therapy-areas/oncology/genitourinary-cancer.html 2026-04-16T08:26:27Z https://www.astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html 2025-11-05T20:20:10.219Z https://www.astrazeneca.com/our-therapy-areas/oncology/haematology-cancer.html 2026-04-16T08:43:29Z https://www.astrazeneca.com/our-therapy-areas/oncology/immuno-oncology.html 2026-04-16T08:10:34Z https://www.astrazeneca.com/our-therapy-areas/oncology/dna-damage-response.html 2024-10-03T10:06:54.946Z https://www.astrazeneca.com/our-therapy-areas/oncology/Liver-cancer.html 2024-10-03T11:21:23.058Z https://www.astrazeneca.com/our-therapy-areas/oncology/breast-cancer.html 2026-04-16T08:59:34Z https://www.astrazeneca.com/our-therapy-areas/oncology/lung-cancer.html 2026-04-16T08:29:36Z https://www.astrazeneca.com/our-therapy-areas/oncology/gastrointestinal-cancer.html 2026-04-16T08:13:57Z https://www.astrazeneca.com/our-therapy-areas/oncology/scientific-platforms.html 2026-04-16T08:13:57Z https://www.astrazeneca.com/our-therapy-areas/oncology/gynaecological-cancer.html 2026-04-16T08:27:04Z https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html 2026-04-29T09:54:58.432Z https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html 2026-06-15T09:49:08.785Z https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/epithelial-science.html 2025-03-04T09:34:39.157Z https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/lupus.html 2026-06-12T10:23:22.936Z https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/immunology.html 2026-05-20T14:35:00.992Z https://www.astrazeneca.com/our-therapy-areas/infectious-disease.html 2026-07-27T20:10:28.028Z https://www.astrazeneca.com/our-therapy-areas/infectious-disease/respiratory-syncytial-virus.html 2024-10-03T09:10:38.710Z https://www.astrazeneca.com/our-therapy-areas/infectious-disease/covid-19.html 2026-04-29T09:54:58.437Z https://www.astrazeneca.com/our-therapy-areas/infectious-disease/hMPV.html 2026-04-29T09:54:58.435Z https://www.astrazeneca.com/our-therapy-areas/rare-disease.html 2026-02-05T01:33:37.475Z https://www.astrazeneca.com/our-therapy-areas/pipeline.html 2026-07-26T09:31:11.103Z https://www.astrazeneca.com/our-therapy-areas/medicines.html 2026-04-29T09:54:58.434Z https://www.astrazeneca.com/our-therapy-areas/eosinophilic-inflammation.html 2025-05-06T15:54:38.498Z https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html 2026-05-29T14:09:58.882Z https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/cardiovascular-disease.html 2024-10-03T09:26:35.732Z https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/renal.html 2026-04-20T22:02:56.173Z https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/metabolism.html 2025-09-30T12:32:06.968Z https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/heart-failure.html 2026-05-07T13:33:44.981Z https://www.astrazeneca.com/government-contract-t-cs.html 2026-04-01T09:20:25Z https://www.astrazeneca.com/az-suppliers.html 2024-07-24T06:04:11.219Z https://www.astrazeneca.com/az-suppliers/supplier-contact-information.html 2026-06-26T16:39:33.401Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier.html 2025-12-18T18:19:42.807Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq.html 2024-01-03T11:30:45.886Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/CSP.html 2023-11-21T04:42:28.555Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/coupa-supplier-portal.html 2023-12-11T10:08:43.848Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/cXML-invoices.html 2023-12-15T13:14:06.820Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/SAN.html 2024-03-18T15:10:40.728Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/CSP-linked.html 2023-11-20T09:54:20.605Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/Supplier-Actionable-Notification.html 2023-11-21T05:11:55.076Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/latest-update.html 2024-01-03T11:30:45.886Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/japanese-suppliers.html 2024-10-07T13:30:38.959Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/german-suppliers.html 2024-01-11T11:01:47.418Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/spanish-suppliers.html 2025-03-24T21:28:52.554Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/french-suppliers.html 2024-01-11T09:13:58.621Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/mexican-suppliers.html 2024-05-27T11:27:10.219Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/brazil-suppliers.html 2024-06-07T06:39:37.211Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/sweden-suppliers.html 2024-01-03T11:30:45.886Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/CSP.html 2023-06-23T12:26:19.693Z https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/selected-suppliers-page.html 2026-06-23T17:55:01.591Z https://www.astrazeneca.com/patient-reported-outcomes.html 2018-09-13T23:13:37.089Z https://www.astrazeneca.com/patient-reported-outcomes/gastrointestinal.html 2024-01-25T16:19:58.213Z https://www.astrazeneca.com/patient-reported-outcomes/cardiovascular.html 2024-01-25T05:50:04.540Z https://www.astrazeneca.com/patient-reported-outcomes/respiratory.html 2026-04-27T17:24:13.837Z https://www.astrazeneca.com/patient-reported-outcomes/order-instrument.html 2024-11-19T09:00:37.697Z https://www.astrazeneca.com/patient-reported-outcomes/faqs.html 2026-07-28T17:03:30.685Z https://www.astrazeneca.com/patient-reported-outcomes/contact-us.html 2025-06-06T22:34:01.563Z https://www.astrazeneca.com/patient-reported-outcomes/confirmation.html 2016-10-03T10:40:27.637Z https://www.astrazeneca.com/astrazeneca-exchange.html 2024-07-24T05:01:34.310Z https://www.astrazeneca.com/media-centre.html 2026-05-21T13:11:11.002Z https://www.astrazeneca.com/media-centre/press-releases.html 2026-06-12T09:30:18.130Z https://www.astrazeneca.com/media-centre/press-releases/2026/positive-and-clinically-meaningful-results-from-the-phase-iii-kalos-and-logos-trials-for-breztri.html 2026-02-13T06:43:59.959Z https://www.astrazeneca.com/media-centre/press-releases/2026/fixed-duration-calquence-combo-approved-in-us.html 2026-02-20T07:02:42.807Z https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-granted-priority-review-in-the-us-as-post-neoadjuvant-treatment-for-patients-with-her2-positive-early-breast-cancer.html 2026-03-09T06:15:28Z https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-approved-in-eu-for-early-gastric-cancer.html 2026-03-16T06:59:22Z https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-met-primary-endpoint-in-oberon-titania-phase-iii-trials-in-patients-with-copd.html 2026-04-16T14:28:02Z https://www.astrazeneca.com/media-centre/press-releases/2026/efzimfotase-alfa-demonstrated-positive-results-global-phase-iii-clinical-programme-hypophosphatasia.html 2026-03-31T06:01:49Z https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-imjudo-improves-pfs-in-early-liver-cancer.html 2026-04-02T05:59:15Z https://www.astrazeneca.com/media-centre/press-releases/2026/alexion-data-2026-aan-annual-meeting-reflects-industry-leading-portfolio-commitment-enhancing-care-across-rare-diseases.html 2026-04-10T05:43:52Z https://www.astrazeneca.com/media-centre/press-releases/2026/third-tozorakimab-positive-phase-iii-in-copd.html 2026-04-20T06:00:56Z https://www.astrazeneca.com/media-centre/press-releases/2026/i-can-phiii-interim-analysis-met-primary-endpoint.html 2026-04-23T17:58:32.702Z https://www.astrazeneca.com/media-centre/press-releases/2026/saphnelo-self-administration-approved-in-the-US.html 2026-04-27T05:57:38.974Z https://www.astrazeneca.com/media-centre/press-releases/2026/breztri-approved-in-the-us-for-asthma.html 2026-04-28T06:01:51.792Z https://www.astrazeneca.com/media-centre/press-releases/2026/saphnelo-self-administration-tulip-sc-trial-demonstrates-statistically-significant-clinically-meaningful-reduction-sle-disease-activity.html 2026-01-06T06:35:24.118Z https://www.astrazeneca.com/media-centre/press-releases/2026/azn-new-head-of-investor-relations-joris-silon.html 2026-01-08T14:03:59.175Z https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-to-complete-direct-listing-on-NYSE.html 2026-01-20T07:08:28.733Z https://www.astrazeneca.com/media-centre/press-releases/2026/full-year-q4-2025-results.html 2026-02-10T07:13:38.053Z https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-invests-15bn-in-china-through-2030.html 2026-01-29T09:47:01.328Z https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-agrees-obesity-and-t2d-deal-with-cspc.html 2026-01-30T06:44:47.466Z https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-begins-trading-on-NYSE.html 2026-02-02T06:04:52.833Z https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-recommended-in-eu-for-early-gastric-cancer.html 2026-02-02T09:17:10.226Z https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-granted-priority-review-in-the-us-as-1st-line-treatment-for-patients.html 2026-02-03T07:11:39.050Z https://www.astrazeneca.com/media-centre/press-releases/2026/update-on-saphnelo-subcutaneous-administration.html 2026-02-03T12:39:19.321Z https://www.astrazeneca.com/media-centre/press-releases/2026/q1-2026-results.html 2026-04-29T06:00:21.406Z https://www.astrazeneca.com/media-centre/press-releases/2026/fda-odac-vote-on-camizestrant-breast-cancer.html 2026-04-30T22:03:16.308Z https://www.astrazeneca.com/media-centre/press-releases/2026/fda-odac-recommends-truqap-prostate-cancer.html 2026-05-01T08:40:03.340Z https://www.astrazeneca.com/media-centre/press-releases/2026/eneboparatide-normalised-serum-calcium-and-achieved-independence-from-supplements-in-31-1-percent-of-adults-with-HypoPT-in-CALYPSO-Phase-iii-trial.html 2026-05-12T10:47:11.158Z https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-ev-improves-efs-os-in-bladder-cancer.html 2026-05-14T05:32:22.049Z https://www.astrazeneca.com/media-centre/press-releases/2026/Baxdrostat-MNR-2026.html 2026-05-18T05:54:00.642Z https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-two-her2-early-bc-settings.html 2026-05-15T22:17:46.635Z https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-recommended-in-eu-for-her2-solid-tumours.html 2026-05-22T11:47:26.820Z https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-to-showcase-phase-iii-data-at-asco-2026.html 2026-05-22T05:58:10.437Z https://www.astrazeneca.com/media-centre/press-releases/2026/camizestrant-recommended-for-breast-cancer-in-eu.html 2026-05-22T11:29:07.750Z https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-approved-in-us-for-1l-triple-negative-bc.html 2026-05-22T13:16:35.136Z https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html 2026-05-27T05:58:32.165Z https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-approved-in-us-for-early-bladder-cancer.html 2026-05-28T17:23:10.848Z https://www.astrazeneca.com/media-centre/press-releases/2026/cares-phase-iii-clinical-programme-did-not-meet-primary-endpoint-in-overall-light-chain-amyloidosis-population.html 2026-05-29T12:29:17.411Z https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-plus-imjudo-combined-with-lenvatinib-and-tace-reduced-the-risk-of-disease-progression-or-death-in-emerald-3-phase-iii-trial.html 2026-06-01T14:59:36.775Z https://www.astrazeneca.com/media-centre/press-releases/2026/camizestrant-combination-delayed-time-to-first-progression-in-patients-with-advanced-hr-positive-breast-cancer-with-an-ESR1-tumour-mutation.html 2026-06-02T12:18:43.286Z https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-demonstrated-43-4-reduction-in-proteinuri-vs-placebo-in-adults-with-immunoglobulin-i-can-phase-iii-trial.html 2026-06-06T05:43:55.114Z https://www.astrazeneca.com/media-centre/press-releases/2026/elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme.html 2026-06-08T20:15:21.187Z https://www.astrazeneca.com/media-centre/press-releases/2026/truqap-approved-in-us-for-prostate-cancer.html 2026-06-12T17:46:26.086Z https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-granted-priority-review-in-the-us-as-treatment-for-adults-with-immunoglobulin-a-nephropathy.html 2026-06-15T05:30:46.840Z https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-recommended-for-approval-in-eu-for-tnbc.html 2026-06-26T10:45:27.131Z https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-eu-for-her-solid-tumours.html 2026-06-29T05:58:45.346Z https://www.astrazeneca.com/media-centre/press-releases/2026/efzimfotase-alfa-demonstrated-improvements-in-bone-health-in-treatment-naive-patients-with-hypophosphatasia-at-week-25-in-mulberry-phase-iii-trial.html 2026-06-28T19:49:49.610Z https://www.astrazeneca.com/media-centre/press-releases/2026/update-cardio-ttransform-phase-iii-trial.html 2026-07-09T05:47:42.671Z https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-licenses-novel-egfr-inhibitor.html 2026-07-14T05:40:25.307Z https://www.astrazeneca.com/media-centre/press-releases/2026/etcamah-approved-eu-for-er-breast-cancer.html 2026-07-23T05:40:45.751Z https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-plus-pertuzumab-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-her2-positive-metastatic-breast-cancer.html 2026-07-24T10:37:16.987Z https://www.astrazeneca.com/media-centre/press-releases/2026/trixeo-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-asthma.html 2026-07-24T10:18:12.906Z https://www.astrazeneca.com/media-centre/press-releases/2026/update-on-ultomiris-phase-iii-trial-in-hsct-tma.html 2026-07-27T05:39:42.158Z https://www.astrazeneca.com/media-centre/press-releases/2026/sone-ve-improved-survival-in-gastric-cancers.html 2026-07-27T05:39:19.829Z https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html 2026-07-27T05:39:28.851Z https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-approved-in-eu-for-tnbc.html 2026-07-31T06:15:18.420Z https://www.astrazeneca.com/media-centre/press-releases/2025/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html 2025-01-13T05:19:40.989Z https://www.astrazeneca.com/media-centre/press-releases/2025/full-year-and-q4-2024-results.html 2025-02-06T06:16:39.451Z https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html 2025-01-17T05:05:47.490Z https://www.astrazeneca.com/media-centre/press-releases/2025/dato-dxd-approved-in-us-for-hr-p-breast-cancer.html 2025-01-17T20:53:09.307Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-c820-million-us570m-investment-in-canada-to-advance-growing-global-hub-and-clinical-delivery.html 2025-01-22T17:58:16.791Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-us-for-breast-cancer-post-et.html 2025-01-28T05:27:28.344Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-ls-sclc.html 2025-01-31T16:11:11.973Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-perioperative-regimen-improved-event-free-survival-and-overall-survival-of-niagara-phase-iii-trial.html 2025-02-25T21:57:59.788Z https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer.html 2025-04-19T12:55:39.721Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-recommended-approval-eu-chmp-patients-low-ultralow-metastatic-breast-cancer-following-least-one-endocrine-therapy.html 2025-02-28T13:10:13.184Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-aegean.html 2025-03-03T04:41:24.840Z https://www.astrazeneca.com/media-centre/press-releases/2025/positive-results-from-the-tezspire-phase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps.html 2025-02-28T21:43:50.502Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-efs-in-early-stage-gastric-cancer.html 2025-03-07T04:30:22.084Z https://www.astrazeneca.com/media-centre/press-releases/2025/eneboparatide-phase-iii-trial-met-primary-endpoint.html 2025-03-17T06:11:59.013Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-license-agreement-with-alteogen-for-subcutaneous-formulations-of-multiple-oncology-assets.html 2025-03-17T02:13:26.953Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-limited-stage-sclc.html 2025-03-16T17:01:07.184Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html 2025-03-17T06:52:00.908Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing.html 2025-03-21T11:00:31.785Z https://www.astrazeneca.com/media-centre/press-releases/2025/new-study-results-reinforce-tagrisso-as-the-backbone-therapy-for-egfr-mutated-lung-cancer-across-stages-and-settings.html 2025-03-25T05:15:51.202Z https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-the-2025-aan-annual-meeting-highlight-advancements-in-improving-care-for-rare-neurological-diseases.html 2025-03-28T22:30:52.605Z https://www.astrazeneca.com/media-centre/press-releases/2025/q1-2025-results.html 2025-04-29T05:57:25.512Z https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-recommended-for-eu-approval-in-1l-mcl.html 2025-03-31T06:07:54.330Z https://www.astrazeneca.com/media-centre/press-releases/2025/azd0780-a-novel-oral-pcsk9-inhibitor-demonstrated-significant-ldl-cholesterol-ldl-c-reduction-in-pursuit-phase-iib-trial.html 2025-03-31T16:02:23.303Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-us-for-bladder-cancer.html 2025-03-31T06:03:39.014Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-aegean.html 2025-04-04T05:52:15.768Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-eu-in-post-et-breast-cancer.html 2025-04-04T05:50:24.188Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-showcases-innovation-in-infectious-disease-protection-at-escmid-global-2025.html 2025-04-08T05:49:20.837Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.html 2025-04-21T06:10:00.299Z https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html 2025-04-29T06:26:35.191Z https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html 2025-04-29T05:37:17.248Z https://www.astrazeneca.com/media-centre/press-releases/2025/breztri-met-primary-endpoints-in-ph3-asthma-trials.html 2025-05-02T05:56:28.201Z https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-eu-for-1l-mcl.html 2025-05-06T09:45:59.387Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-improved-pcr-in-early-stage-breast-cancer.html 2025-05-07T05:52:15.486Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-dfs-in-early-bladder-cancer.html 2025-05-09T05:56:56.793Z https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html 2025-10-01T16:05:12.363Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-showcase-latest-research-on-comprehensive-portfolio-and-pipeline-aimed-at-transforming-respiratory-diseases-at-ats-2025.html 2025-05-13T04:57:57.304Z https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.html 2025-05-19T16:11:42.126Z https://www.astrazeneca.com/media-centre/press-releases/2025/acquisition-of-esobiotec-completed.html 2025-05-20T05:32:57.366Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazenecas-record-seventh-year-of-plenary-data-at-asco-furthers-ambition-to-redefine-breast-cancer-care-and-transform-outcomes-in-gastric-cancer.html 2025-05-21T05:45:48.304Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-in-eu-for-bladder-cancer.html 2025-05-27T05:29:32.404Z https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-tumour-mutation-in-serena-6-phase-iii-trial.html 2025-06-04T09:43:06.164Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-trial.html 2025-06-04T09:32:27.092Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer.html 2025-06-02T11:40:29.383Z https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html 2025-06-06T05:46:25.093Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html 2025-06-13T08:44:47.128Z https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-ean-2025-highlights-its-leadership-and-commitment-to-improving-patient-outcomes-in-rare-neurological-diseases.html 2025-06-21T06:00:23.628Z https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-approved-in-us-for-egfrm-lung-cancer.html 2025-06-23T19:54:45.170Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-eu-for-bladder-cancer.html 2025-07-04T05:32:23.396Z https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html 2025-07-14T05:26:51.379Z https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-anselamimab-in-al-amyloidosis.html 2025-07-16T06:03:50.592Z https://www.astrazeneca.com/media-centre/press-releases/2025/h1-and-q2-2025.html 2025-07-29T05:49:14.763Z https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer.html 2025-07-21T05:05:18.749Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html 2025-07-21T21:29:59.638Z https://www.astrazeneca.com/media-centre/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints.html 2025-07-24T05:31:42.310Z https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-receives-positive-eu-chmp-opinion-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html 2025-10-01T16:04:53.081Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-us-patients-with-resectable-early-stage-gastric-gastroesophageal-junction-cancers.html 2025-07-28T06:02:53.541Z https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html 2025-08-30T14:17:18.157Z https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-a-median-overall-survival-of-nearly-four-years.html 2025-09-07T06:09:29.152Z https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html 2025-09-17T12:48:16.401Z https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-met-primary-endpoint-in-tulip-sc.html 2025-09-17T06:09:51.755Z https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-ectrims-2025-reinforces-ultomiris-leadership-in-transforming-care-for-patients-with-nmosd.html 2025-09-19T05:41:12.720Z https://www.astrazeneca.com/media-centre/press-releases/2025/koselugo-recommended-for-eu-approval.html 2025-09-22T05:19:23.069Z https://www.astrazeneca.com/media-centre/press-releases/2025/tezspire-recommended-for-approval-in-eu-for-crswnp.html 2025-09-22T05:49:38.344Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-granted-priority-review-us-1st-line-treatment-patients-with-her2-positive-metastatic-breast-cancer.html 2025-09-24T03:07:23.174Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-improved-idfs-in-early-bc-in-db-05.html 2025-09-29T06:24:12.041Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-harmonise-its-listing-structure-across-the-london-stock-exchange-nasdaq-stockholm-and-new-york-stock-exchange.html 2025-09-29T05:54:15.332Z https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-improved-os-and-pfs-in-tropion-breast02.html 2025-10-06T06:11:39.318Z https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-the-primary-endpoint-in-bax24-phase-iii-trial-in-patients-with-resistant-hypertension.html 2025-10-07T05:58:14.669Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-increase-investment-and-scope-of-its-virginia-manufacturing-facility-to-dollar45-billion-creating-3600-new-jobs.html 2025-10-09T16:03:28.339Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-announces-historic-agreement-with-us-government-to-lower-the-cost-of-medicines-for-american-patients.html 2025-10-10T21:29:04.378Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-furthers-ambition-to-redefine-cancer-care-with-first-data-from-four-major-pivotal-trials-at-esmo.html 2025-10-13T06:05:20.287Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-based-regimen-reduced-the-risk-of-death-by-22-percent-in-early-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-trial.html 2025-10-17T16:20:06.586Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-regimen-reduced-risk-of-disease-recurrence-death-32-percent-high-risk-non-muscle-invasive-bladder-cancer-in-the-potomac-phase-iii-trial.html 2025-10-17T16:19:56.689Z https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-subcutaneous-self-administration-recommended-for-approval-in-eu-by-chmp-for-systemic-lupus-erythematosus.html 2025-10-17T15:37:03.332Z https://www.astrazeneca.com/media-centre/press-releases/2025/us-fda-approves-tezspire-in-crswnp.html 2025-10-17T20:03:05.244Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-reduced-the-risk-of-disease-recurrence-or-death-by-53-vs-t-dm1-in-patients-with-high-risk-her2-positive-early-breast-cancer.html 2025-10-18T13:07:34.752Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-followed-by-thp-before-surgery-resulted-in-a-pcr-in-67-of-patients-in-db11.html 2025-10-18T13:22:02.905Z https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-demonstrated-an-unprecedented-median-overall-survival-improvement-of-five-months-vs-chemotherapy-as-1st-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-for-whom-immunotherapy-was-not-an-option-in-tropion-breast02.html 2025-10-19T16:32:33.193Z https://www.astrazeneca.com/media-centre/press-releases/2025/tezspire-approved-in-eu-for-crswnp.html 2025-10-22T05:52:56.592Z https://www.astrazeneca.com/media-centre/press-releases/2025/9m-and-q3-2025-results.html 2025-11-06T06:55:06.007Z https://www.astrazeneca.com/media-centre/press-releases/2025/koselugo-approved-in-the-eu-for-plexiform-neurofibromas-in-adults-with-neurofibromatosis-type-1.html 2025-10-28T06:28:02.986Z https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-2025-aanem-annual-meeting-and-mgfa-scientific-session-underscores-pioneering-c5-inhibition-leadership-in-gmg.html 2025-10-29T18:02:18.348Z https://www.astrazeneca.com/media-centre/press-releases/2025/positive-results-from-prevail-phase-iii-trial-at-aanem-mgfa-scientific-session.html 2025-10-30T14:55:24.640Z https://www.astrazeneca.com/media-centre/press-releases/2025/bax24-phase-iii-trial-full-results.html 2025-11-09T21:35:54.304Z https://www.astrazeneca.com/media-centre/press-releases/2025/koselugo-selumetinib-approved-in-the-us.html 2025-11-20T06:42:32.931Z https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-dollar2-billion-manufacturing-investment-in-maryland-supporting-2600-jobs-and-catalysing-economic-growth.html 2025-11-21T20:09:45.794Z https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-us-as-first-and-only-perioperative-immunotherapy-for-patients-with-early-gastric-and-gastroesophageal-cancers.html 2025-11-25T18:24:50.956Z https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-to-control-hypertension.html 2025-12-02T10:22:30.467Z https://www.astrazeneca.com/media-centre/press-releases/2025/astraZeneca-advances-haematology-cell-therapy-ambition-with-largest-ever-presence-at-ash.html 2025-12-04T07:22:34.529Z https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-approved-in-the-eu-for-subcutaneous-self-administration-as-a-new-pre-filled-pen-for-systemic-lupus-erythematosus.html 2025-12-16T07:05:43.869Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-us-for-1l-her2-metastatic-bc.html 2025-12-15T19:26:27.220Z https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-latify-Phase-iii-trial-of-ceralasertib.html 2025-12-22T06:41:03.847Z https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-granted-btd-for-post-neoadjuvant-early-bc.html 2025-12-22T06:34:11.234Z https://www.astrazeneca.com/media-centre/press-releases/2024.html 2024-01-02T09:39:59.102Z https://www.astrazeneca.com/media-centre/press-releases/2024/beyfortus-approved-in-china-for-the-prevention-of-rsv-disease-in-infants-bkp.html 2024-01-02T09:46:30.648Z https://www.astrazeneca.com/media-centre/press-releases/2024/full-year-and-q4-2023-results.html 2024-02-08T07:07:12.549Z https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy.html 2024-01-20T20:55:33.378Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-with-tace-and-bevacizumab-in-patients-with-hepatocellular-carcinoma-eligible-for-embolisation.html 2024-01-31T13:51:19.372Z https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours.html 2024-01-29T04:59:20.345Z https://www.astrazeneca.com/media-centre/press-releases/2024/positive-results-japan-phase-iii-trial-acoramidis-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm-consistency-global-attribute-cm-phase-iii.html 2024-02-02T06:19:06.606Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-improved-pfs-in-stage-iii-lung-cancer.html 2024-02-19T04:54:15.701Z https://www.astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-nonsquamous-nsclc.html 2024-02-19T05:05:09.725Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer.html 2024-03-22T14:01:41.559Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax.html 2024-02-19T14:59:41.692Z https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.html 2024-02-22T11:35:31.512Z https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval.html 2024-02-26T04:46:06.181Z https://www.astrazeneca.com/media-centre/press-releases/2024/ema-validates-dato-dxd-maas-for-nsq-nsclc-and-bc.html 2024-03-04T06:57:08.460Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html 2024-03-14T10:46:04.980Z https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-demonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs-chemotherapy.html 2024-03-18T05:08:14.105Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html 2024-03-19T05:56:44.154Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial.html 2024-03-21T12:00:24.340Z https://www.astrazeneca.com/media-centre/press-releases/2024/ultomiris-approved-in-the-us-for-nmosd.html 2024-03-25T04:11:42.831Z https://www.astrazeneca.com/media-centre/press-releases/2024/beyfortus-approved-in-japan-for-the-prevention-of-rsv-disease-in-infants.html 2024-03-27T04:27:41.773Z https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-japan-for-patients-with-advanced-hr-positive-breast-cancer.html 2024-03-27T04:21:24.478Z https://www.astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-breast-cancer.html 2024-04-02T05:55:51.942Z https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-us.html 2024-04-01T05:34:35.441Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-improved-os-and-pfs-in-limited-stage-sclc.html 2024-04-05T05:07:02.040Z https://www.astrazeneca.com/media-centre/press-releases/2024/alexion-data-at-aan-2024-demonstrate-how-ultomiris-and-soliris-can-transform-outcomes-for-rare-neurological-diseases.html 2024-04-08T04:47:21.104Z https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours.html 2024-04-06T00:32:52.847Z https://www.astrazeneca.com/media-centre/press-releases/2024/q1-2024-results.html 2024-04-25T05:59:45.023Z https://www.astrazeneca.com/media-centre/press-releases/2024/new-modelling-reveals-the-escalating-toll-of-chronic-kidney-disease-on-patients-planet-and-economies.html 2024-04-12T17:00:48.040Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-increases-2024-dividend-by-7.html 2024-04-11T05:53:55.701Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html 2024-04-16T05:23:10.849Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-the-science-of-infectious-disease-protection-at-eccmid-2024.html 2024-04-17T04:56:38.427Z https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia.html 2024-04-23T05:21:18.323Z https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-recommended-for-eu-breast-cancer-approval.html 2024-04-29T04:45:05.150Z https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html 2024-04-29T04:57:59.679Z https://www.astrazeneca.com/media-centre/press-releases/2024/az-unveils-latest-research-across-key-respiratory-and-immune-mediated-diseases-at-ats-2024-showcasing-strength-of-its-broad-pipeline-and-portfolio.html 2024-04-30T18:01:27.061Z https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-combination-improved-pfs-in-1l-mcl.html 2024-05-17T11:40:59.018Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-cellectis-equity-investment.html 2024-05-06T06:17:31.549Z https://www.astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html 2024-05-16T03:23:09.422Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html 2024-05-20T03:50:46.811Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030.html 2024-05-21T08:35:25.607Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-furthers-ambition-to-transform-outcomes-in-early-lung-cancer-and-redefine-metastatic-breast-cancer-treatment-at-asco-2024.html 2024-05-22T05:56:11.548Z https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-improved-os-in-nonsquamous-lung-cancer.html 2024-05-28T16:24:29.127Z https://www.astrazeneca.com/media-centre/press-releases/2024/early-chronic-kidney-disease-intervention-could-save-four-european-health-systems-up-to-15-billion-euro-over-10-years.html 2024-05-30T12:05:21.277Z https://www.astrazeneca.com/media-centre/press-releases/2024/Enhertu-demonstrated-median-progression-free-survival-thirteen-months.html 2024-06-01T23:09:51.749Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-is-first-and-only-immunotherapy-to-show-survival-benefit-in-limited-stage-small-cell-lung-cancer-in-global-phase-iii-trial.html 2024-06-01T23:21:36.826Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-reduced-the-risk-of-disease-progression-or-death-by-84-percent-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs-placebo.html 2024-06-10T14:04:07.268Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-recommended-for-approval-in-eu.html 2024-06-10T14:04:39.900Z https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-fusion-completed.html 2024-06-04T16:52:34.169Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer.html 2024-06-13T08:09:54.723Z https://www.astrazeneca.com/media-centre/press-releases/2024/farxiga-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes.html 2024-06-12T17:27:14.831Z https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percent.html 2024-06-15T14:37:08.895Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-the-us-for-endometrial-cancer.html 2024-06-16T13:00:00.956Z https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-capitello-290-phase-iii-trial.html 2024-06-18T05:07:23.322Z https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-the-eu-for-patients-with-advanced-er-positive-breast-cancer.html 2024-06-20T08:16:21.807Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-addition-chemotherapy-approved-japan-new-first-line-treatment-patients-egfr-mutated-advanced-lung-cancer.html 2024-06-25T04:56:05.477Z https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-imfinzi-adjuvant-br31-trial.html 2024-06-25T05:58:13.704Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-improved-efs-and-os-in-bladder-cancer.html 2024-06-25T04:49:12.846Z https://www.astrazeneca.com/media-centre/press-releases/2024/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention.html 2024-07-01T04:53:57.288Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-china-as-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html 2024-06-26T04:28:20.016Z https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-positive-chmp-in-endometrial.html 2024-07-01T04:47:39.673Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-eu-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html 2024-07-05T04:09:06.946Z https://www.astrazeneca.com/media-centre/press-releases/2024/h1-and-q2-2024-results.html 2024-07-24T21:12:20.157Z https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-amolyt-pharma-completed.html 2024-07-15T04:36:04.973Z https://www.astrazeneca.com/media-centre/press-releases/2024/odac-reviewed-imfinzi-in-resectable-lung-cancer.html 2024-07-25T19:50:06.330Z https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html 2024-07-29T04:44:17.369Z https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer.html 2024-08-13T08:51:38.558Z https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-combination-approved-in-the-eu-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer.html 2024-08-14T04:18:13.459Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us.html 2024-08-15T05:54:14.060Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-resectable-lung-cancer.html 2024-08-16T04:37:56.585Z https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma.html 2024-08-20T05:53:40.745Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at-wclc-and-esmo-2024.html 2024-09-03T05:41:13.321Z https://www.astrazeneca.com/media-centre/press-releases/2024/novel-computational-pathology-based-trop2-biomarker-for-dato-dxd-was-predictive-of-clinical-outcomes-in-patients-with-nsclc-in-tropion-lung01-phase-iii-trial.html 2024-09-08T16:06:57.583Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential.html 2024-10-17T13:30:56.322Z https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-showed-median-overall-survival-of-146-months-in-patients-with-advanced-nsclc-in-tropion-lung01-phase-iii-trial.html 2024-09-09T19:03:50.671Z https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast-cancer-and-brain-metastases.html 2024-09-13T10:47:13.886Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-perioperative-regimen-reduced-risk-recurrence-by-32-risk-death-by-25-vs-neoadjuvant-chemotherapy-alone-in-mibc-niagara-phase-iii-trial.html 2024-09-15T14:16:32.015Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-alc-with-one-in-five-patients-surviving-five-years-himalaya-phase-iii-trial.html 2024-09-16T04:27:18.141Z https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html 2024-09-20T14:51:59.046Z https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html 2024-09-20T16:59:05.471Z https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-recommended-for-eu-approval-in-egpa.html 2024-09-20T20:12:17.094Z https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html 2024-09-23T15:15:12.938Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-us-approval-in-unresectable-lung-cancer.html 2024-09-26T04:55:12.676Z https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-us-for-patients-her2-low-or-her2-ultralow-metastatic-breast-cancer-who-have-received-at-least-1-line-endocrine-therapy.html 2024-10-01T06:04:58.841Z https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma.html 2024-10-03T04:39:54.050Z https://www.astrazeneca.com/media-centre/press-releases/2024/airsupra-positive-results-phase-iii-batura-trial.html 2024-10-07T05:51:36.486Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-licenses-lipid-lowering-lpa-asset.html 2024-10-07T04:38:32.633Z https://www.astrazeneca.com/media-centre/press-releases/2024/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa-scientific-session-further-demonstrate-advancement-in-gmg-care.html 2024-10-10T05:54:34.574Z https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-china-as-first-her2-directe-therapy-for-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html 2024-10-14T06:01:35.956Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-science-of-infectious-disease-protection-at-idweek-2024.html 2024-10-16T07:19:53.325Z https://www.astrazeneca.com/media-centre/press-releases/2024/wainzua-recommended-for-approval-in-the-eu.html 2024-10-21T04:32:25.627Z https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis.html 2024-10-27T17:20:35.911Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-china-president-currently-under-investigation.html 2024-10-30T12:59:18.857Z https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html 2024-11-12T05:45:15.701Z https://www.astrazeneca.com/media-centre/press-releases/2024/azn-share-price-movement.html 2024-11-05T17:08:35.066Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024.html 2024-11-07T06:48:25.169Z https://www.astrazeneca.com/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints.html 2024-11-08T05:23:01.400Z https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-new-bla-submitted-nsq-bla-withdrawn.html 2024-11-12T05:44:44.984Z https://www.astrazeneca.com/media-centre/press-releases/2024/komet-phase-iii-trial-met-primary-endpoint.html 2024-11-12T04:39:14.493Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html 2024-11-12T04:57:50.756Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-recommended-for-eu-approval-laura.html 2024-11-18T04:25:13.846Z https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-improved-rpfs-in-advanced-prostate-cancer.html 2024-11-25T05:07:36.697Z https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-appoints-iskra-reic-as-executive-vice-president-international.html 2024-12-04T18:32:11.401Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-limited-stage-sclc.html 2024-12-05T05:59:21.836Z https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html 2024-12-06T06:39:47.038Z https://www.astrazeneca.com/media-centre/press-releases/2024/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-care-previously-untreated-cll-with-77-of-patients-progression-free-3-years-amplify-phase-iii-trial.html 2024-12-07T12:16:25.462Z https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-us-patients-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html 2024-12-09T06:59:42.033Z https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial.html 2024-12-11T09:38:18.288Z https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-approved-in-eu-based-on-laura-trial.html 2024-12-20T16:33:56.931Z https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-nsq-nsclc-application-withdrawn-in-eu.html 2024-12-24T05:13:07.330Z https://www.astrazeneca.com/media-centre/press-releases/2023.html 2022-12-27T23:44:52.345Z https://www.astrazeneca.com/media-centre/press-releases/2023/nirsevimab-us-regulatory-submission-accepted-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children.html 2023-01-05T06:45:27.246Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html 2024-05-20T11:30:34.967Z https://www.astrazeneca.com/media-centre/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html 2023-01-11T12:49:51.233Z https://www.astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-eu-in-a-new-pre-filled-pen.html 2023-01-13T04:23:12.005Z https://www.astrazeneca.com/media-centre/press-releases/2023/acquisition-of-neogene-therapeutics-completed.html 2023-01-16T02:27:25.685Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html 2023-01-26T03:25:15.905Z https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-evusheld-us-eua.html 2023-01-26T18:18:53.960Z https://www.astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-us-with-a-new-pre-filled-pen.html 2023-02-02T11:06:32.809Z https://www.astrazeneca.com/media-centre/press-releases/2023/full-year-and-q4-2022-results.html 2023-02-09T07:16:55.441Z https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-approved-in-the-eu-for-the-treatment-of-symptomatic-chronic-heart-failure.html 2023-02-07T06:18:06.560Z https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html 2023-02-16T11:54:13.653Z https://www.astrazeneca.com/media-centre/press-releases/2023/resvinet-2023-data-reinforce-astrazenecas-commitment-to-help-prevent-respiratory-syncytial-virus-in-infants.html 2023-02-21T07:42:36.474Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html 2023-02-22T04:41:47.023Z https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia.html 2023-02-22T16:23:03.602Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html 2023-02-23T06:40:30.022Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-for-patients-with-her2-positive-metastatic-breast-cancer.html 2023-02-24T09:52:15.197Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html 2023-02-24T13:47:16.257Z https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-us-regulatory-review-of-lynparza-in-combination-with-abiraterone-for-mcrpc.html 2023-03-02T12:19:48.461Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-destiny-pantumor02-shows-positive-results.html 2023-03-06T04:41:29.188Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-improved-efs-in-resectable-lung-cancer.html 2023-03-09T04:08:03.632Z https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial.html 2023-03-09T04:35:22.030Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-launches-call-for-entries-to-the-2023-global-rd-postdoctoral-challenge.html 2023-03-09T22:14:24.687Z https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-granted-first-regulatory-approval-in-china-for-adults-with-previously-treated-mantle-cell-lymphoma.html 2023-03-23T05:59:39.582Z https://www.astrazeneca.com/media-centre/press-releases/2023/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial.html 2023-03-27T06:05:10.199Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-completes-agreement-with-kym-for-cmg901.html 2023-03-30T03:29:08.925Z https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-recommended-for-nmosd-eu-approval.html 2023-04-03T05:03:16.387Z https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-imfinzi-met-endpoint-in-ovarian-cancer.html 2023-04-05T05:04:34.215Z https://www.astrazeneca.com/media-centre/press-releases/2023/update-to-arrangements-with-sobi-and-sanofi.html 2023-04-11T04:45:06.044Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr.html 2023-04-14T20:42:14.843Z https://www.astrazeneca.com/media-centre/press-releases/2023/eccmid-data-reinforces-astrazenecas-commitment-to-transform-protection-for-the-most-vulnerable-by-advancing-science-in-vaccines-and-immune-therapies.html 2023-11-20T15:45:40.071Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-in-resectable-non-small-cell-lung-cancer.html 2023-04-14T16:44:29.487Z https://www.astrazeneca.com/media-centre/press-releases/2023/q1-2023-results.html 2023-04-27T06:28:28.446Z https://www.astrazeneca.com/media-centre/press-releases/2023/neuro-ttransform-phase-iii-results-presented-at-aan-showed-eplontersen-demonstrated-consistent-and-sustained-improvement.html 2023-04-24T08:55:29.979Z https://www.astrazeneca.com/media-centre/press-releases/2023/odac-vote-on-lynparza-combo-in-prostate-cancer.html 2023-04-28T21:12:25.430Z https://www.astrazeneca.com/media-centre/press-releases/2023/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html 2024-08-06T09:08:18.301Z https://www.astrazeneca.com/media-centre/press-releases/2023/farxiga-extended-in-the-us-for-heart-failure.html 2023-05-09T06:31:36.075Z https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html 2023-05-10T04:45:43.427Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023.html 2023-05-16T05:30:36.180Z https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemo-improved-pfs-in-lung-cancer.html 2023-05-17T03:48:51.188Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-will-highlight-momentum-of-practice-changing-cancer-medicines-across-its-robust-pipeline-at-asco-2023.html 2023-05-25T04:02:07.422Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-lynparza-prolonged-pfs-in-endometrial-cancer.html 2023-05-26T12:06:26.022Z https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-nmosd.html 2023-05-26T12:15:28.322Z https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-approved-in-us-for-brcam-prostate-cancer.html 2023-06-01T04:08:01.549Z https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-brazikumab-development-programme.html 2023-06-01T04:14:57.757Z https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-and-imfinzi-combination-reduced-risk-of-disease-progression-or-death-vs-chemotherapy-and-bevacizumab-in-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-the-duo-o-phase-iii-trial.html 2023-06-03T11:58:44.446Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial.html 2023-06-02T21:27:38.132Z https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial.html 2023-06-04T19:02:52.197Z https://www.astrazeneca.com/media-centre/press-releases/2023/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care.html 2023-06-05T03:22:02.028Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing.html 2023-06-05T07:00:59.291Z https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-combinations-showed-encouraging-tumour-responses-in-patients.html 2023-06-05T09:09:22.125Z https://www.astrazeneca.com/media-centre/press-releases/2023/danicopan-as-add-on-to-ultomiris-or-soliris-improved-haemoglobin-levels-and-maintained-disease-control-in-patients.html 2023-06-08T22:56:09.094Z https://www.astrazeneca.com/media-centre/press-releases/2023/nirsevimab-recommended-for-infant-rsv-protection.html 2023-06-08T21:20:38.569Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-agreement-with-quell-therapeutics.html 2023-06-09T01:44:32.440Z https://www.astrazeneca.com/media-centre/press-releases/2023/capivasertib-in-combination-with-faslodex-granted-priority-review-in-the-us.html 2023-06-12T03:42:34.975Z https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis.html 2023-06-12T16:17:00.172Z https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-recommended-for-approval-in-the-eu-by-chmp-for-children-and-adolescents.html 2023-08-24T10:01:37.298Z https://www.astrazeneca.com/media-centre/press-releases/2023/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes.html 2023-06-27T06:06:52.587Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-announces-400-million-investment-in-reforestation-and-biodiversity-in-support-of-climate-action-and-human-health.html 2024-11-14T10:16:57.862Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-demonstrated-sustained-overall-survival-benefit-in-the-himalaya-phase-iii-trial.html 2023-06-28T10:05:55.829Z https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-met-dual-primary-endpoint-of-progression-free-survival-in-patients-with-advanced-non-small-cell-lung-cancer.html 2023-07-03T06:42:31.203Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html 2023-07-12T09:40:58.511Z https://www.astrazeneca.com/media-centre/press-releases/2023/beyfortus-approved-in-the-us-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html 2023-07-17T17:45:45.938Z https://www.astrazeneca.com/media-centre/press-releases/2023/h1-and-q2-2023-results.html 2023-07-28T06:22:57.025Z https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-the-eu-for-children-and-adolescents-with-refractory-generalised-myasthenia-gravis-gmg.html 2023-08-24T10:01:07.403Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-progression-free-survival-and-overall-survival-in-destiny-pantumor02-phase-ii-trial.html 2023-07-27T06:11:02.915Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-appoints-sharon-barr-as-executive-vice-president-biopharmaceuticals-rd.html 2023-08-08T12:03:28.535Z https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html 2023-07-27T23:09:48.593Z https://www.astrazeneca.com/media-centre/press-releases/2023/wclc-advance-ambition-astrazeneca-medicine-for-more-than-half-of-all-patients-treated-for-lung-cancer-2030.html 2023-08-16T06:56:58.737Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-demonstrates-scientific-leadership-with-compelling-new-data-at-esc-congress-2023-on-the-interconnections-across-chronic-diseases.html 2023-08-21T11:50:53.587Z https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-approved-china-reduce-risk-cardiovascular-death-hospitalisation-patients-with-symptomatic-chronic-heart-failure.html 2023-08-18T04:30:54.931Z https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-japan-paediatric-patients-generalised-myasthenia-gravis-gmg.html 2023-08-24T02:53:23.453Z https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-plus-abiraterone-approved-japan-treatment-brca-mutated-metastatic-castration-resistant-prostate-cancer.html 2023-08-24T02:56:30.285Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-data-ers-2023-demonstrate-leadership-transforming-care-across-broad-respiratory-portfolio-inhaled-biologic-medicines.html 2023-08-29T07:29:37.448Z https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-approved-china-chronic-lymphocytic-leukaemia.html 2023-09-04T04:15:00.746Z https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-us-review-of-ultomiris-for-nmosd.html 2023-09-06T05:27:14.510Z https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-plus-imfinzi-showed-promising-clinical-activity-in-the-first-line-advanced-non-small-cell-lung-cancer-setting.html 2023-09-09T23:14:05.857Z https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-extended-median-progression-free-survival-by-nearly-9-months-in-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial.html 2023-09-11T08:18:44.848Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-strong-and-durable-tumour-responses-in-previously-treated-her2-mutant-advanced-lung-cancer-in-the-destiny-lung02-phase-ii-trial.html 2023-09-11T04:56:45.406Z https://www.astrazeneca.com/media-centre/press-releases/2023/fasenra-phase-iii-egpa-trial-met-primary-endpoint.html 2023-09-11T14:34:30.534Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.html 2023-09-15T13:10:03.576Z https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-completes-purchase-licence-agreement-early-stage-rare-disease-gene-therapy-portfolio-pfizer.html 2023-09-20T05:52:00.862Z https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html 2023-09-22T08:32:23.700Z https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-met-primary-endpoint-in-t2now-phase-iii-trial-one-of-the-largest-paediatric-type-2-diabetes-studies-performed-to-date.html 2023-10-02T08:55:46.781Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-settles-nexium-and-prilosec-product-liability-litigations.html 2023-10-03T05:12:45.253Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-research-reveals-unique-associations-between-rare-changes-in-genes-and-plasma-proteins-that-could-improve-drug-discovery.html 2023-10-04T09:50:47.200Z https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-data-at-9th-joint-ectrims-actrims-meeting-msmilan2023-showcase-impact-of-c5-inhibition-in-nmosd.html 2023-10-11T05:18:15.248Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-across-multiple-cancers-with-first-data-from-four-pivotal-phase-iii-trials-at-esmo.html 2023-10-11T05:12:02.549Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-reinforces-commitment-to-protecting-the-most-vulnerable-from-serious-infectious-diseases-at-idweek-2023.html 2023-10-11T05:26:23.560Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-awards-funding-to-eight-innovative-research-projects.html 2023-10-12T04:07:21.071Z https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-granted-priority-review-us-patients-egfr-mutated-advanced-lung-cancer.html 2023-10-16T04:32:27.237Z https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-china-treatment-adults-neuromyelitis-optica-spectrum-disorder-nmosd.html 2023-10-18T04:30:54.541Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-doubled-pathologic-complete-response-rate-resectable-early-stage-gastric-gastroesophageal-junction-cancers-vs-chemotherapy.html 2023-10-20T03:51:17.990Z https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-reduced-risk-disease-progression-brain-42-percent-patients-egfr-mutated-advanced-lung-cancer-brain-metastases-baseline.html 2023-10-21T06:54:28.700Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-lynparza-reduced-risk-disease-progression-death-45-percent-vs-chemotherapy-advanced-recurrent-endometrial-cancer.html 2023-10-21T06:53:52.747Z https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-plus-imfinzi-robust-durable-tumour-responses-1st-line-treatment-patients-metastatic-triple-negative-breast-cancer-begonia-phase-ibii-trial.html 2023-10-21T17:42:15.236Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.html 2023-10-23T15:33:11.036Z https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-significantly-extended-progression-free-survival-vs-chemotherapy-in-tropion-breast01-phase-iii-trial.html 2023-10-23T14:28:32.239Z https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-improved-progression-free-survival-vs-chemotherapy-in-tropion-lung01-phase-iii-trial.html 2023-10-23T15:33:47.006Z https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-survival-across-multiple-her2-expressing-advanced-solid-tumours-in-destiny-pantumor02-phase-ii-trial.html 2023-10-23T14:29:29.265Z https://www.astrazeneca.com/media-centre/press-releases/2023/us-food-drug-administration-accepts-review-astrazeneca-supplemental-biologics-license-application-self-administration-flumist-quadrivalent.html 2023-10-24T05:56:03.301Z https://www.astrazeneca.com/media-centre/press-releases/2023/9m-and-q3-2023-results.html 2023-11-09T07:55:04.697Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html 2023-11-01T04:18:08.268Z https://www.astrazeneca.com/media-centre/press-releases/2023/zora-real-world-evidence-demonstrates-that-lokelma-substantially-increases-cardiorenal-patients-chances-of-maintaining-lifesaving-raasi-therapy.html 2023-11-02T13:46:11.547Z https://www.astrazeneca.com/media-centre/press-releases/2023/zibotentan-dapagliflozin-combination-demonstrated-significant-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-proteinuria-in-zenith-ckd-phase-IIb-trial.html 2023-11-03T03:59:30.294Z https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html 2023-11-08T18:45:54.355Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-combination-improves-pfs-in-liver-cancer.html 2023-11-09T06:43:44.737Z https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-approved-in-china-as-first-immunotherapy-regimen-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer.html 2023-11-14T06:39:48.763Z https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-pacific-2-phase-iii-trial-for-imfinzi.html 2023-11-14T03:48:05.152Z https://www.astrazeneca.com/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer.html 2023-11-17T06:11:00.328Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-launches-evinova-health-tech-business-to-accelerate-innovation-across-the-life-sciences-sector.html 2023-11-19T22:22:55.282Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-in-haematology-at-ash-2023.html 2023-11-30T17:08:10.881Z https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-crystalize-evidence-trials.html 2023-11-30T17:13:43.972Z https://www.astrazeneca.com/media-centre/press-releases/2023/long-term-alpha-phase-iii-trial-data-danicopan-ultomiris-soliris-improvement-patients-pnh-experiencing-clinically-significant-extravascular-haemolysis.html 2023-12-08T22:43:03.820Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data.html 2023-12-12T06:29:29.886Z https://www.astrazeneca.com/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis.html 2023-12-21T23:51:19.718Z https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html 2023-12-25T22:48:52.555Z https://www.astrazeneca.com/media-centre/press-releases/2022.html 2022-05-05T05:56:59.551Z https://www.astrazeneca.com/media-centre/press-releases/2022/full-year-2021-and-q4-results.html 2022-02-10T12:51:10.707Z https://www.astrazeneca.com/media-centre/press-releases/2022/transfer-of-global-rights-for-eklira-and-duaklir-to-covis-pharma-completed.html 2022-01-04T20:51:04.276Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-neurimmune-sign-deal-for-ni006.html 2022-01-18T14:27:11.280Z https://www.astrazeneca.com/media-centre/press-releases/2022/new-vaxzevria-data-further-support-its-use-as-third-dose-booster.html 2022-01-12T21:47:46.344Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-scorpion-therapeutics-enter-agreement-to-discover-develop-and-commercialise-novel-cancer-treatments-against-undruggable-targets.html 2022-01-13T06:23:09.418Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-liver-biliary-tract-and-prostate-cancer-treatment-with-practice-changing-imfinzi-and-lynparza-data-at-asco-gi-and-gu.html 2022-01-13T06:33:14.999Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-breast-cancer.html 2022-01-16T18:22:09.257Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-reduced-risk-of-death-by-20-in-1st-line-advanced-biliary-tract-cancer.html 2022-01-18T21:47:51.237Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-tremelimumab-unprecedented-survival-1st-line-unresectable-liver-cancer.html 2022-01-18T21:49:31.072Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-combo-delays-progression-risk-in-prostate-cancer.html 2022-02-14T18:42:29.034Z https://www.astrazeneca.com/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle.html 2022-02-15T22:38:09.610Z https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-ema-regulatory-submission-accepted-under-accelerated-assessment-for-rsv-protection-in-all-infants.html 2022-02-17T13:33:09.709Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improves-pfs-and-os-in-her2-low-bc.html 2022-02-21T06:35:41.655Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers.html 2022-02-21T22:11:57.754Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-neurimmune-close-deal-for-ni006.html 2022-04-04T14:38:46.967Z https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-significantly-protected-infants-against-rsv-disease-in-phase-iii-melody-trial.html 2022-03-03T06:50:28.999Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.html 2022-03-11T21:05:37.242Z https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-us-review-of-fasenra-in-nasal-polyps.html 2022-03-13T21:22:08.142Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-reduced-risk-of-death-by-32-percent-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer.html 2022-03-16T16:42:28.352Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-launches-global-rd-postdoctoral-challenge-to-accelerate-scientific-discovery-and-diversity.html 2022-03-17T07:35:12.131Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-reaches-settlement-agreement-resolving-patent-litigation-related-to-ultomiris.html 2022-03-17T07:07:40.063Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html 2022-03-18T10:34:56.321Z https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-imfinzi.html 2022-03-24T06:02:00.709Z https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19.html 2022-03-29T05:57:15.254Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-transform-the-oncology-treatment-landscape-with-diverse-early-pipeline-and-novel-combinations-at-aacr.html 2022-03-30T06:48:55.014Z https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-in-the-eu-for-covid-19.html 2022-03-27T19:47:53.483Z https://www.astrazeneca.com/media-centre/press-releases/2022/ondexxya-approved-in-japan-for-fxai-reversal.html 2022-03-28T15:40:06.507Z https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-demonstrated-sustained-improvements-functional-activities-quality-life-adults-generalised-myasthenia-gravis-60-weeks.html 2022-04-06T05:45:43.037Z https://www.astrazeneca.com/media-centre/press-releases/2022/human-ventricular-progenitor-cells-promote-formation-new-heart-tissue-following-heart-attack.html 2022-05-13T08:26:44.442Z https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html 2022-04-28T06:04:51.833Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-transform-cancer-care-practice-changing-data-asco-2022.html 2022-05-22T20:15:46.858Z https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-hfpef-phase-iii-trial-met-primary-endpoint.html 2022-05-05T05:56:59.551Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-combo-granted-priority-review-for-btc.html 2022-05-04T05:58:48.803Z https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-nmosd-ph-iii-trial-met-primary-endpoint.html 2022-05-05T05:49:56.736Z https://www.astrazeneca.com/media-centre/press-releases/2022/azd8233-reduced-low-density-lipoprotein-cholesterol-levels-73-patients-high-risk-hypercholesterolemia-etesian-phase-iib-trial.html 2022-04-04T13:54:24.609Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2m-nsclc.html 2022-04-18T20:47:26.029Z https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-approved-eu-third-dose-booster-covid-19.html 2022-05-23T05:59:49.493Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-us-for-2l-her2-positive-breast-cancer.html 2022-05-05T06:00:15Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-signs-licence-agreement-with-rq-biotechnology-for-monoclonal-antibodies-against-covid-19.html 2022-05-16T20:46:25.841Z https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1.html 2022-04-22T13:51:34.296Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-plans-for-new-strategic-rd-centre-and-alexion-headquarters-in-cambridge-massachusetts.html 2022-04-28T21:25:34.776Z https://www.astrazeneca.com/media-centre/press-releases/2022/q1-2022-results.html 2022-04-29T06:18:02.429Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-btd-her2-low-breast-cancer.html 2022-04-26T20:43:34.333Z https://www.astrazeneca.com/media-centre/press-releases/2022/tremelimumab-us-priority-review-imfinzi-combo.html 2022-04-24T21:33:06.170Z https://www.astrazeneca.com/media-centre/press-releases/2022/pt027-significantly-reduced-the-risk-of-a-severe-exacerbation-compared-to-albuterol-in-patients-with-asthma.html 2022-05-15T16:36:46.350Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-pascal-soriot-awarded-british-knighthood-services-uk-life-sciences-leadership-global-response-covid-pandemic.html 2022-06-01T21:25:44.337Z https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-plus-obinutuzumab-demonstrated-sustained-survival-benefit-in-1st-line-chronic-lymphocytic-leukaemia.html 2022-06-04T12:53:45.388Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-efficacy-results-in-her2-low-breast-cancer.html 2022-06-05T11:53:27.342Z https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html 2022-06-07T15:52:09.503Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-demonstrates-pipeline-and-portfolio-strength-across-malignant-and-rare-haematological-diseases-at-eha-2022.html 2022-06-08T20:01:19.327Z https://www.astrazeneca.com/media-centre/press-releases/2022/eplontersen-phase-iii-trial-met-co-primary-endpoints.html 2022-06-20T21:07:35.687Z https://www.astrazeneca.com/media-centre/press-releases/2022/alxn1840-shows-rapid-and-sustained-improvement-in-copper-mobilisation-from-tissues.html 2022-06-23T12:41:19.064Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-recommended-in-eu-for-early-breast-cancer.html 2022-06-26T12:02:32.032Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-breast-cancer-eu-approval.html 2022-06-26T12:03:12.672Z https://www.astrazeneca.com/media-centre/press-releases/2022/new-chronic-kidney-disease-ckd-study-indicates-that-ckd-is-present-in-one-out-of-ten-adults.html 2022-06-29T18:29:02.626Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-improved-pcr-in-resectable-lung-cancer.html 2022-06-30T09:29:33.434Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-teneotwo-and-t-cell-engager.html 2022-07-05T05:56:13.551Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-her2-positive-mbc.html 2023-01-02T06:09:49.041Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2-low-mbc.html 2022-07-24T20:42:47.337Z https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-recommended-for-approval-in-the-eu-by-chmp.html 2022-07-25T05:18:04.995Z https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-recommended-for-approval-in-the-eu-by-chmp.html 2022-07-25T05:22:50.882Z https://www.astrazeneca.com/media-centre/press-releases/2022/h1-2022-results.html 2022-07-29T06:15:51.915Z https://www.astrazeneca.com/media-centre/press-releases/2022/michel-demare-to-succeed-leif-johansson-as-non-executive-chair-of-the-board.html 2022-07-29T05:03:23.614Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-eu-for-early-breast-cancer.html 2023-01-02T06:14:47.447Z https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html 2023-01-02T06:18:33.864Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-the-us-for-her2-low-mbc.html 2022-09-08T08:33:20.057Z https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-plus-savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-in-savannah-phase-ii-trial.html 2022-09-08T08:31:36.066Z https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-based-combinations-show-promising-clinical-activity-in-patients.html 2023-01-02T06:41:59.848Z https://www.astrazeneca.com/media-centre/press-releases/2022/acquisition-of-teneotwo-for-its-clinical-stage-t-cell-engager-completed.html 2023-01-02T09:31:21.103Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-us-for-her2-mutant-nsclc.html 2023-01-02T10:20:13.884Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improved-pfs-in-mbc-in-destiny-breast02.html 2022-09-08T08:36:04.857Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-granted-fda-priority-review-for-propel.html 2023-01-02T10:21:58.999Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-transform-cancer-outcomes-with-new-data-across-industry-leading-portfolio-at-esmo-2022.html 2023-01-02T10:23:58.486Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-japan-for-early-breast-cancer.html 2023-01-02T10:27:52.109Z https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-approved-in-japan-for-early-lung-cancer.html 2023-01-02T10:29:16.957Z https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.html 2023-01-02T10:33:49.835Z https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-deliver-phase-III-trial-reduced-cv-death.html 2022-08-27T15:18:32.214Z https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-lowers-risk-cv-death-heart-failure.html 2022-08-27T12:39:21.696Z https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-for-covid-19-in-japan.html 2023-01-24T14:16:49.772Z https://www.astrazeneca.com/media-centre/press-releases/2022/forxiga-approved-in-china-for-ckd.html 2023-01-02T10:36:21.585Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-us-for-biliary-tract-cancer.html 2023-01-02T10:39:14.042Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-in-combination-with-bevacizumab-demonstrates-clinically-meaningful-survival-benefit-in-advanced-ovarian-cancer.html 2022-09-23T16:30:37.760Z https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html 2022-09-10T22:37:31.672Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer.html 2022-09-11T07:00:41.132Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-continues-to-demonstrate-clinically-meaningful-tumour-response-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html 2022-09-11T06:38:26.615Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-further-improved-overall-survival-benefit-in-advanced-biliary-tract-cancer-in-the-topaz-1-phase-iii-trial.html 2022-09-12T04:49:46.143Z https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-recommended-for-approval-in-eu-by-chmp.html 2022-09-16T05:53:17.458Z https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-positive-chmp-opinion-in-eu.html 2023-01-10T06:58:26.717Z https://www.astrazeneca.com/media-centre/press-releases/2022/danicopan-phase-iii-trial-met-primary-endpoint.html 2023-01-10T07:02:57.730Z https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-in-eu-for-covid-19-treatment.html 2023-01-24T14:15:56.764Z https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma.html 2022-09-21T04:39:52.375Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-china-for-ovarian-cancer.html 2022-09-22T19:41:02.092Z https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-eu-for-gmg.html 2023-01-11T05:21:06.234Z https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html 2022-09-27T04:28:09.133Z https://www.astrazeneca.com/media-centre/press-releases/2022/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas.html 2024-08-06T09:07:17.324Z https://www.astrazeneca.com/media-centre/press-releases/2022/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-efficacy-data-at-ectrims-2022.html 2023-01-11T05:33:46.663Z https://www.astrazeneca.com/media-centre/press-releases/2022/idweek-data-reinforces-astrazenecas-commitment-to-advance-science-in-vaccines-and-immune-therapies.html 2023-01-24T13:53:27.881Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html 2022-10-24T05:42:20.386Z https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-messina-phase-iii-trial.html 2022-10-25T04:35:22.613Z https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-phase-iii-trial-met-primary-endpoints.html 2023-01-11T05:44:02.693Z https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-improved-progression-free-survival.html 2022-10-26T13:39:58.515Z https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-showed-zero-relapses-in-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-with-median-treatment-duration-of-73-weeks.html 2022-10-27T05:13:39.962Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-advances-scientific-leadership-in-cardiovascular-and-renal-diseases-with-over-60-abstracts.html 2022-10-31T09:00:04.183Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-funds-rd-postdoctoral-challenge-finalists.html 2022-11-01T16:32:09.909Z https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-receives-full-marketing-authorisation-in-the-eu-for-the-prevention-of-covid-19.html 2023-01-24T13:52:03.795Z https://www.astrazeneca.com/media-centre/press-releases/2022/beyfortus-approved-in-the-eu-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html 2023-01-24T13:54:37.478Z https://www.astrazeneca.com/media-centre/press-releases/2022/az-data-at-asn-kidney-week-reinforces-urgent-need-for-early-screening-of-ckd-and-benefits-of-earlier-treatment-for-patients-and-healthcare-systems.html 2022-11-05T09:37:21.704Z https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-improved-symptom-burden-in-deliver-phase-iii-trial.html 2022-11-07T16:51:48.135Z https://www.astrazeneca.com/media-centre/press-releases/2022/year-to-date-and-q3-2022-results.html 2022-11-10T07:25:24.147Z https://www.astrazeneca.com/media-centre/press-releases/2022/fda-advisory-committee-recommends-pt027-in-asthma.html 2022-11-09T08:11:11.066Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html 2022-11-11T06:54:38.139Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-expands-global-footprint-in-rare-disease-with-availability-of-first-alexion-rare-disease-therapy-for-patients-in-china.html 2022-11-11T06:53:36.890Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-in-combination-with-abiraterone-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer.html 2022-11-14T07:50:06.381Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer.html 2022-11-14T07:44:24.624Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer.html 2022-11-14T07:42:53.798Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-ranked-in-top-three-in-the-access-to-medicine-index.html 2022-11-15T11:47:44.727Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-breast-cancer-care-with-new-data-across-the-treatment-spectrum-at-sabcs-2022.html 2022-11-22T06:33:54.841Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-neogene-therapeutics-accelerating-ambition-in-oncology-cell-therapy.html 2022-11-29T05:23:56.769Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-sale-of-west-chester-site.html 2022-11-29T16:07:26.286Z https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ash-2022.html 2022-11-30T06:56:58.149Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-achieved-statistically-significant-overall-survival.html 2022-12-09T14:37:52.929Z https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-pfs-in-hr-positive-breast-cancer.html 2022-12-09T14:42:26.143Z https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer.html 2022-12-08T12:10:08.829Z https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-encouraging-and-durable-efficacy-in-patients-with-metastatic-breast-cancer.html 2022-12-08T20:05:37.262Z https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-promising-responses-as-monotherapy-and-in-combination-with-imfinzi-in-patients.html 2022-12-09T06:19:18.381Z https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-us-review-of-lynparza-propel-snda.html 2022-12-15T05:14:15.969Z https://www.astrazeneca.com/media-centre/press-releases/2022/forxiga-chmp-opinion-for-symptomatic-chronic-hf.html 2022-12-19T07:14:48.182Z https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-imfinzi-pearl-trial.html 2022-12-18T23:00:23.187Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-recommended-for-approvals-in-eu.html 2022-12-18T23:06:24.145Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-gastric-cancer.html 2022-12-19T05:56:38.074Z https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-eu-approval-in-her2-low-bc.html 2022-12-19T05:59:57.840Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-eu-for-biliary-tract-cancer.html 2022-12-21T04:23:44.384Z https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-eu-for-prostate-cancer.html 2022-12-21T04:31:26.474Z https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-japan-approval-for-treatment-naive-cll.html 2022-12-28T00:14:39.325Z https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-approved-in-japan-for-3-cancers.html 2022-12-28T00:11:38.887Z https://www.astrazeneca.com/media-centre/press-releases/2021.html 2021-01-12T14:21:16.208Z https://www.astrazeneca.com/media-centre/press-releases/2021/us-clearance-of-proposed-acquisition-of-alexion.html 2023-01-06T20:38:07.409Z https://www.astrazeneca.com/media-centre/press-releases/2021/atacand-divestment-in-over-70-countries-completed.html 2021-01-03T10:54:27.629Z https://www.astrazeneca.com/media-centre/press-releases/2021/farxiga-granted-us-priority-review-for-ckd.html 2021-01-06T00:10:03.126Z https://www.astrazeneca.com/media-centre/press-releases/2021/serum-institute-of-india-obtains-emergency-use-authorisation-in-india-for-astrazenecas-covid-19-vaccine.html 2021-01-06T14:11:46.752Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-showcase-transformative-data-across-diverse-pipeline-at-world-conference-on-lung-cancer.html 2021-01-15T10:49:56.337Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-new-dosing-approved-in-eu.html 2021-01-14T22:44:12.806Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-us-for-gastric-cancer.html 2021-01-17T20:16:24.353Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-eu-for-breast-cancer.html 2021-01-19T22:52:00.697Z https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-approved-in-japan-for-cll.html 2021-01-24T20:42:07.886Z https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-ibrutinib.html 2021-07-14T10:27:46.947Z https://www.astrazeneca.com/media-centre/press-releases/2021/symbicort-approved-in-china-for-mild-asthma.html 2021-01-25T16:02:45.291Z https://www.astrazeneca.com/media-centre/press-releases/2021/datopotamab-deruxtecan-and-enhertu-show-promising-early-clinical-activity-in-patients-with-advanced-non-small-cell-lung-cancer.html 2021-01-28T23:43:17.532Z https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-extended-disease-free-survival-regardless-of-prior-adjuvant-chemotherapy-in-early-stage-egfr-mutated-lung-cancer.html 2021-01-29T00:14:38.411Z https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-recommended-for-use-in-the-eu.html 2021-01-29T15:56:02.335Z https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-authorised-for-use-in-the-eu.html 2021-01-29T21:08:03.660Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-agrees-to-divest-viela-shareholding.html 2021-02-01T11:32:23.966Z https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html 2021-02-03T07:10:14.335Z https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-china-for-heart-failure.html 2021-02-04T07:26:58.995Z https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-kestrel-phase-iii-trial-for-imfinzi.html 2021-02-04T22:48:50.370Z https://www.astrazeneca.com/media-centre/press-releases/2021/full-year-2020-results.html 2021-02-11T07:58:14.610Z https://www.astrazeneca.com/media-centre/press-releases/2021/divestment-of-crestor-in-europe-completed.html 2021-02-10T07:28:56.684Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-covid-19-vaccine-manufacturing-in-europe-and-secure-long-term-supply-capacity.html 2021-02-10T12:12:16.642Z https://www.astrazeneca.com/media-centre/press-releases/2021/olympia-trial-of-lynparza-idmc-recommend-early-analysis.html 2021-02-17T07:09:11.448Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization.html 2021-02-22T16:01:18.201Z https://www.astrazeneca.com/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html 2021-02-21T14:25:08.122Z https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-is-the-first-biologic-to-consistently-and-significantly-reduce-exacerbations-in-broad-population-of-severe-asthma-patients.html 2021-02-26T14:12:24.429Z https://www.astrazeneca.com/media-centre/press-releases/2021/further-update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html 2021-03-02T11:37:01.653Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html 2021-03-02T12:53:59.746Z https://www.astrazeneca.com/media-centre/press-releases/2021/us-court-decision-favours-symbicort-patents.html 2021-03-03T07:41:34.095Z https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html 2021-03-14T18:35:37.216Z https://www.astrazeneca.com/media-centre/press-releases/2021/divestment-of-viela-shareholding-completed.html 2021-03-15T22:11:23.856Z https://www.astrazeneca.com/media-centre/press-releases/2021/us-supply-agreement-for-additional-azd7442-doses.html 2021-03-15T23:40:03.103Z https://www.astrazeneca.com/media-centre/press-releases/2021/uk-and-eu-regulatory-agencies-confirm-covid-19-vaccine-astrazeneca-is-effective-and-generally-well-tolerated.html 2022-03-09T16:22:55.230Z https://www.astrazeneca.com/media-centre/press-releases/2021/statement-on-the-passing-of-jose-baselga.html 2021-03-21T19:08:31.453Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html 2021-03-22T07:47:31.779Z https://www.astrazeneca.com/media-centre/press-releases/2021/update-following-statement-by-niaid-on-azd1222-us-phase-iii-trial-data.html 2021-04-15T15:05:33.140Z https://www.astrazeneca.com/media-centre/press-releases/2021/statement-on-covid-19-vaccine-supply-at-anagni-plant-in-italy.html 2021-04-15T15:05:18.766Z https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html 2021-03-29T11:54:01.716Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-accelerates-early-oncology-pipeline-across-key-strategic-scientific-platforms-at-aacr.html 2021-04-09T06:00:30.076Z https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-farxiga-covid-19-dare-19-phase-iii-trial.html 2021-04-12T15:52:56.566Z https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-approved-in-china-in-early-lung-cancer.html 2021-04-20T08:02:35.578Z https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-adjuvant-receives-positive-chmp-opinion.html 2021-04-26T06:02:16.794Z https://www.astrazeneca.com/media-centre/press-releases/2021/selumetinib-recommended-for-eu-approval-in-nf1.html 2021-10-26T09:23:05.596Z https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phase-iii-trial-met-primary-endpoint.html 2021-07-23T11:19:04.734Z https://www.astrazeneca.com/media-centre/press-releases/2021/q1-2021-results.html 2021-04-30T06:08:58.954Z https://www.astrazeneca.com/media-centre/press-releases/2021/farxiga-approved-in-the-us-for-ckd.html 2021-04-30T20:50:53.150Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-showed-survival-in-poseidon.html 2021-05-07T05:15:41.922Z https://www.astrazeneca.com/media-centre/press-releases/2021/results-of-annual-general-meeting-held-on-11-may-2021.html 2021-05-11T13:56:43.342Z https://www.astrazeneca.com/media-centre/press-releases/2021/approval-recognises-acquisitions-advancement-of-the-companys-strategic-and-financial-development.html 2023-01-06T20:39:32.805Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-asco-2021-data-support-ambition-to-revolutionise-cancer-outcomes-by-treating-earlier-and-transforming-the-patient-experience.html 2021-07-14T10:29:23.593Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan.html 2021-05-21T05:56:13.177Z https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-approved-in-eu-in-early-lung-cancer.html 2021-05-27T22:01:52.930Z https://www.astrazeneca.com/media-centre/press-releases/2021/anifrolumab-showed-benefit-across-different-measures-of-skin-and-joint-disease-activity-in-patients-with-systemic-lupus-erythematosus.html 2021-06-02T05:46:24.689Z https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-reduced-the-risk-of-cancer-recurrence-by-42-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer-in-olympia-phase-iii-trial.html 2021-07-14T10:28:55.432Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-lung-cancer-with-43-percent-of-patients-surviving-five-years.html 2021-06-03T21:42:02.571Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-appoints-aradhana-sarin-as-new-chief-financial-officer.html 2023-01-11T15:26:54.619Z https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-head-to-head-results-versus-ibrutinib.html 2021-06-07T05:54:29.945Z https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-effective-against-delta-indian-variant.html 2021-06-17T09:14:07.314Z https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html 2021-06-15T05:35:31.418Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-welcomes-court-ruling-on-supply-of-its-covid-19-vaccine-to-europe.html 2021-06-18T13:12:06.811Z https://www.astrazeneca.com/media-centre/press-releases/2021/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html 2021-10-26T09:31:18.539Z https://www.astrazeneca.com/media-centre/press-releases/2021/orpathys-approved-in-china-for-patients-with-lung-cancer-and-met-gene-alterations.html 2021-06-23T05:25:54.541Z https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-approved-in-china-for-prostate-cancer.html 2021-06-23T22:12:20.228Z https://www.astrazeneca.com/media-centre/press-releases/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial-participants-vaccinated.html 2021-06-27T11:45:17.856Z https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-recommended-in-eu-for-patients-with-ckd.html 2021-06-27T19:07:26.504Z https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phii-iii-trial-confirms-safety-profile.html 2021-07-23T11:16:32.484Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-appoints-dr-susan-galbraith-as-executive-vice-president-oncology-research-and-development.html 2021-07-22T10:22:45.431Z https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-induced-immunity-for-at-least-1-year-following-a-single-dose-and-strong-immune-responses-following-either-a-late-second-dose-or-a-third-dose.html 2021-06-28T13:36:16.395Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-eu.html 2023-01-06T20:41:40.335Z https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-fda-priority-review-for-asthma.html 2021-07-07T20:44:50.195Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-uk.html 2023-01-06T20:42:17.942Z https://www.astrazeneca.com/media-centre/press-releases/2021/status-on-us-fda-advisory-committee-for-roxadustat.html 2021-07-16T06:06:26.517Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-approved-in-china-for-extensive-stage-sclc.html 2021-07-18T19:43:05.067Z https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html 2023-01-11T15:27:16.019Z https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern.html 2021-07-23T06:39:26.574Z https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-recommended-in-eu-for-children-with-pnh.html 2022-01-18T14:07:17.501Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-regeneron-to-research-develop-and-commercialise-new-small-molecule-medicines-for-obesity.html 2021-07-27T09:05:40.436Z https://www.astrazeneca.com/media-centre/press-releases/2021/h1-2021-results.html 2021-07-29T06:11:45.357Z https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose.html 2021-07-27T21:38:23.858Z https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-and-mrna-covid-19-vaccines-showed-similar-and-favourable-safety-profiles-in-a-population-based-cohort-study-of-over-a-million-people.html 2021-07-27T21:49:03.789Z https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html 2021-08-02T05:58:36.748Z https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-the-eu-for-ckd.html 2021-08-09T05:33:51.501Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-head-to-head-trial-meets-primary-endpoint.html 2021-08-09T05:30:51.897Z https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-us-review-of-roxadustat.html 2021-08-11T19:48:06.377Z https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-ultomiris-phase-iii-als-trial.html 2022-01-18T14:21:16.416Z https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html 2021-08-19T22:18:56.615Z https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-japan-for-ckd.html 2021-08-25T21:30:41.370Z https://www.astrazeneca.com/media-centre/press-releases/2021/alxn1840-wilson-phase-iii-met-primary-endpoint.html 2022-01-18T14:22:33.495Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-combined-with-novel-immunotherapies-improved-clinical-outcomes-for-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer.html 2021-09-16T15:22:42.123Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-lung-and-breast-cancer-data-at-wclc-and-esmo-2021-underscore-ambition-to-revolutionise-outcomes-for-patients.html 2021-09-02T12:32:46.176Z https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-approved-in-eu-for-children-with-pnh.html 2022-01-18T14:17:02.478Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-european-commission-reach-settlement-agreement-over-vaccine-supply-ending-litigation.html 2021-09-03T07:47:57.081Z https://www.astrazeneca.com/media-centre/press-releases/2021/international-respiratory-coalition-launches-to-transform-post-pandemic-respiratory-healthcare.html 2021-09-09T08:05:24.030Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improves-survival-in-nsclc-in-poseidon.html 2021-09-09T08:43:17.018Z https://www.astrazeneca.com/media-centre/press-releases/2021/pt027-phiii-asthma-trials-met-primary-endpoints.html 2021-09-09T05:31:06.257Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian-phase-iii-trial-in-extensive-stage-small-cell-lung-cancer.html 2021-09-18T15:29:38.854Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-demonstrated-clinically-meaningful-and-durable-response-in-patients-with-her2-positive-advanced-gastric-cancer-in-destiny-gastric02-phase-ii-trial.html 2021-09-18T11:26:54.548Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-demonstrated-robust-and-durable-tumour-response-of-549-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html 2021-09-18T15:40:31.156Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-reduced-the-risk-of-disease-progression-or-death-by-72-vs-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer.html 2022-08-17T20:03:04.340Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-360m-irish-manufacturing-investment.html 2021-09-20T21:23:10.205Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-discover-and-develop-self-amplifying-rna-therapeutics-in-new-collaboration-with-vaxequity.html 2021-09-22T15:54:59.836Z https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-propel-trial-meets-primary-endpoint.html 2021-09-24T05:31:53.273Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-and-rsv-presentations-at-idweek-2021-will-showcase-scientific-progress-in-infectious-diseases.html 2021-09-26T20:00:23.333Z https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle.html 2021-09-27T19:26:42.108Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-fully-acquire-caelum-biosciences.html 2023-10-16T13:04:51.854Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-granted-btd-for-breast-cancer.html 2021-10-03T20:01:00.552Z https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us.html 2021-10-04T20:07:13.443Z https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html 2021-10-08T10:44:16.720Z https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html 2021-10-10T17:54:08.115Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-improved-os-in-liver-cancer.html 2021-10-15T05:26:47.209Z https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improved-survival-in-biliary-tract-cancer.html 2021-10-26T09:49:36.555Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-transfer-rights-to-eklira-duaklir.html 2021-10-31T19:05:16.820Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-ambition-to-redefine-care-for-blood-cancer-at-ash-2021.html 2021-11-05T06:46:41.311Z https://www.astrazeneca.com/media-centre/press-releases/2021/year-to-date-and-q3-2021-results.html 2021-11-12T07:20:48.131Z https://www.astrazeneca.com/media-centre/press-releases/2021/azd8601-epiccure-phase-ii-trial-demonstrated-safety-and-tolerability-in-patients-with-heart-failure.html 2021-11-15T13:21:37.566Z https://www.astrazeneca.com/media-centre/press-releases/2021/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html 2021-11-16T06:33:26.075Z https://www.astrazeneca.com/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html 2021-11-17T22:41:48.356Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge.html 2025-08-21T11:29:34.267Z https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-granted-fda-priority-review-for-olympia.html 2021-11-30T06:34:16.695Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-reinforces-leadership-in-breast-cancer-at-sabcs-2021-with-new-data-underscoring-ambition-to-redefine-cancer-care.html 2021-12-08T08:20:11.191Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-ionis-to-collaborate-on-eplontersen.html 2021-12-06T22:22:21.541Z https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html 2021-12-08T20:50:31.829Z https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-additional-analyses-further-reinforce-ground-breaking-efficacy-in-patients-with-her2-positive-metastatic-breast-cancer.html 2021-12-09T14:49:41.602Z https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-reduced-the-risk-of-disease-progression-or-death-vs-standard-of-care-combinations-at-three-years-in-the-ascend-phase-iii-trial.html 2021-12-12T08:52:15.143Z https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study.html 2021-12-16T13:59:23.855Z https://www.astrazeneca.com/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html 2021-12-17T21:47:41.662Z https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-recommended-for-eu-approval-for-sle.html 2021-12-19T20:43:10.979Z https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-accepted-for-fda-priority-review-for-gmg.html 2022-01-18T14:24:45.230Z https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities.html 2021-12-22T22:49:48.027Z https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-significantly-boosted-antibody-levels-against-omicron.html 2021-12-23T07:14:10.274Z https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-ionis-close-eplontersen-deal.html 2021-12-28T16:10:47.059Z https://www.astrazeneca.com/media-centre/press-releases/2020.html 2020-09-01T06:02:41.774Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-fast-track-designation-in-the-us-for-heart-failure-following-acute-myocardial-infarction-leveraging-an-innovative-registry-based-trial-design.html 2020-07-16T12:01:51.322Z https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-i-ii-trial.html 2020-11-19T16:48:33.573Z https://www.astrazeneca.com/media-centre/press-releases/2020/h1-2020-results.html 2020-07-30T07:12:57.063Z https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd.html 2020-07-23T20:51:37.697Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate.html 2020-07-27T06:38:35.930Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-recommended-for-approval-in-the-eu-by-chmp-for-extensive-stage-small-cell-lung-cancer.html 2020-07-27T06:05:52.108Z https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-recommended-for-approval-in-the-eu-by-chmp-for-chronic-lymphocytic-leukaemia.html 2020-07-27T06:11:04.189Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease.html 2020-07-28T06:38:27.174Z https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-us-btd-for-egfrm-adjuvant-lung-cancer.html 2020-07-29T22:17:00.737Z https://www.astrazeneca.com/media-centre/press-releases/2020/nirsevimab-reduced-respiratory-syncytial-virus-infections-and-hospitalisations-in-preterm-infants-in-phase-iib-trial.html 2020-07-29T22:25:10.461Z https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in-patients.html 2020-07-16T06:11:24.445Z https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack.html 2020-07-09T06:14:36.372Z https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-approved-in-china-for-the-treatment-of-adult-patients-with-hyperkalaemia-06012020.html 2020-01-06T06:53:57.714Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-fda-priority-review-for-patients-with-heart-failure-with-reduced-ejection-fraction-06012020.html 2020-01-06T07:19:29.822Z https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html 2020-01-13T06:50:56.529Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer-13012020.html 2020-01-13T06:57:13.920Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-hrr-mutated-metastatic-castration-resistant-prostate-cancer-20012020.html 2020-01-19T22:46:03.237Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-and-tremelimumab-granted-orphan-drug-designation-in-the-us-for-liver-cancer-20012020.html 2020-01-20T06:52:56.919Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-young-health-programme-to-partner-with-unicef-to-prevent-non-communicable-diseases-among-young-people.html 2021-06-08T15:22:48.779Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-ambition-zero-carbon-strategy-to-eliminate-emissions-by-2025-and-be-carbon-negative-across-the-entire-value-chain-by-2030-22012020.html 2020-01-21T21:39:54.092Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divests-rights-to-established-hypertension-medicines-27012020.html 2020-01-26T22:01:45.546Z https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-met-primary-endpoint-in-phase-iii-thales-trial-in-stroke-27012020.html 2020-01-27T06:47:16.612Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020.html 2020-01-27T06:35:23.909Z https://www.astrazeneca.com/media-centre/press-releases/2020/phase-ii-destiny-gastric01-trial-of-enhertu-versus-chemotherapy-met-primary-endpoint-27012020.html 2020-01-27T06:41:13.661Z https://www.astrazeneca.com/media-centre/press-releases/2020/full-year-and-q4-2019-results.html 2020-02-14T14:41:09.545Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divests-global-rights-to-movantik-25022020.html 2020-02-25T07:04:07.313Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-completes-divestment-agreement-with-atnahs-pharma-for-established-hypertension-medicines.html 2020-03-02T07:30:45.702Z https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html 2020-03-06T06:57:54.729Z https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-gy004-trial-for-cediranib-added-to-lynparza-in-platinum-sensitive-relapsed-ovarian-cancer.html 2020-03-12T06:54:01.898Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-confirmed-a-sustained-overall-survival-benefit-in-final-analysis-of-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer.html 2020-03-17T06:48:11.510Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-granted-orphan-drug-designation-in-japan-for-brca-mutated-metastatic-pancreatic-cancer.html 2020-03-19T06:59:04.918Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-donate-9-million-face-masks-to-support-healthcare-workers-around-the-world-in-the-fight-against-covid-19.html 2020-11-19T16:45:46.590Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-sirna-therapeutics-for-cardiovascular-renal-metabolic-and-respiratory-diseases-in-new-collaboration.html 2020-03-25T07:12:32.098Z https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-approved-in-japan-for-the-treatment-of-hyperkalaemia.html 2021-09-07T09:55:42.098Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-reduced-the-incidence-of-heart-failure-worsening-or-cardiovascular-death-in-a-sub-analysis-from-landmark-phase-iii-dapa-hf-trial.html 2020-03-28T13:48:44.309Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html 2020-03-30T05:55:49.275Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-the-us-for-extensive-stage-small-cell-lung-cancer.html 2020-03-30T05:57:45.992Z https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-reduced-bleeding-vs-dual-therapy-in-high-risk-coronary-patients-in-sub-analyses-from-phase-iv-twilight-trial.html 2020-03-30T13:33:59.822Z https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-recommended-for-approval-in-eu-for-patients-with-hyperkalaemia-on-stable-haemodialysis.html 2021-09-07T09:57:47.061Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divestment-of-movantik-to-redhill-biopharma-completed.html 2020-04-01T19:17:50.947Z https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html 2020-04-11T13:29:27.172Z https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html 2020-04-13T06:33:55.071Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html 2020-11-19T16:44:51.745Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-saint-lukes-mid-america-heart-institute-initiate-phase-iii-dare-19-trial-with-farxiga-in-covid-19-patients.html 2020-11-19T16:43:58.166Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-shows-overall-survival-in-prostate-cancer.html 2020-04-24T05:56:28.973Z https://www.astrazeneca.com/media-centre/press-releases/2020/q1-2020-results.html 2020-04-29T06:58:13.718Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html 2020-11-19T16:41:58.947Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction.html 2020-05-06T05:56:31.985Z https://www.astrazeneca.com/media-centre/press-releases/2020/tlynparza-approved-in-the-us-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer.html 2020-05-11T05:55:21.768Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-recovery-of-global-rights-to-brazikumab-medi2070-from-allergan-completed.html 2020-05-11T06:05:51.643Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-positive-metastatic-gastric-cancer.html 2020-05-11T06:13:40.250Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-the-science-of-cancer-medicine-with-practice-changing-data-at-the-asco20-virtual-scientific-program.html 2020-05-13T21:14:00.112Z https://www.astrazeneca.com/media-centre/press-releases/2020/bevespi-aerosphere-approved-in-china-for-patients-with-copd.html 2020-05-18T06:34:26.813Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer.html 2020-05-18T06:11:37.265Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.html 2020-05-19T22:39:15.669Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html 2020-10-29T12:33:45.684Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-orphan-drug-designation-in-the-us-for-gastric-cancer.html 2020-05-22T06:10:56.698Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-collaborates-with-archerdx-to-use-personalised-cancer-assays-to-detect-minimal-residual-disease-in-lung-cancer-trials.html 2020-05-26T14:16:57.819Z https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer.html 2020-05-28T20:02:24.324Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-achieved-a-tumour-response-rate-of-45p-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-ii-destiny-crc01-trial.html 2020-05-29T12:49:39.959Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-demonstrated-meaningful-clinical-activity-in-patients-with-her2-mutant-non-small-cell-lung-cancer.html 2020-05-29T12:49:18.830Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-significantly-improved-tumour-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer.html 2020-05-29T12:54:30.916Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-showed-a-sustained-overall-survival-benefit-in-1st-line-extensive-stage-small-cell-lung-cancer-in-the-phase-iii-caspian-trial.html 2020-05-29T13:29:00.805Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-plus-tremelimumab-demonstrated-promising-clinical-activity-and-tolerability-in-patients-with-advanced-liver-cancer.html 2020-05-29T13:29:42.149Z https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease.html 2020-06-01T05:49:26.783Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-recommended-for-approval-in-eu-by-chmp-for-brca-mutated-metastatic-pancreatic-cancer.html 2020-06-01T06:10:26.354Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-novel-therapies-targeting-rna-modifying-proteins-in-oncology-collaboration-with-accent-therapeutics.html 2020-06-03T17:25:29.955Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-covid-19-vaccine.html 2020-11-19T16:40:51.215Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-presents-new-data-across-continuum-of-care-from-its-broad-renal-portfolio-at-era-edta-2020-virtual-congress.html 2020-10-29T12:32:12.565Z https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-promising-clinical-improvement-in-majority-of-19-hospitalised-covid-19-patients.html 2020-11-19T16:40:14.294Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-showcase-leadership-in-treating-type-2-diabetes-and-cardiorenal-complications-at-ada-2020.html 2020-06-11T06:36:00.102Z https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-long-term-efficacy-and-tolerability-for-patients-with-chronic-lymphocytic-leukaemia-in-two-trials.html 2020-06-12T06:55:33.334Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit.html 2020-11-19T16:39:31.499Z https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial.html 2020-06-24T18:52:11.752Z https://www.astrazeneca.com/media-centre/press-releases/2020/selumetinib-granted-orphan-drug-designation-in-japan-for-neurofibromatosis-type-1.html 2020-06-30T06:03:56.476Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-brca-mutated-metastatic-pancreatic-cancer.html 2020-07-08T06:05:24.214Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-concludes-agreement-with-the-european-commission-for-the-supply-of-up-to-400-million-doses-of-azd1222-covid-19-vaccine.html 2020-11-19T16:37:17.294Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-granted-fda-priority-review-for-less-frequent-fixed-dose-use.html 2020-08-18T06:12:16.799Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-japan-for-sclc.html 2020-08-21T06:11:59.112Z https://www.astrazeneca.com/media-centre/press-releases/2020/phase-1-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19.html 2020-10-28T15:18:32.734Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-paradigm-shifting-data-to-be-presented-at-esc-2020.html 2020-08-27T06:01:01.385Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-demonstrated-reduction-in-the-risk-of-kidney-failure-and-cardiovascular-or-renal-death-in-patients-with-ckd-in-the-phase-iii-dapa-ckd-trial.html 2020-08-30T15:56:38.793Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-scientific-and-social-commitment-for-covid-19-vaccine.html 2020-10-28T15:17:53.539Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-EU-for-small-cell-lung-cancer.html 2020-09-01T06:06:45.157Z https://www.astrazeneca.com/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html 2020-10-28T15:17:20.378Z https://www.astrazeneca.com/media-centre/press-releases/2020/new-analyses-from-breztri-aerosphere-phase-iii-ethos-trial-to-be-presented-at-the-european-respiratory-society-international-congress-2020.html 2020-09-07T21:08:30.835Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-aims-to-transform-cancer-treatment-and-advance-clinical-practice-with-data-presented-at-esmo-2020.html 2020-09-07T21:03:38.998Z https://www.astrazeneca.com/media-centre/press-releases/2020/biopharma-leaders-unite-to-stand-with-science.html 2020-09-08T08:21:53.498Z https://www.astrazeneca.com/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html 2020-10-28T15:16:47.684Z https://www.astrazeneca.com/media-centre/press-releases/2020/fasenra-met-both-co-primary-endpoints-of-reduced-nasal-polyp-size-and-blockage-in-the-ostro-phase-iii-trial.html 2020-09-10T06:09:40.817Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-list-us-adr-equity-and-all-us-debt-securities-on-nasdaq.html 2020-09-10T07:04:18.607Z https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-reduces-brain-recurrence-in-early-lung.html 2020-10-01T22:44:00.641Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-III-nsclc.html 2020-09-17T21:23:48.294Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-reduced-the-risk-of-death-by-31-percent-in-brca-or-atm-mcrpc-in-profound.html 2020-09-20T17:09:46.666Z https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html 2020-10-28T15:05:58.466Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-acquires-oral-pcsk9-inhibitor-programme-from-dogma-therapeutics.html 2020-09-17T06:19:24.583Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-improved-median-time-patients-lived-without-disease-progression-to-over-four-and-half-years-in-BRCA-mutated-advanced-ovarian-cancer.html 2020-09-18T07:29:53.691Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-eu-recommendation-in-prostate-cancer.html 2020-09-21T06:20:41.571Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-eu-recommendation-in-ovarian-cancer.html 2020-09-21T06:21:08.250Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease.html 2020-10-02T06:10:07.312Z https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trial-resumed-in-japan-follows-restart-of-trials-in-the-uk-brazil-south-africa-and-india.html 2020-10-28T15:05:01.649Z https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html 2020-10-28T15:04:24.336Z https://www.astrazeneca.com/media-centre/press-releases/2020/trixeo-aerosphere-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-copd.html 2020-10-19T06:07:05.248Z https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-heart-failure.html 2020-10-19T06:10:18.671Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-leadership-in-renal-disease-with-more-than-80-abstracts-at-asn-kidney-week-2020-reimagined.html 2020-10-20T06:14:28.466Z https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-adjuvant-lung-cancer-us-priority-review.html 2020-10-20T06:08:00.870Z https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-dapa-ckd-phase-iii-trial-reduced-worsening-of-kidney-function-risk-of-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease.html 2020-10-23T14:50:27.799Z https://www.astrazeneca.com/media-centre/press-releases/2020/fda-authorises-restart-of-the-covid-19-azd1222-vaccine-us-phase-iii-trial.html 2020-10-28T15:02:31.148Z https://www.astrazeneca.com/media-centre/press-releases/2020/year-to-date-and-q3-2020-results.html 2020-11-05T08:14:58.086Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-us-priority-review-in-gastric-cancer.html 2020-10-28T07:08:56.676Z https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-cv-outcomes-benefit-approved-in-china.html 2020-10-28T07:08:03.205Z https://www.astrazeneca.com/media-centre/press-releases/2020/fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial.html 2021-10-26T09:36:44.474Z https://www.astrazeneca.com/media-centre/press-releases/2020/atacand-to-be-divested-to-cheplapharm-in-more-than-70-countries.html 2020-10-30T07:07:51.856Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-prostate-cancer.html 2020-11-04T18:43:47.409Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-wider-ovarian-use.html 2020-11-04T18:37:27.755Z https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-approved-in-the-eu-for-heart-failure.html 2020-11-05T07:31:54.790Z https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-approved-in-the-eu-for-cll.html 2020-11-09T07:13:02.639Z https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-in-stroke.html 2020-11-05T21:35:17.409Z https://www.astrazeneca.com/media-centre/press-releases/2020/tezepelumab-navigator-phase-iii-trial-met-primary-endpoint.html 2020-11-10T07:16:36.497Z https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19.html 2020-11-12T07:00:57.593Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-demonstrates-strengths-in-haematology-with-robust-data-at-ash-2020.html 2020-11-18T23:06:29.758Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-new-dosing-approved-in-the-us.html 2020-11-20T07:06:00.221Z https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html 2024-02-01T15:15:07.817Z https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-approved-in-japan-for-heart-failure.html 2020-11-30T07:09:02.047Z https://www.astrazeneca.com/media-centre/press-releases/2020/crestor-to-be-divested-to-grunenthal-in-europe.html 2020-12-01T07:07:15.357Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-demonstrates-growing-leadership-in-breast-cancer-at-sabcs.html 2020-12-02T23:15:37.200Z https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-shows-long-term-efficacy-and-tolerability-at-three-years-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma.html 2020-12-07T16:05:49.841Z https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-data-across-four-trials-reinforces-cardiovascular-safety-profile-in-patients-with-chronic-lymphocytic-leukaemia.html 2020-12-07T14:50:57.296Z https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222-oxford-phase-iii-trials-interim-analysis-results-published-in-the-lancet.html 2020-12-08T19:00:26.742Z https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-continues-to-demonstrate-durable-responses-with-new-data-from-destiny-breast01-in-her2-positive-metastatic-breast-cancer.html 2020-12-10T11:00:47.660Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion.html 2023-01-06T20:37:02.185Z https://www.astrazeneca.com/media-centre/press-releases/2020/trixeo-aerosphere-approved-in-the-eu-for-copd.html 2020-12-13T20:59:29.347Z https://www.astrazeneca.com/media-centre/press-releases/2020/trastuzumab-deruxtecan-positive-chmp.html 2020-12-13T21:04:46.727Z https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-new-dose-receives-positive-eu-chmp-opinion.html 2020-12-14T21:17:13.432Z https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html 2020-12-18T22:56:04.942Z https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-approved-in-the-us-for-early-lung-cancer.html 2020-12-20T18:40:53.452Z https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma.html 2020-12-22T07:37:02.256Z https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-japan-for-three-cancers.html 2020-12-27T23:35:26.836Z https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html 2022-03-09T15:40:09.384Z https://www.astrazeneca.com/media-centre/press-releases/2019.html 2019-12-11T13:16:26.873Z https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-review-of-pt010-in-copd-01102019.html 2019-10-01T06:28:19.501Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-for-losec-to-cheplapharm-01102019.html 2019-10-01T06:33:39.320Z https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen-04102019.html 2019-10-04T06:29:35.368Z https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019.html 2019-10-17T06:26:22.322Z https://www.astrazeneca.com/media-centre/press-releases/2019/year-to-date-and-q3-2019-results.html 2019-10-24T06:44:13.001Z https://www.astrazeneca.com/media-centre/press-releases/2019/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019.html 2019-10-21T06:25:30.574Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-commits-35m-to-help-young-people-tackle-the-threat-of-non-communicable-diseases-22102019.html 2024-07-24T06:50:52.356Z https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer.html 2019-10-28T15:56:44.488Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-30102019.html 2019-10-30T07:25:34.227Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-pivotal-roxadustat-phase-iii-data-at-the-american-society-of-nephrology-kidney-week-2019-30102019.html 2019-10-30T07:34:27.377Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-announces-three-large-scale-initiatives-in-china-to-advance-global-medicine-research-and-development-061120119.html 2019-11-07T08:46:25.395Z https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-data-to-show-improved-progression-free-survival-in-phase-iii-front-line-chronic-lymphocytic-leukaemia-trial-at-ash-2019-annual-meeting.html 2019-11-06T14:54:45.017Z https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-significantly-increased-haemoglobin-levels-for-chronic-kidney-disease-patients-with-anaemia-in-phase-iii-olympus-and-rockies-trials.html 2019-11-07T21:47:24.480Z https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-phase-iii-programme-pooled-analyses-showed-positive-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-chronic-kidney-disease.html 2019-11-08T19:18:12.343Z https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-demonstrated-superiority-across-multiple-efficacy-endpoints-in-patients-with-systemic-lupus-erythematosus-in-phase-iii-tulip-2-trial.html 2019-11-12T16:26:13.200Z https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-accepts-regulatory-submission-for-selumetinib-in-neurofibromatosis-type-1-and-grants-priority-review-14112019.html 2019-11-14T07:15:39.640Z https://www.astrazeneca.com/media-centre/press-releases/2019/qtrilmet-approved-in-the-eu-for-the-treatment-of-type-2-diabetes-15112019.html 2019-11-15T06:54:17.592Z https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html 2019-11-21T20:59:00.171Z https://www.astrazeneca.com/media-centre/press-releases/2019/harvard-business-review-names-pascal-soriot-among-best-performing-top-100-ceos-in-the-world-2019.html 2019-11-22T13:56:12Z https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer.html 2019-11-29T07:21:58.683Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-the-us-and-canada-03122019.html 2019-12-02T16:58:21.107Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer.html 2019-12-05T07:44:38.161Z https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukaemia.html 2019-12-09T10:32:30.070Z https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-achieved-a-tumour-response-rate-of-60-in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial-11122019.html 2019-12-11T13:27:11.405Z https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-approved-in-china-for-the-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-based-on-the-phase-iii-pacific-trial-12122019.html 2019-12-12T07:06:05.507Z https://www.astrazeneca.com/media-centre/press-releases/2019/agreement-with-cheplapharm-for-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-completed-16122019.html 2019-12-16T07:53:38.701Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-recommended-by-fda-advisory-committee-for-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer.html 2019-12-18T09:17:05.780Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-arimidex-and-casodex-in-europe-and-certain-additional-countries-20122019.html 2019-12-20T07:00:53.310Z https://www.astrazeneca.com/media-centre/press-releases/2019/enhertu-trastuzumab-deruxtecan-approved-in-the-us-for-her2-positive-unresectable-or-metastatic-breast-cancer-following-2-or-more-prior-anti-her2-based-regimens.html 2019-12-23T11:35:52.429Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd-23122019.html 2019-12-23T12:31:29.098Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-mene-pangalos-awarded-knighthood-in-the-new-year-2020-honours-list-28122019.html 2022-07-13T09:58:19.864Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-30122019.html 2019-12-30T07:10:42.592Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-use-in-germline-brca-mutated-her2-negative-advanced-breast-cancer-01032019.html 2019-03-01T13:31:42.019Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-announces-organisational-changes.html 2019-01-14T17:38:14.225Z https://www.astrazeneca.com/media-centre/press-releases/2019/linzess-linaclotide-approved-in-china-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-18012019.html 2021-10-22T09:11:42.557Z https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-the-treatment-of-adults-with-type-1-diabetes.html 2019-02-01T13:44:25.287Z https://www.astrazeneca.com/media-centre/press-releases/2019/ema-grants-prime-eligibility-for-potential-next-generation-rsv-medicine-medi8897-05022019.html 2019-02-04T22:41:47.313Z https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897.html 2019-02-04T22:41:54.101Z https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-fasenra-orphan-drug-designation-for-hypereosinophilic-syndrome.html 2019-02-06T06:10:52.816Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progression-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer-26022019.html 2019-02-26T00:37:16.786Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-new-cardiovascular-data-on-farxiga-in-type-2-diabetes-at-acc-2019-11032019.html 2019-03-08T17:58:50.796Z https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-saracatinib-orphan-drug-designation-for-idiopathic-pulmonary-fibrosis-18032019.html 2019-03-17T21:46:13.459Z https://www.astrazeneca.com/media-centre/press-releases/2019/brilintas-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes-25022019.html 2019-02-26T09:18:04.170Z https://www.astrazeneca.com/media-centre/press-releases/2019/full-year-2018-results-14022019.html 2019-02-14T09:07:20.011Z https://www.astrazeneca.com/media-centre/press-releases/2019/first-sub-analyses-from-the-declare-timi-58-trial-further-support-the-cardiovascular-effects-of-farxiga-in-type-2-diabetes-18032019.html 2019-03-18T10:09:20.114Z https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-japan-for-type-1-diabetes-27032019.html 2019-03-26T19:50:51.362Z https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-europe-for-type-1-diabetes22032019.html 2019-03-22T16:41:39.722Z https://www.astrazeneca.com/media-centre/press-releases/2019/astraZeneca-showcases-next-generation-oncology-pipeline-addressing-unmet-patient-needs-at-aacr-annual-meeting.html 2019-03-13T20:48:50.283Z https://www.astrazeneca.com/media-centre/press-releases/2019/proposed-placing-of-new-ordinary-shares.html 2019-04-03T10:00:18.391Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate.html 2019-03-28T23:37:41.557Z https://www.astrazeneca.com/media-centre/press-releases/2019/positive-results-from-fasenra-phase-ii-trial-in-hypereosinophilic-syndrome-published-in-new-england-journal-of-medicine-04042019.html 2019-04-03T15:33:15.829Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer-10042019.html 2019-04-10T05:29:31.432Z https://www.astrazeneca.com/media-centre/press-releases/2019/selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1-01042019.html 2019-04-01T05:21:17.854Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-26042019.html 2019-04-29T05:17:26.868Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-starts-artificial-intelligence-collaboration-to-accelerate-drug-discovery-30042019.html 2019-04-30T05:38:47.908Z https://www.astrazeneca.com/media-centre/press-releases/2019/qternmet-xr-approved-in-the-us-for-the-treatment-of-type-2-diabetes-03052019.html 2019-05-03T05:20:46.986Z https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-phase-iii-ascend-trial-met-primary-endpoint-at-interim-analysis-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-and-will-stop-early-07052019.html 2019-05-07T06:13:31.214Z https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need-08052019.html 2019-05-08T06:33:52.883Z https://www.astrazeneca.com/media-centre/press-releases/2019/pooled-analyses-of-the-roxadustat-global-phase-3-programme-confirmed-cardiovascular-safety.html 2019-05-10T06:16:10.717Z https://www.astrazeneca.com/media-centre/press-releases/2019/new-data-on-symbicort-as-a-potential-anti-inflammatory-reliever-in-mild-asthma-to-be-presented-at-ats-2019-16052019.html 2019-05-16T05:55:25.816Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-continues-to-redefine-cancer-treatment-at-the-2019-asco-annual-meeting-16052019.html 2019-05-16T05:54:27.545Z https://www.astrazeneca.com/media-centre/press-releases/2019/new-data-show-symbicort-reduces-attacks-in-mild-asthma-when-used-as-an-anti-inflammatory-reliever-20052019.html 2019-05-20T06:08:04.945Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019.html 2019-06-02T12:36:49.533Z https://www.astrazeneca.com/media-centre/press-releases/2019/Q1-2019-results.html 2019-04-26T22:04:05.225Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019-2.html 2019-06-02T20:38:57.345Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-achieved-a-72-objective-response-rate-in-patients-with-relapsed-germline-brca-mutated-advanced-ovarian-cancer-03062019.html 2019-06-03T20:47:19.616Z https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-phase-iii-elevate-tn-trial-met-primary-endpoint-at-interim-analysis-in-previously-untreated-chronic-lymphocytic-leukaemia06062019.html 2019-09-02T16:30:06.203Z https://www.astrazeneca.com/media-centre/press-releases/2019/lokelma-demonstrated-efficacy-in-treating-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis14062019.html 2019-09-02T16:29:20.373Z https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-is-the-only-immunotherapy-to-demonstrate-overall-survival-at-three-years-in-unresectable-stage-iii-non-small-cell-lung-cancer02062019.html 2021-10-22T15:20:56.907Z https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia15062019.html 2019-06-17T06:54:01.325Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-18062019.html 2019-06-18T06:46:05.532Z https://www.astrazeneca.com/media-centre/press-releases/2019/bevespi-aerosphere-approved-by-the-japanese-ministry-of-health-labour-and-welfare-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html 2019-09-02T16:26:26.455Z https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html 2019-09-02T16:25:31.228Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-19062019.html 2019-09-02T16:24:30.669Z https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer-27062019.html 2021-10-22T14:57:21.768Z https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-receives-positive-eu-chmp-opinion-for-self-administration-and-the-new-fasenra-pen-a-pre-filled-single-use-auto-injector-01072019.html 2019-07-01T06:25:11.196Z https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-declare-timi-58-cardiovascular-outcomes-data-01072019.html 2019-07-01T06:26:31.239Z https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-granted-us-orphan-drug-designation-for-small-cell-lung-cancer12072019.html 2021-10-22T14:53:00.649Z https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html 2019-09-02T16:22:05.119Z https://www.astrazeneca.com/media-centre/press-releases/2019/H1-2019-results.html 2019-07-25T06:57:11.231Z https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes.html 2019-08-05T06:30:24.056Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-07082019.html 2019-08-21T06:15:21.319Z https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-significantly-improves-overall-survival-in-the-phase-iii-flaura-trial-for-1st-line-egfr-mutated-non-small-cell-lung-cancer-09082019.html 2019-08-21T06:14:47.025Z https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia-14082019.html 2019-08-19T16:37:34.364Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer-14082019.html 2019-08-19T16:36:08.176Z https://www.astrazeneca.com/media-centre/press-releases/2019/farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure-20082019.html 2019-08-20T06:35:00.737Z https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer-21082019.html 2021-10-22T14:54:26.682Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi-22082019.html 2019-08-22T06:29:09.514Z https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease-22082019.html 2019-09-02T16:17:37.503Z https://www.astrazeneca.com/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease-27082019.html 2019-08-26T21:25:59.647Z https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-phase-iii-ethos-trial-met-its-primary-endpoint-in-chronic-obstructive-pulmonary-disease-28082019.html 2019-09-02T16:01:48.930Z https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-granted-us-orphan-drug-designation-for-eosinophilic-oesophagitis-28082019.html 2019-09-02T16:03:09.903Z https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html 2019-08-29T06:38:50.030Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-data-at-esc-congress-2019-that-potentially-redefines-the-treatment-of-heart-failure-29082019.html 2019-09-02T16:16:16.215Z https://www.astrazeneca.com/media-centre/press-releases/2019/detailed-results-from-phase-iii-dapa-hf-trial-showed-farxiga-significantly-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure-01092019.html 2019-09-01T13:05:06.560Z https://www.astrazeneca.com/media-centre/press-releases/2019/brilinta-reduced-the-risk-of-cardiovascular-events-in-patients-with-coronary-artery-disease-and-type-2-diabetes-in-phase-iii-themis-trial-01092018.html 2019-09-02T16:15:08.557Z https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-approved-in-china-as-a-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-04092019.html 2019-09-04T06:50:00.757Z https://www.astrazeneca.com/media-centre/press-releases/2019/rns1.html 2019-11-07T13:54:51.264Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-redefines-cancer-treatment-with-practice-changing-data-at-esmo-2019.html 2019-09-16T06:32:08.179Z https://www.astrazeneca.com/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-heart-failure.html 2019-09-16T06:50:15.572Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-amends-collaboration-with-ironwood-for-linzess-in-china.html 2019-09-18T06:31:29.932Z https://www.astrazeneca.com/media-centre/press-releases/2019/qtrilmet-recommended-for-approval-in-eu-by-chmp-for-the-treatment-of-type-2-diabetes-23092019.html 2019-09-23T06:33:07.432Z https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-next-wave-of-science-in-respiratory-disease-at-ers-international-congress-25092019.html 2019-09-25T06:32:28.892Z https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-is-the-only-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-to-deliver-a-median-overall-survival-of-more-than-three-years.html 2019-09-30T08:02:32.854Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-improved-the-time-women-lived-without-disease-progression-to-22-months-in-the-broad-population-and-to-37-months-in-hrd-positive-patients.html 2019-09-30T08:03:35.174Z https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html 2019-09-30T15:58:53.541Z https://www.astrazeneca.com/media-centre/press-releases/2018.html 2018-09-20T05:11:09.816Z https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia-22032018.html 2018-04-02T22:04:18.205Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018.html 2018-01-10T15:07:51.640Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018.html 2018-01-15T13:38:48.402Z https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-recieves-approval-in-japan-19012018.html 2018-01-18T22:11:19.282Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer-19012018.html 2018-01-18T22:05:43.626Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-listed-as-one-of-the-worlds-top-100-most-sustainable-companies-and-recognised-for-its-three-fold-increase-in-renewable-energy-usage-23012018.html 2018-01-23T07:52:37.266Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-top-line-phase-iii-kronos-trial-results-for-pt010-triple-combination-therapy-in-chronic-obstructive-pulmonary-disease-26102018.html 2018-01-26T18:31:56.609Z https://www.astrazeneca.com/media-centre/press-releases/2018/full-year-2017-results.html 2018-02-02T08:08:45.295Z https://www.astrazeneca.com/media-centre/press-releases/2018/brilinta-significantly-reduces-cv-events-and-coronary-death-beyond-one-year-in-heart-attack-survivors-with-multi-vessel-disease-07022018.html 2018-02-07T07:08:35.088Z https://www.astrazeneca.com/media-centre/press-releases/2018/selumetinib-granted-orphan-drug-designation-by-the-us-fda-for-neurofibromatosis-type-1-15022018.html 2018-02-15T06:53:14.414Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-180202018.html 2018-02-23T06:48:59.242Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer-23022018.html 2018-02-23T12:25:13.406Z https://www.astrazeneca.com/media-centre/press-releases/2018/medimmune-to-create-stand-alone-company-for-early-stage-inflammation-and-autoimmunity-biologics-28022018.html 2018-02-28T06:28:49.957Z https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-forxiga-in-adults-with-type-1-diabetes-05032018.html 2018-03-05T06:27:47.333Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-aims-to-advance-clinical-practice-in-cv-risk-management-with-new-data-at-acc-2018-05032018.html 2018-03-05T06:25:25.526Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-mystic-trial-timeline-12032018.html 2021-10-22T15:44:26.451Z https://www.astrazeneca.com/media-centre/press-releases/2018/new-data-from-landmark-cvd-real-study-of-patients-with-type-2-diabetes-confirms-cv-benefits-associated-with-sglt-2-inhibitors-12032018.html 2018-03-12T07:00:40.061Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-03042018.html 2018-04-03T05:48:00.427Z https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-03042018.html 2018-04-03T05:45:00.103Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazenecas-early-and-late-stage-oncology-portfolio-showcased-at-aacr-annual-meeting-and-elcc-04042018.html 2018-04-06T17:21:10.245Z https://www.astrazeneca.com/media-centre/press-releases/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progression-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-13042018.html 2018-04-13T13:52:55.714Z https://www.astrazeneca.com/media-centre/press-releases/2018/updated-overall-survival-data-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr-16042018.html 2018-04-16T10:51:08.349Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-EGFR-mutated-non-small-cell-lung-cancer.html 2018-04-19T15:41:53.280Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer-24042018.html 2018-04-24T05:22:23.881Z https://www.astrazeneca.com/media-centre/press-releases/2018/tagrisso-receives-positive-eu-chmp-opinion-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer27042018.html 2018-04-27T14:03:20.591Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer08052018.html 2018-05-08T10:17:45.404Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-and-luye-pharma-group-enter-agreement-for-rights-to-seroquel-and-seroquel-xr-in-the-uk-china-and-other-international-markets.html 2018-05-07T13:14:40.181Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018.html 2018-05-11T06:06:22.118Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-is-advancing-clinical-practice-in-respiratory-medicine-with-new-data-at-the-american-thoracic-society-2018-international-congress.html 2018-05-16T05:46:23.318Z https://www.astrazeneca.com/media-centre/press-releases/2018/new-england-journal-of-medicine-publishes-two-trials-for-symbicort-as-an-anti-inflammatory-reliever-therapy-as-needed-in-mild-asthma16052018.html 2018-05-17T13:37:29.771Z https://www.astrazeneca.com/media-centre/press-releases/2018/q1-2018-results.html 2018-05-18T06:21:48.563Z https://www.astrazeneca.com/media-centre/press-releases/2018/regulatory-submission-in-japan-for-forxiga-in-type-1-diabetes-21052018.html 2018-06-05T08:57:09.815Z https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html 2018-06-04T16:02:06.989Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-heads-to-2018-asco-annual-meeting-with-its-diversified-oncology-portfolio-and-next-generation-pipeline24052018.html 2018-05-24T21:37:17.047Z https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html 2018-05-24T23:55:11.430Z https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018.html 2018-05-30T04:54:50.340Z https://www.astrazeneca.com/media-centre/press-releases/2018/moxetumomab-pasudotox-pivotal-data-in-patients-with-previously-treated-hairy-cell-leukaemia-presented-at-the-2018-asco-meeting-04062018.html 2018-06-04T13:12:10.299Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-in-combination-with-abiraterone-delayed-disease-progression-in-metastatic-castration-resistant-prostate-cancer-04062018.html 2018-06-04T21:02:58.634Z https://www.astrazeneca.com/media-centre/press-releases/2018/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-08062018.html 2018-06-11T13:00:30.120Z https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html 2018-06-12T05:22:15.675Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-share-latest-data-from-an-industry-leading-portfolio-that-aims-to-advance-clinical-understanding-of-diabetes-and-cv-risk-management-at-ada-2018-19062018.html 2018-06-19T05:52:04.974Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-significantly-delays-disease-progression-in-phase-iii-1st-line-solo-1-trial-for-ovarian-cancer.html 2018-06-27T06:42:44.767Z https://www.astrazeneca.com/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-new-bcise-device-for-patients-with-type-2-diabetes-29062018.html 2018-06-29T12:45:18.345Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-in-japan-for-brca-mutated-metastatic-breast-cancer-02072018.html 2018-06-29T16:18:53.866Z https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-approved-in-japan-for-unresectable-stage-iii-non-small-cell-lung-cancer-02072018.html 2018-06-29T16:32:21.097Z https://www.astrazeneca.com/media-centre/press-releases/2018/Atacand-to-be-divested-to-Cheplapharm-in-Europe24072018.html 2018-07-24T06:10:06.129Z https://www.astrazeneca.com/media-centre/press-releases/2018/h1-2018-results-25072018.html 2018-07-26T10:05:57.248Z https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-receives-positive-eu-chmp-opinion-for-locally-advanced-unresectable-non-small-cell-lung-cancer-27072018.html 2018-07-27T12:56:20.900Z https://www.astrazeneca.com/media-centre/press-releases/2018/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1-03082018.html 2018-08-03T05:51:47.544Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-is-advancing-understanding-of-cardio-renal-metabolic-interconnectivity-with-new-evidence-at-esc-2018-20082018.html 2018-08-17T14:47:46.834Z https://www.astrazeneca.com/media-centre/press-releases/2018/tagrisso-approved-in-japan-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-21082018.html 2018-08-21T05:57:45.099Z https://www.astrazeneca.com/media-centre/press-releases/2018/european-commission-approves-new-easy-to-use-once-weekly-bydureon-bcise-device-for-patients-with-type-2-diabetes30082018.html 2018-08-30T05:51:20.252Z https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html 2018-08-30T21:48:28.209Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-aeristo-phase-iiib-trial-for-bevespi-aerosphere-in-chronic-obstructive-pulmonary-disease23082018.html 2018-08-23T05:37:09.413Z https://www.astrazeneca.com/media-centre/press-releases/2018/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-07092018.html 2018-09-11T16:47:39.320Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-present-fasenra-long-term-safety-and-efficacy-data-at-european-respiratory-society-international-congress-2018-13092018.html 2018-09-12T15:05:42.520Z https://www.astrazeneca.com/media-centre/press-releases/2018/new-data-on-mechanisms-of-acquired-resistance-after-1st-line-tagrisso-in-nsclc-support-initiation-of-orchard-trial-to-explore-post-progression-treatment-options-19102018.html 2018-10-19T13:53:30.394Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukaemia.html 2018-09-14T06:24:41.549Z https://www.astrazeneca.com/media-centre/press-releases/2018/the-lancet-respiratory-medicine-publishes-first-phase-iii-trial-for-pt010-triple-combination-therapy-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-16092018.html 2018-09-16T18:01:20.742Z https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-shows-consistent-safety-and-sustained-efficacy-in-long-term-phase-iii-bora-trial-in-severe-eosinophilic-asthma-18092018.html 2018-09-18T05:13:15.220Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-further-data-showing-the-interconnectivity-between-cardiovascular-and-renal-risks-in-diabetes-at-easd-2018-20092018.html 2018-09-20T05:40:40.741Z https://www.astrazeneca.com/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-exscel-cardiovascular-outcomes-data-25092018.html 2018-09-25T05:16:11.862Z https://www.astrazeneca.com/media-centre/press-releases/2018/european-commission-approves-imfinzi-for-locally-advanced-unresectable-nsclc-24092018.html 2018-10-11T18:25:24.114Z https://www.astrazeneca.com/media-centre/press-releases/2018/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-24092018.html 2018-09-24T05:38:23.196Z https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-is-the-first-immunotherapy-to-demonstrate-significant-overall-survival-benefit-in-unresectable-stage-iii-lung-cancer25092018.html 2018-10-11T18:27:20.982Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-advances-in-improving-treatment-options-for-ovarian-and-lung-cancer-patients-at-esmo-2018-09102018.html 2018-10-10T07:10:04.137Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-grants-lynparza-orphan-drug-designation-for-pancreatic-cancer-16102018.html 2018-10-16T06:01:25.174Z https://www.astrazeneca.com/media-centre/press-releases/2018/chmp-issues-a-positive-opinion-for-bevespi-aerosphere-for-the-treatment-of-chronic-obstructive-pulmonary-disease-19102018.html 2018-10-19T12:22:12.467Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-present-new-data-demonstrating-breadth-of-research-portfolio-in-renal-disease-at-asn-kidney-week-22102018.html 2021-10-26T09:37:48.404Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-strengthens-and-expands-oncology-development-and-commercialisation-collaboration-with-innate-pharma23102018.html 2018-10-24T09:09:48.268Z https://www.astrazeneca.com/media-centre/press-releases/2018/agreement-with-grunenthal-for-rights-to-nexium-in-europe-and-vimovo-worldwide-ex-us-30102018.html 2018-10-30T06:08:53.913Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-regulatory-submission-for-lynparza-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review-12112018.html 2018-11-12T06:58:42.217Z https://www.astrazeneca.com/media-centre/press-releases/2018/year-to-date-and-q3-2018-results-08112018.html 2018-11-08T07:27:30.053Z https://www.astrazeneca.com/media-centre/press-releases/2018/the-landmark-declare-timi-58-cardiovascular-outcomes-trial-of-farxiga-in-patients-with-type-2-diabetes-to-be-featured-at-aha-01112018.html 2018-11-01T06:12:33.799Z https://www.astrazeneca.com/media-centre/press-releases/2018/solo-1-phase-III-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer.html 2018-10-22T05:48:04.456Z https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-harmonize-global-trial-of-lokelma-confirms-efficacy-in-maintaining-normal-potassium-levels-in-asian-patients-with-hyperkalaemia-25102018.html 2021-10-22T15:27:18.968Z https://www.astrazeneca.com/media-centre/press-releases/2018/divestment-of-rights-to-alvescoomnaris-and-zetonna-to-covis-pharma06112018.html 2018-11-06T15:34:06.482Z https://www.astrazeneca.com/media-centre/press-releases/2018/farxiga-significantly-reduced-hospitalisation-for-heart-failure-or-cv-death-in-a-broad-patient-population-with-type-2-diabetes-in-the-landmark-declare-timi-58-trial.html 2018-11-11T10:30:39.626Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-divest-us-synagis-rights-to-sobi131120180.html 2018-11-13T06:54:29.185Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer16112018.html 2021-10-26T09:39:55.563Z https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-the-phase-iii-eagle-trial-of-imfinzi-and-tremelimumab-in-advanced-head-and-neck-cancer-07122018.html 2021-10-22T15:48:22.522Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-and-cancer-research-uk-launch-functional-genomics-centre-to-accelerate-the-discovery-of-new-medicines-10122018.html 2018-12-07T16:25:57.327Z https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-grants-fasenra-orphan-drug-designation-for-eosinophilic-granulomatosis-with-polyangiitis-26112018.html 2018-11-25T19:56:39.893Z https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-primary-endpoints-in-chronic-kidney-disease-patients-with-anaemia20122018.html 2018-12-20T07:12:10.540Z https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-clinical-research-advances-for-blood-cancer-patients-at-2018-american-society-of-hematology-annual-meeting-27112018.html 2018-11-27T06:48:29.535Z https://www.astrazeneca.com/media-centre/press-releases/2018/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-chronic-kidney-disease-patients-on-dialysis18122018.html 2018-12-18T10:13:58.453Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-meets-primary-endpoint-in-phase-iii-solo-3-trial-for-the-treatment-of-relapsed-brca-mutated-advanced-ovarian-cancer20122018.html 2018-12-20T06:48:23.185Z https://www.astrazeneca.com/media-centre/press-releases/2018/new-long-term-data-on-calquence-presented-at-ash-2018-03122018.html 2018-12-03T18:47:41.560Z https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-by-us-fda-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer19122018.html 2018-12-19T18:57:05.974Z https://www.astrazeneca.com/media-centre/press-releases/2018/bevespi-aerosphere-approved-in-the-eu-for-chronic-obstructive-pulmonary-disease-20122018.html 2021-10-22T15:42:37.182Z https://www.astrazeneca.com/media-centre/press-releases/2017.html 2017-05-30T20:30:41.086Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-pieris-pharmaceuticals-collaborate-to-develop-and-commercialise-anticalin-based-inhaled-treatments-for-respiratory-diseases-03052017.html 2017-05-03T05:31:31.251Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities-17012017.html 2017-01-26T14:47:40.196Z https://www.astrazeneca.com/media-centre/press-releases/2017/symbicort-granted-paediatric-exclusivity-in-the-us-26012017.html 2017-01-26T10:12:39.603Z https://www.astrazeneca.com/media-centre/press-releases/2017/full-year-and-q4-2016-results-02022017.html 2018-07-05T13:09:10.856Z https://www.astrazeneca.com/media-centre/press-releases/2017/Siliq-brodalumab-approved-by-the-US-FDA-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-160220170.html 2017-02-16T12:06:07.300Z https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutated-metastatic-breast-cancer-17022017.html 2017-02-17T06:53:58.246Z https://www.astrazeneca.com/media-centre/press-releases/2017/updated-durvalumab-monotherapy-data-confirm-results-in-urothelial-bladder-cancer-17022017.html 2017-02-17T17:23:06.562Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-tersera-therapeutics-for-zoladex-in-the-us-and-canada-20022017.html 2017-03-21T10:34:17.144Z https://www.astrazeneca.com/media-centre/press-releases/2017/zs-9-sodium-zirconium-cyclosilicate-receives-positive-chmp-opinion-for-the-treatment-of-hyperkalaemia-24022017.html 2017-02-24T12:50:26.828Z https://www.astrazeneca.com/media-centre/press-releases/2017/fda-approves-once-daily-qtern-dapagliflozin-and-saxagliptin-tablets-for-adults-with-type-2-diabetes-240217.html 2017-02-28T06:40:45.511Z https://www.astrazeneca.com/media-centre/press-releases/2017/medimmune-and-sanofi-pasteur-form-alliance-to-develop-and-commercialise-potential-next-generation-respiratory-syncytial-virus-antibody-medi8897-030317.html 2017-03-03T06:57:12.544Z https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-phase-iii-solo-2-data-demonstrate-progression-free-survival-benefit-in-brca-mutated-ovarian-cancer-as-maintenance-therapy-14032017.html 2017-03-14T18:10:09.196Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-receives-complete-response-letter-from-us-fda-for-zs-sodium-zirconium-cyclosilicate-for-hyperkalaemia-17032017.html 2017-03-17T07:08:09.857Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-circassia-enter-strategic-collaboration-in-respiratory-disease-17032017.html 2017-03-17T07:28:05.690Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-s-cvd-real-study-shows-sglt-2-inhibitors-significant-reduced-death-and-hospitalisations-for-heart-failure-versus-other-type-2-diabetes-medicines-19032017.html 2017-03-20T06:20:19.010Z https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-approved-in-china-as-first-in-class-treatment-for-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer-27032017.html 2017-03-27T05:49:39.829Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-share-its-robust-early-science-in-oncology-with-the-medical-community-at-aacr-28032017.html 2017-03-28T05:21:24.217Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazenecas-potential-medicine-for-neuromyelitis-optica-spectrum-disorder-receives-orphan-designation-in-europe-29032017.html 2017-03-31T05:14:50.251Z https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-osimertinib-receives-us-fda-full-approval-31032017.html 2017-03-31T05:36:39.526Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-marks-a-key-milestone-with-the-topping-out-of-new-global-r-and-d-centre-and-hq-in-cambridge-uk-25042017.html 2017-04-25T12:46:29.260Z https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-receives-full-approval-in-the-eu-25042017.html 2017-04-25T12:36:16.314Z https://www.astrazeneca.com/media-centre/press-releases/2017/q1-2017-results.html 2017-05-02T12:15:24.070Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazenecas-imfinzi-durvalumab-receives-us-fda-accelerated-approval-for-previously-treated-patients-with-advanced-bladder-cancer-01052017.html 2017-05-08T09:36:46.641Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-on-stratos-1-phase-iii-trial-of-tralokinumab-in-severe-uncontrolled-asthma-100517.html 2017-05-10T11:40:11.286Z https://www.astrazeneca.com/media-centre/press-releases/2017/imfinzi-significantly-reduces-the-risk-of-disease-worsening-or-death-in-the-phase-iii-pacific-trial-for-stage-iii-unresectable-lung-cancer-12052017.html 2021-10-22T15:39:48.054Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-scientific-advancements-from-growing-respiratory-portfolio-at-the-american-thoracic-society-conference-2017-18052017.html 2017-05-18T07:15:49.656Z https://www.astrazeneca.com/media-centre/press-releases/2017/brodalumab-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-moderate-to-severe-plaque-psoriasis-19052017.html 2017-05-19T12:57:23.937Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-recordati-for-seloken-in-europe-22052017.html 2017-05-22T06:36:49.962Z https://www.astrazeneca.com/media-centre/press-releases/2017/phase-iii-zonda-trial-for-benralizumab-shows-ability-to-reduce-oral-steroid-use-in-severe-asthma-patients-22052017.html 2017-05-22T18:44:40.502Z https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html 2017-05-23T06:05:03.053Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-delivers-new-data-on-expanding-portfolio-of-cancer-medicines-at-2017-american-society-of-clinical-oncology-(asco)-annual-meeting-26052017.html 2017-07-06T12:56:48.548Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-appoints-professor-nazneen-rahman-to-its-board-of-directors-and-science-committee-31052017.html 2017-05-31T05:29:38.254Z https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-significantly-reduces-the-risk-of-disease-worsening-or-death-in-patients-with-BRCA-mutated-metastatic-breast-cancer-04062017.html 2017-06-04T20:36:26.317Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html 2017-06-07T12:03:13.932Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-scientific-advances-in-cardiovascular-and-metabolic-diseases-at-2017-ada-scientific-sessions-08062017.html 2017-06-08T05:36:08.741Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-new-data-underpinning-safety-profile-and-real-world-cv-outcomes-of-farxiga-at-ada-2017-12062017.html 2017-06-12T05:29:08.925Z https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-fulvestrant-receives-positive-chmp-opinion-for-use-in-1st-line-hormone-receptor-positive-advanced-breast-cancer-23062017.html 2017-06-23T12:18:52.189Z https://www.astrazeneca.com/media-centre/press-releases/2017/kyntheum-approved-in-the-eu-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis-20072017.html 2017-07-20T16:08:05.358Z https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-eu-approval-as-first-line-therapy-for-advanced-breast-cancer-26072017.html 2017-07-26T16:43:28.704Z https://www.astrazeneca.com/media-centre/press-releases/2017/h1-2017-results.html 2017-08-01T14:03:37.641Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-merck-establish-strategic-oncology-collaboration-27072017.html 2017-07-27T07:11:01.617Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html 2021-10-22T15:40:52.162Z https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-significantly-improves-progression-free-survival-in-the-phase-iii-flaura-trial-for-lung-cancer-27072017.html 2017-07-27T07:16:13.408Z https://www.astrazeneca.com/media-centre/press-releases/2017/imfinzi-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer-31072017.html 2021-10-22T15:41:41.418Z https://www.astrazeneca.com/media-centre/press-releases/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-01082017.html 2017-08-01T06:02:24.592Z https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-acalabrutinib-and-grants-priority-review-02082017.html 2017-08-02T06:04:22.752Z https://www.astrazeneca.com/media-centre/press-releases/2017/lynparza-receives-additional-and-broad-approval-in-the-us-for-ovarian-cancer-17082017.html 2017-08-17T19:38:25.677Z https://www.astrazeneca.com/media-centre/press-releases/2017/extended-treatment-with-brilinta-reduces-risk-of-cardiovascular-death-by-29-percent-in-patients-with-history-of-heart-attack-24082017.html 2017-08-24T06:08:34.500Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-takeda-establish-collaboration-to-develop-and-commercialise-medi1341-for-parkinsons-disease-25082017.html 2017-08-27T20:03:16.984Z https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer.html 2017-08-27T20:14:25.567Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-highlights-latest-advances-in-lung-cancer-at-the-esmo-2017-congress-31082017.html 2017-08-31T08:14:42.645Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-present-data-on-next-generation-of-biologics-at-european-respiratory-society-international-congress-04092017.html 2017-09-04T05:35:03.895Z https://www.astrazeneca.com/media-centre/press-releases/2017/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma-06092017.html 2017-09-06T20:46:07.674Z https://www.astrazeneca.com/media-centre/press-releases/2017/duaklir-significantly-improves-lung-function-in-copd-patients-07092017.html 2017-09-07T05:54:56.617Z https://www.astrazeneca.com/media-centre/press-releases/2017/celgene-and-astrazeneca-provide-update-on-the-fusion-clinical-trial-programme-07092017.html 2017-09-07T11:58:18.645Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-tagrisso-shows-potential-as-a-new-standard-of-care-in-1st-line-egfr-mutated-lung-cancer-at-esmo-2017-congress-08092017.html 2017-09-08T21:45:09.126Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html 2017-09-09T14:45:23.444Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-new-results-identifying-severe-asthma-patients-who-would-benefit-most-from-benralizumab-11092017.html 2017-09-11T05:46:34.971Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-aspen-enter-agreement-for-remaining-rights-to-anaesthetics-medicines14092017.html 2017-09-14T05:13:15.761Z https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-demonstrates-favourable-cardiovascular-cv-safety-profile-and-fewer-cv-events-in-patients-with-type-2-diabetes-at-wide-range-of-cv-risk14092017.html 2017-09-14T16:27:16.660Z https://www.astrazeneca.com/media-centre/press-releases/2017/bevespi-aerosphere-demonstrates-statistically-significant-improvement-in-lung-function-in-patients-with-copd-25092017.html 2017-09-25T06:00:53.117Z https://www.astrazeneca.com/media-centre/press-releases/2017/the-european-medicines-agency-accepts-marketing-authorisation-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-09102017.html 2017-10-09T05:20:06.911Z https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-the-1st-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-09102017.html 2017-10-09T05:40:07.849Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-shares-its-comprehensive-scientific-approach-at-the-world-conference-on-lung-cancer-2017-16102017.html 2017-10-16T05:53:58.209Z https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-171017.html 2017-10-17T05:35:56.834Z https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-lynparza-in-metastatic-breast-cancer-and-grants-priority-review-18102017.html 2017-10-18T05:56:14.471Z https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-231017.html 2017-10-23T05:21:09.010Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-msd-rapidly-advance-lynparza-in-japan-with-a-second-regulatory-submission-231017.html 2017-10-23T06:10:33.578Z https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html 2017-10-31T17:25:53.479Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-incyte-enter-clinical-trial-collaboration-in-early-lung-cancer-31102017.html 2017-10-31T07:28:04.679Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-on-tralokinumab-phase-iii-programme-in-severe-uncontrolled-asthma-01112017.html 2017-11-01T06:43:33.635Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-shares-scientific-updates-from-its-extensive-cardiovascular-renal-and-metabolic-diseases-cvmd-portfolio-at-aha-2017-08112017.html 2017-11-07T19:50:30.563Z https://www.astrazeneca.com/media-centre/press-releases/2017/year-to-date-and-q3-2017-results.html 2017-11-13T13:07:46.608Z https://www.astrazeneca.com/media-centre/press-releases/2017/benralizumab-receives-positive-eu-chmp-opinion-for-severe-uncontrolled-eosinophilic-asthma-10112017.html 2022-03-04T10:36:08.423Z https://www.astrazeneca.com/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html 2017-11-14T23:14:46.133Z https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-for-the-treatment-of-advanced-breast-cancer-in-combination-with-abemaciclib-15112017.html 2017-11-15T06:27:52.979Z https://www.astrazeneca.com/media-centre/press-releases/2017/the-european-medicines-agency-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-24112017.html 2017-11-28T06:06:50.359Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-chinese-future-industry-investment-fund-establish-joint-venture-to-develop-new-medicines-in-china-27112017.html 2017-11-27T06:50:34.415Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-makes-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-in-japan-27112017.html 2017-11-27T06:31:12.310Z https://www.astrazeneca.com/media-centre/press-releases/2017/tudorza-reduces-exacerbations-and-demonstrates-cardiovascular-safety-in-copd-patients-041217.html 2017-12-03T21:47:29.824Z https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-to-highlight-its-commitment-to-blood-cancers-at-the-2017-american-society-of-hematology-annual-meeting-06122017.html 2017-12-06T06:11:19.215Z https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-18122017.html 2017-12-18T07:12:49.366Z https://www.astrazeneca.com/media-centre/press-releases/2016.html 2016-11-22T17:01:57.829Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-head-and-neck-cancer-trials-27102016.html 2017-01-13T15:03:23.012Z https://www.astrazeneca.com/media-centre/press-releases/2016/q3-2016-results.html 2018-07-05T11:50:11.958Z https://www.astrazeneca.com/media-centre/press-releases/2016/fda-accepts-for-review-new-drug-application-for-sodium-zirconium-18102016.html 2017-01-13T15:14:20.554Z https://www.astrazeneca.com/media-centre/press-releases/2016/lynparza-phase-iii-solo-2-trial-shows-significant-progression-free-survival-benefit-261020161.html 2017-01-13T15:14:36.328Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-acquisition-of-takedas-respiratory-business.html 2017-01-13T15:14:49.529Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin-diseases-01072016.html 2017-01-13T15:15:02.939Z https://www.astrazeneca.com/media-centre/press-releases/2016/Tagrisso-met-primary-endpoint-in-phase-III-2nd-line-lung-cancer-trial-18072016.html 2021-10-22T15:38:00.832Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-receives-approval-in-the-EU-for-Qtern-saxagliptin-and-dapagliflozin-for-treatment-of-Type-2-diabetes.html 2017-01-13T15:15:29.146Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZenecas-antibiotic-Zavicefta-met-primary-endpoints-in-Phase-III-trial-for-treatment-of-hospital-acquired-pneumonia-21072016.html 2017-01-13T15:15:44.953Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-files-first-clinical-trial-application-in-Moderna-messenger-RNA-collaboration-26072016.html 2017-01-13T15:15:59.540Z https://www.astrazeneca.com/media-centre/press-releases/2016/h1-2016-results.html 2018-07-05T11:55:12.058Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-provides-update-on-Phase-III-trial-of-Selumetinib-in-non-small-cell-lung-cancer-09082016.html 2017-01-13T15:16:29.002Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-and-lilly-receive-fda-fast-track-designation-for-azd3293-as-potential-treatment-for-early-alzheimers-disease-22082016.html 2017-01-13T15:16:44.473Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-to-sell-small-molecule-antibiotics-business-to-Pfizer-24082016.html 2021-10-26T09:34:33.846Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-to-present-new-data-highlighting-its-growing-respiratory-portfolio-ERS-30082016.html 2017-01-13T15:17:24.404Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-completes-commercialisation-agreement-with-Aspen-for-anaesthetics-portfolio-01092016.html 2017-01-13T15:17:58.782Z https://www.astrazeneca.com/media-centre/press-releases/2016/benralizumub-phase-III-trials-show-positive-results-in-severe-asthma-05092016.html 2017-01-13T15:18:13.339Z https://www.astrazeneca.com/media-centre/press-releases/2016/pepfar-and-astrazeneca-launch-partnership-across-hiv-and-hypertension-services-in-africa-080920161.html 2017-01-13T15:18:27.625Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-two-new-phase-IIIb-trials-for-Forxiga-in-chronic-kidney-disease-and-chronic-heart-failure-120920161.html 2017-01-13T15:18:42.470Z https://www.astrazeneca.com/media-centre/press-releases/2016/phase-III-combination-trial-of-bydureon-and-forxiga-shows-significant-benefits-in-patients-with-type-2-diabetes-1609201611.html 2017-01-13T15:18:56.662Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-update-on-cediranib-eu-marketing-authorisation-application-21092016.html 2017-01-13T15:19:11.904Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-presents-new-data-on-Faslodex-in-breast-cancer-and-provides-immuno-oncology-update-at-ESMO-2016-congress-30092016.html 2017-01-13T15:19:30.729Z https://www.astrazeneca.com/media-centre/press-releases/2016/medimmune-out-licenses-potential-medicine-for-inflammatory-diseases-to-allergan-03102016.html 2017-01-13T15:19:54.093Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-results-from-the-brilinta-euclid-trial-in-patients-with-peripheral-artery-disease-04102016.html 2017-01-13T15:20:17.191Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-agreement-with-aralez-for-beta-blocker-medicine-in-the-us-04102016.html 2017-01-13T15:20:38.108Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-agreement-with-cilag-gmbh-international-to-divest-rights-to-rhinocort-aqua-outside-the-us-071020161.html 2017-01-13T15:20:56.394Z https://www.astrazeneca.com/media-centre/press-releases/2016/MedImmune-completes-out-licensing-agreement-with-Allergan-for-MEDI2070-17112016.html 2017-01-13T15:21:12.026Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Moderna-Therapeutics-announce-new-collaboration-to-co-develop-and-co-commercialise-immuno-oncology-mRNA-therapeutics-11012016.html 2017-01-13T15:21:28.239Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-and-incyte-announce-new-lung-cancer-clinical-trial-collaboration-11012016.html 2017-01-13T15:22:36.102Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-partners-with-peers-and-academia-to-establish-translational-research-fund.html 2017-01-13T15:22:52.687Z https://www.astrazeneca.com/media-centre/press-releases/2016/Lynparza-Olaparib-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-BRCA1-2-or-ATM-gene-mutated-metastatic-Castration-Resistant-Prostate-Cancer-28012016.html 2017-01-13T15:23:10.653Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-transaction-for-majority-equity-stake-investment-in-acerta-pharma-01022016.html 2017-01-13T15:23:29.237Z https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-osimertinib-approved-in-eu-as-first-in-class-treatment-for-lung-cancer-03022016.html 2017-01-13T15:23:48.978Z https://www.astrazeneca.com/media-centre/press-releases/2016/full-year-and-q4-2015-results-04022016.html 2018-07-05T13:12:00.178Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Medimmune-enter-consortium-to-deliver-new-treatments-for-chronic-kidney-disease-11022016.html 2017-01-13T15:24:26.184Z https://www.astrazeneca.com/media-centre/press-releases/2016/Durvalumab-granted-Breakthrough-Therapy-designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.html 2017-01-13T15:24:43.419Z https://www.astrazeneca.com/media-centre/press-releases/2016/zurampic-lesinurad-approved-in-the-european-union-for-patients-with-gout-19022016.html 2017-01-13T15:25:03.001Z https://www.astrazeneca.com/media-centre/press-releases/2016/Brilique-ticagrelor-approved-in-EU-for-extended-treatment-of-patients-with-history-of-heart-attack-19022016.html 2017-01-13T15:25:18.277Z https://www.astrazeneca.com/media-centre/press-releases/2016/acalabrutinib-recommended-for-orphan-drug-designation-in-europe-for-three-indications-25022016.html 2017-01-13T15:25:35.697Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-enters-licensing-agreement-with-China-Medical-System-Holdings-for-hypertension-medicine-29022016.html 2017-01-13T15:25:51.337Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html 2017-01-13T15:26:19.482Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-into-agreement-with-prostrakan-for-rights-to-moventig-in-europe-03012016.html 2017-01-13T15:26:37.699Z https://www.astrazeneca.com/media-centre/press-releases/2016/Medimmune-receives-fast-track-designation-in-the-US-for-MEDI8852-for-treatment-of-patients-hospitalised-with-influenza-A-07032016.html 2017-01-13T15:26:54.499Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazenecas-potential-medicine-for-neuromyelitis-optica-receives-fda-orphan-drug-designation-09032016.html 2017-01-13T15:27:11.189Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-results-from-the-brilinta-socrates-trial-in-stroke-23032016.html 2017-01-13T15:27:38.302Z https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-approved-in-japan-for-patients-with-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer-29032016.html 2017-01-13T15:28:08.763Z https://www.astrazeneca.com/media-centre/press-releases/2016/brilinta-preferred-over-clopidogrel-in-updated-american-college-of-cardiology-and-american-heart-association-guideline-in-acute-coronary-syndrome-31032016.html 2017-01-13T15:28:33.767Z https://www.astrazeneca.com/media-centre/press-releases/2016/pandemic-influenza-vaccine-receives-positive-chmp-opinion-01042016.html 2017-01-13T15:29:19.477Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-to-showcase-clinical-and-scientific-leadership-in-lung-cancer-at-ELCC-2016-06042016.html 2017-01-13T15:29:36.560Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Eli-Lilly-and-company-announce-continuation-of-pivotal-clinical-trial-for-people-with-early-alzheimers-disease-08042016.html 2017-01-13T15:29:54.788Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-showcases-breadth-of-oncology-portfolio-at-aacr-2016-annual-meeting-14042016.html 2017-01-13T15:30:14.856Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-launches-integrated-genomics-approach-to-transform-drug-discovery-and-development-22042016.html 2017-01-13T15:30:42.708Z https://www.astrazeneca.com/media-centre/press-releases/2016/bevespi-aerosphere-approved-by-the-us-fda-for-patients-with-copd-25042016.html 2021-09-29T08:23:44.114Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-into-us-licensing-agreement-with-ironwood-pharmaceuticals-for-lesinurad-26042016.html 2017-01-13T15:31:18.061Z https://www.astrazeneca.com/media-centre/press-releases/2016/q1-2016-results.html 2017-01-13T15:31:42.691Z https://www.astrazeneca.com/media-centre/press-releases/2016/positive-chmp-opinion-for-caz-avi-in-the-eu-for-serious-bacterial-infections-29042016.html 2017-01-13T15:32:11.137Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-divestment-of-imdur-to-china-medical-system-holdings-03052016.html 2017-01-13T15:32:31.586Z https://www.astrazeneca.com/media-centre/press-releases/2016/selumetinib-granted-orphan-drug-designation-in-the-US-for-adjuvant-treatment-of-differentiated-thyroid-cancer-12052016.html 2017-01-13T15:33:06.526Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-to-highlight-the-breadth-of-its-respiratory-medicines-at-american-thoracic-society-2016-international-conference-12052016.html 2017-01-13T15:33:29.893Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-positive-results-from-benralizumab-phase-iii-programme-in-severe-asthma-17052016.html 2017-01-13T15:34:36.280Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-top-line-results-from-lynparza-gold-trial-in-advanced-gastric-cancer-1805206.html 2021-10-22T15:36:28.809Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-highlights-continued-progress-of-oncology-pipeline-at-asco-2016-19052016.html 2017-01-13T15:35:08.458Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazenecas-faslodex-met-primary-endpoint-in-first-line-treatment-of-advanced-breast-cancer.html 2017-01-13T15:35:26.436Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-receives-complete-response-letter-from-us-fda-for-sodium-zirconium-cyclosilicate-zs-9-for-oral-suspension-for-treatment-of-hyperkalaemia-27052016.html 2017-01-13T15:35:44.564Z https://www.astrazeneca.com/media-centre/press-releases/2016/positive-chmp-opinion-in-eu-for-saxa-dapa-for-adults-with-type-2-diabetes-27052016.html 2017-01-13T15:36:04.452Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-licenses-Zurampic-to-Grunenthal-GmbH-in-Europe-and-Latin-America-02062016.html 2017-01-13T15:36:20.308Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-us-licensing-agreement-with-ironwood-pharmaceuticals-for-lesinurad-03062016.html 2017-01-13T15:36:36.736Z https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Foundation-Medicine-enter-strategic-collaboration-for-Lynparza-companion-diagnostic-assay-04062016.html 2017-01-13T15:37:00.298Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-commercialisation-agreement-with-aspen-for-anaesthetic-medicines-portfolio-08062016.html 2017-01-13T15:38:02.861Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-update-on-flumist-quadrivalent-vaccine-in-the-us-for-the-2016-17-influenza-season-23062016.html 2017-01-13T15:38:26.811Z https://www.astrazeneca.com/media-centre/press-releases/2016/New-antibiotic-Zavicefta-approved-in-the-European-Union-for-patients-with-serious-bacterial-infections-28062016.html 2017-01-13T15:38:43.365Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-head-and-neck-cancer-trials-resume-new-patient-enrolment-as-fda-lifts-partial-clinical-hold-22112016.html 2017-01-13T15:39:01.542Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-takes-latest-scientific-advances-in-oncology-to-major-us-and-european-congresses29112016.html 2017-01-13T15:39:36.952Z https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-agreement-with-cilag-gmbh-international-for-rights-to-rhinocort-aqua-outside-the-us-05122016.html 2017-01-13T15:39:57.631Z https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-demonstrates-superiority-over-chemotherapy-in-egfr-t790m-mutation-positive-non-small-cell-lung-cancer-06122016.html 2021-10-26T09:35:42.913Z https://www.astrazeneca.com/media-centre/press-releases/2016/Astrazeneca-and-Lilly-to-develop-second-potentially-disease-modifying-treatment-for-alzheimers-disease-09122016.html 2017-01-13T15:40:35.984Z https://www.astrazeneca.com/media-centre/press-releases/2016/US-FDA-accepts-first-biologics-license-application-for-AstraZenecas-durvalumab-in-bladder-cancer-09122016.html 2017-01-13T15:40:58.617Z https://www.astrazeneca.com/media-centre/press-releases/2015.html 2016-11-22T17:01:47.383Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-archaeological-dig-cambridge-biomedical-campus-11062015.html 2023-03-21T22:47:12.387Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-pam-cheng-executive-vice-president-operations-16062015.html 2023-03-21T23:12:08.224Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-oncology-research-european-cancer-congress-2015-24092015.html 2023-03-21T23:08:35.750Z https://www.astrazeneca.com/media-centre/press-releases/2015/real-world-data-saxagliptin-sitagliptin-heart-failure-risk-08062015.html 2023-03-21T23:41:19.375Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-type-2-diabetes-triple-therapy-treatment-data-06062015.html 2023-03-21T23:25:36.546Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-diabetes-data-american-diabetes-association-scientific-sessions-03062015.html 2023-03-21T22:58:03.593Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-immuno-oncology-combinations-development-programme-asco-2015-02062015.html 2017-01-19T11:35:34.688Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-medimmune-positive-immuno-oncology-combination-data-asco-30052015.html 2023-03-21T23:07:23.431Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-lilly-immuno-oncology-clinical-trial-solid-tumours-29052015.html 2023-03-21T23:06:40.658Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-brodalumab-development-programme-psoriasis-arthritis-22052015.html 2023-03-21T22:49:45.266Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-biologics-manufacturing-sodertalje-sweden-18052015.html 2023-03-21T22:48:53.860Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-immuno-oncology-pipeline-combination-treatments-asco-2015-13052015.html 2023-03-21T23:04:15.303Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-abbott-companion-diagnostic-tests-tralokinumab-severe-asthma-13052015.html 2023-03-21T22:40:36.185Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-montreal-heart-institute-cardiovascular-diabetes-genetic-screening-13052015.html 2023-03-21T23:08:02.624Z https://www.astrazeneca.com/media-centre/press-releases/2015/us-fda-priority-review-brilinta-heart-attack-history-patients-29042015.html 2023-03-21T23:43:37.079Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-first-quarter-results-2015-24042015.html 2023-03-21T23:13:22.241Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-celgene-corporation-immuno-oncology-collaboration-blood-cancers-24042015.html 2023-03-21T22:50:40.186Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-innate-pharma-global-collaboration-immuno-oncology-24042015.html 2023-03-21T23:04:36.446Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-non-small-cell-lung-cancer-medicine-data-european-lung-cancer-congress-17042015.html 2023-03-21T23:08:20.597Z https://www.astrazeneca.com/media-centre/press-releases/2015/selumetinib-orphan-drug-designation-us-fda-uveal-melanoma-treatment-17042015.html 2023-03-21T23:41:35.118Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-immunocore-immuno-oncology-combination-trials-melanoma-16042015.html 2023-03-21T23:35:07.419Z https://www.astrazeneca.com/media-centre/press-releases/2015/tremelimumab-orphan-drug-designation-us-fda-malignant-mesothelioma-treatment-15042015.html 2023-03-21T23:42:22.790Z https://www.astrazeneca.com/media-centre/press-releases/2015/fda-advisory-committee-reviews-saxagliptin-type-2-diabetes-14042015.html 2023-03-21T23:33:07.366Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-patientslikeme-research-oncology-diabetes-lupus-respiratory-disease-13042015.html 2023-03-21T23:12:28.935Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-oncology-science-american-association-cancer-research-annual-meeting-2015-13042015.html 2023-03-21T23:09:05.137Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-genomics-england-consortium-26032015.html 2023-03-21T23:02:32.931Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-harvard-stem-cell-institute-diabetes-25032015.html 2023-03-21T23:03:16.666Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-daiichi-sankyo-commercialise-movantik-19032015.html 2023-03-21T22:56:48.421Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-pt003-results-chronic-obstructive-pulmonary-disease-18032015.html 2023-03-21T23:15:19.573Z https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-study-brilinta-long-term-treatment-reduces-cardiovascular-thrombotic-events-14032015.html 2023-03-21T23:40:46.728Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-us-fda-endocrinologic-metabolic-drugs-advisory-committee-04032015.html 2023-03-21T23:26:58.649Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-actavis-respiratory-portfolio-chronic-obstructive-pulmonary-disease-03032015.html 2023-03-21T22:45:35.565Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-board-annual-general-meeting-17022015.html 2023-03-21T22:49:10.795Z https://www.astrazeneca.com/media-centre/press-releases/2015/us-district-court-decision-pulmicort-respulses-patent-litigation-13022015.html 2023-03-21T23:42:36.573Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-actavis-aclidinium-respiratory-franchise-05022015.html 2023-03-21T22:43:30.338Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-fourth-quarter-full-year-results-2014-05022015.html 2023-03-21T23:13:41.622Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-research-development-centre-corporate-headquarters-cambridge-uk-04022015.html 2023-03-21T23:19:52.185Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-crispr-technology-genome-editing-29012015.html 2023-03-21T22:56:19.390Z https://www.astrazeneca.com/media-centre/press-releases/2015/lesinurad-gout-treatment-european-medicines-agency-22012015.html 2023-03-21T23:33:42.432Z https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-study-brilinta-reduction-cardiovascular-thrombotic-events-14012015.html 2023-03-21T23:41:03.969Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-omnis-pharmaceuticals-oncolytic-viruses-immuno-oncology-12012015.html 2023-03-21T23:39:10.175Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-daiichi-sankyo-flumist-influenza-vaccine-02092015.html 2023-03-21T22:57:46.961Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-valeant-pharmaceuticals-brodalumab-dermatology-psoriasis-01092015.html 2023-03-21T23:27:42.227Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-peregrine-pharmaceuticals-immuno-oncology-combination-clinical-trial-24082015.html 2023-03-21T23:12:55.465Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-mirati-therapeutics-immuno-oncology-combination-lung-cancer-05082015.html 2023-03-21T23:35:54.423Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-heptares-therapeutics-immuno-oncology-treatments-06082015.html 2023-03-21T23:03:33.964Z https://www.astrazeneca.com/media-centre/press-releases/2015/medimmune-inovio-pharmaceuticals-cancer-vaccine-10082015.html 2023-03-21T23:35:30.684Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-isis-pharmaceuticals-antisense-drugs-cardiovascular-metabolic-renal-diseases-03082015.html 2023-03-21T23:05:12.861Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-genzyme-rare-disease-medicine-caprelsa-27072015.html 2023-03-21T23:02:49.555Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-tillotts-pharma-entocort-gastroenterology-medicine-17072015.html 2023-03-21T23:24:09.490Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-kyowa-hakko-kirin-benralizumab-asthma-chronic-obstructive-pulmonary-disease-16072015.html 2023-03-21T23:05:52.951Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-tillotts-pharma-entocort-gastroenterology-09072015.html 2023-03-21T23:22:27.422Z https://www.astrazeneca.com/media-centre/press-releases/2015/iressa-fda-approved-non-small-cell-lung-cancer-treatment-13072015.html 2023-03-21T23:33:25.727Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-selumetinib-uveal-melanoma-oncology-22072015.html 2023-03-21T23:20:45.557Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-h1-results-2015-30072015.html 2023-03-21T23:14:11.098Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-dr-sean-bohen-chief-medical-officer-24082015.html 2023-03-21T22:58:38.021Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-cardiovascular-events-prevention-esc-congress-2015-29082015.html 2023-03-21T22:50:24.796Z https://www.astrazeneca.com/media-centre/press-releases/2015/pegasus-timi-54-brilinta-treatment-following-heart-attack-31082015.html 2023-03-21T23:40:16.533Z https://www.astrazeneca.com/media-centre/press-releases/2015/antibiotic-medicine-caz-avi-complicated-urinary-tract-infections-02092015.html 2023-03-21T22:39:36.206Z https://www.astrazeneca.com/media-centre/press-releases/2015/us-fda-approves-brilinta-long-term-use-heart-attack-history-patients-03092015.html 2023-03-21T23:43:22.416Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-lung-cancer-portfolio-world-conference-lung-cancer-2015-04092015.html 2023-03-21T23:06:56.937Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-manchester-clinical-oncology-bioinformatics-collaboration-08092015.html 2023-03-21T23:26:14.969Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-biologics-manufacturing-boulder-colorado-11092015.html 2023-03-21T22:47:51.284Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-diabetes-data-pre-clinical-research-easd-2015-11092015.html 2023-03-21T22:58:19.424Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-respiratory-disease-data-european-respiratory-society-international-congress-2015-22092015.html 2023-03-21T23:20:11.775Z https://www.astrazeneca.com/media-centre/press-releases/2015/new-england-journal-medicine-brodalumab-ustekinumab-psoriasis-30092015.html 2023-03-21T23:39:25.432Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-orca-pharmaceuticals-rory-inhibitors-auto-immune-diseases-treatment-25022015.html 2023-03-21T23:11:51.990Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-cambridge-judge-business-school-biotech-start-ups-03032015.html 2023-03-21T22:50:02.183Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-singapore-research-organisations-heart-failure-11032015.html 2023-03-21T23:21:20.519Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-scientific-review-board-clinical-trial-data-transparency-19032015.html 2023-03-21T23:20:30.540Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-bina-genomic-management-solution-21042015.html 2023-03-21T22:47:38.211Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-mene-pangalos-fellowship-academy-medical-sciences-11052015.html 2023-03-21T23:07:40.587Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-michigan-chronic-kidney-disease-treatments-17062015.html 2023-03-21T23:26:35.800Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-inserm-type-2-diabetes-chronic-kidney-disease-studies-17062015.html 2023-03-21T23:04:54.800Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-university-cambridge-phd-clinical-research-scholarships-30062015.html 2023-03-21T23:25:55.226Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-crowd-sourcing-challenge-combination-therapies-cancer-22092015.html 2023-03-21T22:56:32.686Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-receives-complete-response-letter-from-us-16102015.html 2023-03-21T23:15:36.511Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-opens-new-manufacturing-facility-to-support-continued20102015.html 2023-03-21T23:11:31.758Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-and-lilly-expand-immuno-oncology-research-collaborat-22102015.html 2023-03-21T22:46:01.573Z https://www.astrazeneca.com/media-centre/press-releases/2015/-fda-advisory-committee-recommends-the-approval-of-lesinurad-for-gout-patients-23102015.html 2018-07-25T10:50:37.046Z https://www.astrazeneca.com/media-centre/press-releases/2015/Year-To-Date-and-Q3-2015-Results-05112015.html 2023-03-21T23:43:54.440Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-strengthens-Cardiovascular-and-Metabolic-disease-portfolio-with-acquisition-of-ZS-Pharma-06112015.html 2023-03-21T23:22:12.730Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-presents-positive-new-data-on-anifrolumab-in-lupus-at-American-College-of-Rheumatology-Annual-Scientific-Meeting-10112015.html 2023-03-21T23:14:28.074Z https://www.astrazeneca.com/media-centre/press-releases/2015/TAGRISSO-AZD9291-approved-by-the-US-FDA-for-patients-with-EGFR-T790M-mutation-positive-metastatic-non-small-cell-lung-cancer-13112015.html 2023-03-21T23:41:50.928Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-expands-technological-investment-in-new-Cambridge-lead-discovery-centre-20112015.html 2018-03-05T09:21:00.970Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-and-Sanofi-exchange-over-200000-chemical-compounds-20112015.html 2023-03-21T22:46:21.154Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-enters-into-agreement-with-Perrigo-for-rights-to-Entocort-in-the-US.html 2023-03-21T23:00:28.347Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-and-Voluntis-to-test-companion-mobile-app-in-ovarian-cancer-studies-07122015.html 2023-03-21T22:46:41.708Z https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-stand-alone-company-small-molecule-early-stage-antibiotic-research-development-26022015.html 2023-03-21T23:21:38.992Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-presents-positive-pooled-analysis-demonstrating-the-effect-of-dapagliflozin-on-albuminuria-in-hypertensive-patients-with-type-2-diabetes-17092015.html 2023-03-21T23:14:55.575Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-announces-new-tolerability-long-term-efficacy-and-real-world-adherence-data-for-exenatide-once-weekly-in-patients-with-type-2-diabetes-15092015.html 2023-03-21T22:46:55.248Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-to-harness-power-of-the-Secretome-and-develop-next-generation-biologics-11122015.html 2023-03-21T23:24:32.566Z https://www.astrazeneca.com/media-centre/press-releases/2015/Discussions-with-Acerta-Pharma-BV-14122015.html 2023-03-21T23:29:49.893Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-completes-agreement-with-Perrigo-for-rights-to-Entocort-in-the-US-15122015.html 2023-03-21T22:52:39.641Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-continues-strategic-investment-in-China-to-accelerate-delivery-of-innovative-biologics-and-targeted-medicines-16122015.html 2023-03-21T22:53:09.280Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-to-strengthen-therapy-area-franchise-through-acquisition-of-Takedas-respiratory-business-16122015.html 2023-03-21T23:25:15.560Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-enhances-long-term-growth-through-Oncology-investment-in-Acerta-Pharma.html 2023-03-21T22:59:38.650Z https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-completes-acquisition-of-ZS-Pharma-17122015.html 2023-03-21T22:52:12.315Z https://www.astrazeneca.com/media-centre/press-releases/2015/Durvalumab-ATLANTIC-trial-supports-clinical-activity-and-AstraZenecas-overall-immuno-oncology-strategy.html 2023-03-21T23:32:27.085Z https://www.astrazeneca.com/media-centre/press-releases/2015/CHMP-issues-positive-opinion-on-lesinurad-for-Gout18122015.html 2023-03-21T23:28:31.215Z https://www.astrazeneca.com/media-centre/press-releases/2015/tagrisso-osimertinib--receives-positive-chmp-opinion-18122015.html 2023-03-21T23:42:06.060Z https://www.astrazeneca.com/media-centre/press-releases/2015/BRILIQUE-ticagrelor-receives-positive-European-Union-CHMP-opinion-for-extended-treatment-18122015.html 2023-03-21T23:28:03.651Z https://www.astrazeneca.com/media-centre/press-releases/2015/ZURAMPIC-lesinurad-approved-by-US-FDA-for-patients-with-gout-22122015.html 2017-01-13T09:55:30.336Z https://www.astrazeneca.com/media-centre/press-releases/2014.html 2016-11-22T17:01:35.567Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-immunocore-immunotherapy-novel-cancer-therapies-08012014.html 2017-01-18T17:21:54.831Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-bristol-myers-squibb-farxiga-us-fda-approval-08012014.html 2017-01-19T11:29:29.731Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-farxiga-treatment-type-2-diabetes-patients-13012014.html 2017-01-11T19:46:24.742Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazenca-scientific-leadership-growth-jp-morgan-healthcare-conference-14012014.html 2017-01-19T13:09:53.658Z https://www.astrazeneca.com/media-centre/press-releases/2014/xigduo-approved-european-union-type-2-diabetes-21012014.html 2017-01-19T13:55:44.186Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-aquisition-bristol-myers-squibb-global-diabetes-alliance-03022014.html 2017-01-19T12:06:15.929Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-fourth-quarter-full-year-results-2013-06022014.html 2017-07-06T12:56:48.481Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-myalept-lepti-deficiency-treatment-25022014.html 2017-01-19T13:55:27.260Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-bydureon-pen-treatment-type-2-diabetes-03032014.html 2017-01-11T19:46:46.158Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-alderley-park-site-cheshire-uk-sale-11032014.html 2017-01-19T11:51:43.674Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-non-executive-director-ann-cairns-20032014.html 2017-01-19T13:09:37.429Z https://www.astrazeneca.com/media-centre/press-releases/2014/forxiga-approval-japan-type-2-diabetes-treatment-24032014.html 2017-01-19T13:35:40.883Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-sumitomo-chemicals-astrazeneca-kk-japan-26032014.html 2017-01-19T12:05:42.665Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-early-drug-discovery-centre-cambridge-uk-31032014.html 2017-01-19T11:39:04.590Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-first-quarter-results-2014-24042014.html 2017-07-06T12:56:48.509Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-announcement-28042014.html 2017-01-19T13:52:37.493Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-proposal-announcement-02052014.html 2017-01-11T19:38:09.991Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-rejects-pfizer-proposal-02052014.html 2017-01-19T11:54:28.854Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-epanova-severe-hypertriglyceridaemia-treatment-06052014.html 2017-01-19T13:54:56.894Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-updated-strategy-value-for-shareholders-06052014.html 2017-01-19T12:08:59.358Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-immunotherapy-study-medi4736-lung-cancer-patients-08052014.html 2017-01-19T12:06:44.509Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-study-results-plaque-psoriasis-patients-09052014.html 2017-01-19T11:27:48.536Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-respiratory-data-ats-2014-international-conference-12052014.html 2017-01-19T12:07:35.589Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-medimmune-mavrilimumab-sifalimumab-studies-rheumatoid-arthritis-global-disease-12052014.html 2017-01-19T11:43:07.811Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-saxagliptin-dapagliflozin-combination-type-2-diabetes-patients-13052014.html 2017-01-19T11:51:11.464Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-updated-statement-regarding-pfizer-announcement-13052014.html 2017-01-11T19:38:33.633Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-incyte-immuno-oncology-combination-clinical-trial-14052014.html 2017-01-19T13:41:11.600Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-acceleration-asco-2014-14052014.html 2017-01-19T13:27:41.573Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-laboratory-molecular-biology-joint-research-fund-15052014.html 2017-01-19T11:39:29.904Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-late-stage-pipeline-acceleration-strategy-15052014.html 2017-01-19T13:30:17.355Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-rejects-pfizers-final-proposal-19052014.html 2017-01-19T12:05:26.895Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-clarification-regarding-pfizer-statement-20052014.html 2017-01-19T13:30:02.094Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-statement-regarding-pfizer-withdrawal-26052014.html 2017-01-11T19:38:41.791Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-olaparib-cediranib-combination-data-ovarian-cancer-treatment-31052014.html 2017-01-19T13:28:14.615Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-progress-asco-2014-03062014.html 2017-01-19T13:27:55.375Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-novel-antibiotic-azd0914-us-fda-fast-track-03062014.html 2017-01-19T13:28:29.392Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-diabetes-data-american-diabetes-association-scientific-sessions-11062014.html 2017-01-19T12:08:25.402Z https://www.astrazeneca.com/media-centre/press-releases/2014/brodalumab-treatment-psoriatic-arthritis-study-new-england-journal-medicine-11062014.html 2017-01-19T13:29:10.349Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-synairgen-sng001-novel-immuno-modulatory-therapy-asthma-12062014.html 2017-01-19T12:07:01.613Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-advisory-committee-movantik-cardiovascular-safety-12062014.html 2017-01-19T13:53:32.980Z https://www.astrazeneca.com/media-centre/press-releases/2014/fda-advisory-committee-olaparib-ovarian-cancer-treatment-25062014.html 2017-01-19T13:32:14.278Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-global-research-development-centre-corporate-headquarters-cambridge-uk-18072014.html 2017-01-19T13:10:09.488Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-and-advaxis-partner-on-immuno-oncology-combination-clinical-trial-22072014.html 2017-01-19T13:40:32.287Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-qiagen-lung-cancer-diagnostic-test-iressa-treatment-28072014.html 2017-01-19T11:40:10.253Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-roche-azd9291-companion-diagnostic-test-lung-cancer-28072014.html 2017-01-19T11:40:57.792Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-kyowa-hakko-kirin-immuno-oncology-clinical-study-30072014.html 2017-01-19T11:36:35.794Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-almirall-respiratory-disease-30072014.html 2017-01-19T13:59:16.009Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-second-quarter-half-year-results-2014-31072014.html 2018-07-05T13:26:52.063Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-lesinurad-xanthine-oxidase-results-gout-patients-13082014.html 2017-01-19T11:52:00.207Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-tralokinumab-treatment-severe-asthma-14082014.html 2017-01-19T13:59:32.161Z https://www.astrazeneca.com/media-centre/press-releases/2014/united-states-department-justice-closes-investigation-plato-clinical-trial-brilinta-19082014.html 2017-01-19T13:53:08.322Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-caz-avi-results-complicated-intra-abdominal-infections-19082014.html 2017-01-19T11:51:28.236Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-illumina-gene-sequencing-panel-companion-diagnostic-tests-oncology-21082014.html 2017-01-19T11:50:53.105Z https://www.astrazeneca.com/media-centre/press-releases/2014/brilinta-brilique-stemi-patients-cardiology-01092014.html 2017-01-19T13:45:05.417Z https://www.astrazeneca.com/media-centre/press-releases/2014/benralizumab-study-lancet-respiratory-medicine-08092014.html 2017-01-19T13:28:43.059Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-diabetes-research-2014-meeting-european-association-study-of-diabetes-10092014.html 2017-01-19T12:07:52.365Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-lilly-bace-inhibitor-azd3293-alzheimers-disease-16092014.html 2017-01-19T11:37:12.105Z https://www.astrazeneca.com/media-centre/press-releases/2014/fda-approved-movatnik-opioid-induced-constipation-chronic-non-cancer-pain-patients-16092014.html 2017-01-19T13:34:11.957Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-exenatide-study-results-byetta-type-2-diabetes-patients-19092014.html 2017-01-19T13:52:53.260Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-cancer-research-uk-cruk-media-alliance-laboratory-biologic-cancer-medicines-25092014.html 2017-01-19T13:38:22.309Z https://www.astrazeneca.com/media-centre/press-releases/2014/iressa-chmp-positive-opinion-blood-based-diagnostic-testing-european-label-26092014.html 2017-01-11T18:47:49.048Z https://www.astrazeneca.com/media-centre/press-releases/2014/moventig-naloxegol-chmp-positive-opinion-opioid-induced-constipation-treatment-26092014.html 2017-01-11T18:48:03.305Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-oncology-pipeline-progress-esmo-2014-congress-27092014.html 2017-01-19T12:07:17.761Z https://www.astrazeneca.com/media-centre/press-releases/2014/benralizumab-study-positive-results-severe-asthma-lancet-respiratory-medicine-09102014.html 2017-01-19T13:51:31.554Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-university-cambridge-partnership-16102014.html 2017-01-19T13:27:22.752Z https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-positive-chmp-opinion-ovarian-cancer-treatment-24102014.html 2017-01-19T13:36:50.610Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-xigduo-type-2-diabetes-patients-30102014.html 2017-01-19T13:55:12.029Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-healthy-heart-africa-programme-hypertension-28102014.html 2017-01-19T13:08:31.371Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-almirall-respiratory-disease-transaction-complete-03112014.html 2017-01-19T12:05:59.702Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-pharmacyclics-oncology-clinical-trial-collaborations-04112014.html 2017-01-19T11:39:48.739Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-pharmacyclics-janssen-immuno-oncology-combination-trials-haematological-cancers-04112014.html 2017-01-19T13:58:38.666Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-immuno-oncology-capabilities-definiens-04112014.html 2017-01-19T13:58:56.994Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-myalept-aegerion-leptin-deficiency-06112014.html 2021-10-22T15:31:49.317Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-plc-third-quarter-nine-months-results-2014-06112014.html 2017-07-06T12:56:48.482Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-inflammation-autoimmunity-pipeline-data-american-college-rheumatology-2014-annual-meeting-11112014.html 2017-01-19T12:08:08.648Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-study-positive-results-plaque-psoriasis-patients-11112014.html 2017-01-19T11:28:24.400Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-isis-pharmaceuticals-oligonucleotide-oncology-cardiovascular-metabolic-diseases-13112014.html 2017-01-19T11:31:49.709Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-brilinta-development-programme-cardiovascular-13112014.html 2017-01-19T11:42:27.681Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-strategy-update-institutional-investors-financial-analysts-18112014.html 2017-01-19T13:10:43.747Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-successful-pricing-euro-medium-term-notes-19112014.html 2017-01-19T13:08:16.661Z https://www.astrazeneca.com/media-centre/press-releases/2014/duaklir-genuiar-approved-european-union-chronic-obstructive-pulmonary-disease-24112014.html 2017-01-19T13:30:30.843Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-brodalumab-final-study-positive-results-plaque-psoriasis-25112014.html 2017-01-19T11:28:41.731Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-definiens-aquisition-tissue-phenomics-26112014.html 2017-01-19T13:42:16.793Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-eli-lilly-clinical-trial-early-alzheimers-disease-patients-01122014.html 2017-01-19T11:30:13.348Z https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-accept-new-drug-application-iressa-lung-cancer-02122014.html 2017-01-19T13:49:38.721Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-nexium-antitrust-litigation-jury-verdict-05122014.html 2017-01-19T13:35:55.715Z https://www.astrazeneca.com/media-centre/press-releases/2014/moventig-approved-european-union-opioid-induced-constipation-09122014.html 2017-01-19T13:43:46.260Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-amgen-amagine-1-results-brodalumab-plaque-psoriasis-11122014.html 2017-01-19T11:29:10.972Z https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-approved-european-union-brca-mutated-ovarian-cancer-treatment-18122014.html 2017-01-19T13:38:02.395Z https://www.astrazeneca.com/media-centre/press-releases/2014/lynparza-approved-us-fda-brca-mutated-ovarian-cancer-treatment-19122014.html 2017-01-19T13:37:07.439Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-max-planck-institute-satellite-chemistry-unit-cardiovascular-metabolic-diseases-08072014.html 2017-01-19T11:38:08.165Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mitsubishi-tanabe-pharma-corporation-diabetic-nephropathy-20082014.html 2017-01-19T11:38:42.563Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-scientists-cancer-research-uk-cambridge-institute-17022014.html 2017-01-19T13:10:29.310Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-shanghai-institutes-biological-sciences-cardiovascular-metabolic-diseases-research-23012014.html 2017-01-19T11:41:17.922Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-korea-health-industry-development-institute-oncology-research-programme-06032014.html 2021-10-22T15:30:40.421Z https://www.astrazeneca.com/media-centre/press-releases/2014/new-open-innovation-platform-compound-bank-partnering-programmes-25032014.html 2021-10-22T15:32:58.406Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-shenzhen-university-health-science-center-chronic-kidney-disease-27032014.html 2017-01-19T11:41:43.020Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-tianjin-medical-university-cardiovascular-research-china-15052014.html 2017-01-19T11:42:01.762Z https://www.astrazeneca.com/media-centre/press-releases/2014/nobel-laureate-tim-hunt-nobel-prize-inspiration-initiative-astrazeneca-china-03062014.html 2017-01-19T13:50:31.742Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-addc-novel-drug-development-academic-research-community-17062014.html 2017-01-18T15:31:50.233Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-mrc-technology-novel-targets-discovery-research-03072014.html 2017-01-19T13:44:12.725Z https://www.astrazeneca.com/media-centre/press-releases/2014/pharma-companies-astrazeneca-virtual-library-pharmaceutical-compounds-22072014.html 2017-01-19T13:52:19.040Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-redx-pharma-genetic-drivers-tumour-growth-research-03092014.html 2017-01-19T11:40:32.597Z https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-fda-medi3902-nosocomial-pneumonia-prevention-23092014.html 2017-01-19T13:43:06.590Z https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-cancer-research-uk-new-cancer-medicine-screening-mrc-uk-centre-lead-discovery-28112014.html 2017-01-19T13:57:34.794Z https://www.astrazeneca.com/media-centre/press-releases/2013.html 2024-08-22T11:10:10.304Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-shionogi-crestor-licence-agreement26122013.html 2023-03-17T21:02:39.639Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-global-diabetes-alliance-assets-19122013.html 2017-01-19T09:58:09.323Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-statement-esomeprazole-strontium-product-launch-17122013.html 2023-03-17T21:02:55.614Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-lesinurad-study-results-gout-patients-13122013.html 2023-03-17T20:51:52.040Z https://www.astrazeneca.com/media-centre/press-releases/2013/fda-advisory-committee-recommends-dapagliflozin-type-2-diabetes-treatment-12122013.html 2023-03-17T21:05:56.442Z https://www.astrazeneca.com/media-centre/press-releases/2013/fda-advisory-committee-metreleptin-lipodystrophy-treatment-12122013.html 2023-03-17T21:05:23.744Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-brixham-environmental-laboratory-plymouth-university-09122013.html 2023-03-17T20:49:20.206Z https://www.astrazeneca.com/media-centre/press-releases/2013/fluenz-tetra-european-commission-approval-seasonal-influenza-prevention-children-06122013.html 2023-03-17T21:07:54.997Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-prilosec-patent-litigation-ruling-03122013.html 2023-03-17T21:00:08.874Z https://www.astrazeneca.com/media-centre/press-releases/2013/xigduo-chmp-positive-opinion-european-union-type-2-diabetes-treatment-22112013.html 2023-03-17T21:16:54.826Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centre-corporate-headquarters-cambridge-uk-herzog-meuron-architect-19112013.html 2023-03-17T21:00:27.369Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-fda-new-drug-application-naloxegol-opioid-induced-constipation-treatment-19112013.html 2023-03-17T21:16:24.565Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-manufacturing-facility-macclesfield-zoladex-prostate-cancer-treatment-11112013.html 2023-03-17T20:52:08.961Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-third-quarter-nine-months-results-2013-31102013.html 2017-01-19T10:04:57.827Z https://www.astrazeneca.com/media-centre/press-releases/2013/marc-dunoyer-new-chief-financial-officer-astrazeneca-31102013.html 2023-03-17T21:08:41.235Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-pulmicort-respules-patent-litigation-decision-30102013.html 2023-03-17T21:14:08.575Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-benralizumab-severe-asthma-treatment-30102013.html 2023-03-17T20:53:03.672Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-brixham-environmental-laboratory-closing-24102013.html 2023-03-17T20:48:51.962Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-selumetinib-non-small-cell-lung-cancer-treatment-22102013.html 2023-03-17T21:01:19.165Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oncology-medimmune-spirogen-acquisition-15102013.html 2023-03-17T20:55:47.852Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-janssen-japan-prostate-cancer-treatment-11102013.html 2023-03-17T20:51:16.950Z https://www.astrazeneca.com/media-centre/press-releases/2013/medimmune-amplimmune-aquisition-07102013.html 2023-03-17T21:09:07.245Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-lifts-temporary-injunction-hanmi-505b2-nda-esomeprazole-strontium-02102013.html 2023-03-17T21:13:47.607Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-alderley-park-biohub-research-development-centre-01102013.html 2023-03-17T20:46:21.685Z https://www.astrazeneca.com/media-centre/press-releases/2013/olaparib-european-medicines-agency-brca-mutated-ovarian-cancer-treatment-27092013.html 2023-03-17T21:10:53.194Z https://www.astrazeneca.com/media-centre/press-releases/2013/naloxegol-european-medicines-agency-opioid-induced-constipation-treatment-27092013.html 2023-03-17T21:10:00.955Z https://www.astrazeneca.com/media-centre/press-releases/2013/onglyza-hypoglycemia-pancreatitis-subanalyses-savor-cardiovascular-trial-outcomes-easd-26092013.html 2023-03-17T21:11:22.637Z https://www.astrazeneca.com/media-centre/press-releases/2013/dapagliflozin-hba1c-type-2-diabetes-patients-metformin-sulfonylurea-24092013.html 2023-03-17T21:04:57.383Z https://www.astrazeneca.com/media-centre/press-releases/2013/fluenz-tetra-nasal-spray-vaccine-eu-chmp-positive-opinion-seasonal-influenza-prevention-children-20092013.html 2023-03-17T21:08:23.861Z https://www.astrazeneca.com/media-centre/press-releases/2013/fda-new-drug-application-epanova-severe-hypertriglyceridaemia-treatment-18092013.html 2023-03-17T21:06:30.733Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-temporary-injunction-hanmi-505b2-nda-esomeprazole-strontium-13092013.html 2023-03-17T21:14:25.674Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-merck-wee1-kinase-inhibitor-therapy-cancer-11092013.html 2023-03-17T20:54:08.672Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-olaparib-clinical-programme-brca-mutated-ovarian-cancer-treatment-04092013.html 2023-03-17T20:55:11.838Z https://www.astrazeneca.com/media-centre/press-releases/2013/onglyza-saxagliptin-safety-cardiovascular-heart-attack-stroke-02092013.html 2023-03-17T21:13:28.779Z https://www.astrazeneca.com/media-centre/press-releases/2013/medimmune-immune-mediated-cancer-therapy-amplimmune-26082013.html 2023-03-17T21:09:43Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-second-quarter-half-year-results-2013-01082013.html 2017-01-19T10:14:28.144Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-fibrogen-fg4592-anaemia-treatment-chronic-kidney-disease-renal-disease-31072013.html 2023-03-17T20:50:13.400Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-fda-new-drug-application-dapagliflozin-type-2-diabetes-treatment-25072013.html 2023-03-17T21:16:04.734Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-dapagliflozin-type-2-diabetes-treatment-25072013.html 2023-03-17T20:47:12.449Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-chief-financial-officer-simon-lowth-15072013.html 2017-01-19T10:16:17.992Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-university-cambridge-cancer-research-09072013.html 2023-03-17T21:03:11.595Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-pearl-therapeutics-acquisition-28062013.html 2023-03-17T20:59:23.801Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-savor-timi-53-results-onglyza-cardiovascular-trial-outcomes-19062013.html 2023-03-17T20:48:10.708Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-new-global-research-development-centre-corporate-headquarters-cambridge-uk-18062013.html 2023-03-17T20:54:55.680Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-ngm-biopharamaceuticals-diabetes-obesity-therapies-17062013.html 2023-03-17T20:53:51.447Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-pearl-therapeutics-respiratory-disease-10062013.html 2023-03-17T20:59:38.337Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oskira-trials-fostamatinib-results-04062013.html 2023-03-17T20:57:47.872Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-hanmi-pharmaceuticals-amneal-pharmaceuticals-us-nexium-patent-litigation-03062013.html 2023-03-17T20:51:00.264Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-omthera-pharmaceuticals-dyslipidemia-treatment-cardiovascular-28052013.html 2023-03-17T20:55:23.804Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-appeals-court-temporary-injunction-pulmicort-respules-25052013.html 2023-03-17T21:14:43.646Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-accelerated-oncology-pipeline-2013-asco-annual-meeting-16052013.html 2023-03-17T20:46:03.405Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-alderley-park-cheshire-future-29042013.html 2023-03-17T20:46:39.443Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-first-quarter-results-2013-25042013.html 2017-01-19T10:24:56.404Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bind-therapeutics-cancer-nanomedicine-accurin-22042013.html 2023-03-17T20:46:55.603Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-oskira-1-study-results-fostamatinib-rheumatoid-arthritis-05042013.html 2023-03-17T20:56:01.633Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-medimmune-alphacore-pharma-biologics-03042013.html 2023-03-17T20:52:47.286Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-district-court-pulmicort-respules-patent-invalid-02042013.html 2023-03-17T21:15:46.016Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-crestor-patent-litigation-settled-25032013.html 2023-03-17T20:49:50.036Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-marc-dunoyer-executive-vice-president-global-portfolio-product-strategy-21032013.html 2023-03-17T20:52:31.029Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-growth-scientific-leadership-strategy-21032013.html 2017-01-19T10:27:56.421Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-karolinska-institutet-research-centre-cardiovascular-metabolic-disease-regnerative-medicine-21032013.html 2023-03-17T20:51:31.071Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-moderna-therapeutics-cardiometabolic-diseases-cancer-treatment-21032013.html 2023-03-17T20:54:24.603Z https://www.astrazeneca.com/media-centre/press-releases/2013/copd-medicines-pathos-study-journal-internal-medicine-19032013.html 2023-03-17T21:04:35Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centres-innovation-pipeline-18032013.html 2023-03-17T21:01:03.863Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centre-global-headquarters-cambridge-18032013.html 2023-03-17T21:00:48.754Z https://www.astrazeneca.com/media-centre/press-releases/2013/australia-federal-court-crestor-patents-05032013.html 2023-03-17T21:04:16.738Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-naloxegol-long-term-safety-opioid-induced-constipation-patients-26022013.html 2023-03-17T20:54:43.476Z https://www.astrazeneca.com/media-centre/press-releases/2013/us-court-appeals-seroquel-patent-descision-15022013.html 2023-03-17T21:15:06.680Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-plc-fourth-quarter-full-year-results-2012-31012013.html 2023-03-17T20:59:53.479Z https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-senior-executive-team-15012013.html 2023-03-17T21:01:33.305Z https://www.astrazeneca.com/media-centre/press-releases/2012.html 2016-11-22T17:02:18.764Z https://www.astrazeneca.com/media-centre/press-releases/2012/astrazeneca-reaffirms-december-2011-financial-guidance-for-2011-.html 2023-03-16T22:38:54.669Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-IMS-Health-announce-real-world-evidence-collaboration-in-Europe-11012015.html 2023-03-16T22:27:28.215Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-receive-complete-response-letter-from-US-Food-and-Drug-Administration-for-dapagliflozin-19012012.html 2023-03-16T22:27:10.775Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Fourth-quarter-and-full-year-results-2011-02022012.html 2023-03-16T22:37:26.870Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZenecas-new-restructuring-initiatives-to-drive-productivity-and-support-innovation-02022012.html 2023-03-16T22:40:19.155Z https://www.astrazeneca.com/media-centre/press-releases/2012/European-Commission-approves-CAPRELSA-vandetanib-for-patients-with-advanced-medullary-thyroid-cancer-21022012.html 2023-03-16T22:44:15.534Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-Non-Executive-changes-retirement-of-Chairman-and-appointment-of-successor-01032012.html 2023-03-16T22:35:30.766Z https://www.astrazeneca.com/media-centre/press-releases/2012/FDA-approves-first-four-strain-flu-vaccine-01032012.html 2023-03-16T22:44:45.245Z https://www.astrazeneca.com/media-centre/press-releases/2012/FDA-responds-AstraZeneca-Citizen-Petitions-quetiapine-product-labelling-09032012.html 2023-03-16T22:44:59.460Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-files-against-the-fda-for-decision-on-quetiapine-13032012.html 2023-03-16T22:36:42.459Z https://www.astrazeneca.com/media-centre/press-releases/2012/Remaining-TC-5214-Phase-III-efficacy-studies-do-not-meet-endpoint-regulatory-filing-will-not-be-pursued-20032012.html 2023-03-16T22:47:01.665Z https://www.astrazeneca.com/media-centre/press-releases/2012/UK-court-finds-SEROQUEL-XR-formulation-patent-invalid-22032012.html 2023-03-16T22:47:16.180Z https://www.astrazeneca.com/media-centre/press-releases/2012/US-court-denies-preliminary-injunction-application-against-the-FDA-and-dismisses-AstraZenecas-lawsuit-without-prejudice-26032012.html 2023-03-16T22:47:31.922Z https://www.astrazeneca.com/media-centre/press-releases/2012/US-District-Court-finds-SEROQUEL-XR-formulation-patent-valid-and-infringed-30032012.html 2023-03-16T22:47:46.374Z https://www.astrazeneca.com/media-centre/press-releases/2012/astrazeneca-and-amgen-announce-collaboration-02042012.html 2023-03-16T22:26:29.796Z https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-type-2-diabetes-20042012.html 2023-03-16T22:45:15.604Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-to-acquire-Ardea-Biosciences-for-1-billion-23042012.html 2023-03-16T22:40:06.108Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-The-Medicines-Company-announce-global-collaboration-in-acute-ischaemic-heart-disease-25042012.html 2023-03-16T22:34:57.109Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-First-quarter-results-2012-26042012.html 2023-03-16T22:37:13.621Z https://www.astrazeneca.com/media-centre/press-releases/2012/David-Brennan-to-retire-as-AstraZenecas-Chief-Executive-Officer-26042012.html 2017-01-13T08:38:45.397Z https://www.astrazeneca.com/media-centre/press-releases/2012/Innovative-public-private-collaboration-launches-to-tackle-antibiotic-research-24052012.html 2023-03-16T22:45:51.391Z https://www.astrazeneca.com/media-centre/press-releases/2012/Investigational-compound-dapagliflozin-demonstrated-significant-reductions-in-blood-sugarlevels-09062012.html 2023-03-16T22:46:30.152Z https://www.astrazeneca.com/media-centre/press-releases/2012/Zinforo-ceftaroline-fosamil-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-patients-with-serious-skin-infections-or-community-acquired-pneumonia-22062012.html 2023-03-16T22:48:01.745Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Merck-agree-to-amend-second-option-27062012.html 2023-03-16T22:34:20.190Z https://www.astrazeneca.com/media-centre/press-releases/2012/Bristol-Myers-Squibb-and-AstraZeneca-expand-diabetes-alliance-30062012.html 2023-03-16T22:40:42.975Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-completes-sale-of-Aptium-Oncology-assets-06072012.html 2023-03-16T22:36:28.266Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-reports-terms-of-David-Brennans-retirement-16072012.html 2023-03-16T22:39:29.942Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Second-quarter-and-half-year-results-2012-26072012.html 2023-03-16T22:37:40.044Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-complete-expansion-of-diabetes-alliance-through-Bristol-Myers-Squibbs-acquisition-of-Amylin-Pharmaceuticals-09082012.html 2023-03-16T22:26:55.894Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Pfizer-enter-agreement-for-over-the-counter-NEXIUM-AstraZeneca-raises-2012-guidance-13082012.html 2023-03-16T22:34:35.228Z https://www.astrazeneca.com/media-centre/press-releases/2012/Pascal-Soriot-appointed-Chief-Executive-Officer-of-AstraZeneca-28082012.html 2023-03-16T22:46:46.688Z https://www.astrazeneca.com/media-centre/press-releases/2012/European-Commission-approves-ZINFORO-ceftaroline-fosamil-for-adult-patients-with-serious-skin-infections-or-community-acquired-pneumonia-28082012.html 2023-03-16T22:44:30.626Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-prices-a-2-billion-bond-issue-12092012.html 2023-03-16T22:38:38.803Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-suspends-share-repurchase-programme-01102012.html 2023-03-16T22:39:42.979Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Ardelyx-announce-worldwide-licensing-deal-for-NHE3-inhibitor-programme-for-complications-of-renal-disease-including-diabetes-induced-renal-disease-08102012.html 2023-03-16T22:26:42.253Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Ironwood-announce-Linaclotide-collaboration-23102012.html 2023-03-16T22:27:40.571Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-PLC-Third-quarter-and-nine-months-results-2012-25102012.html 2023-03-16T22:38:26.584Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-details-of-Chief-Executive-Officer-Pascal-Soriot-remuneration-29102012.html 2023-03-16T22:35:12.004Z https://www.astrazeneca.com/media-centre/press-releases/2012/Alzheimers-cancer-and-rare-disease-research-to-benefit-from-landmark-MRC-AstraZeneca-compound-collaboration-31102012.html 2023-03-16T22:26:10.637Z https://www.astrazeneca.com/media-centre/press-releases/2012/Definition-of-Core-Financial-Measures-12112012.html 2023-03-16T22:43:58.158Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-top-line-phase-III-results-from-naloxegol-pivotal-trials-in-patients-with-opioid-induced-constipation-12112012.html 2023-03-16T22:35:45.768Z https://www.astrazeneca.com/media-centre/press-releases/2012/Court-in-Germany-finds-SEROQUEL-XR-formulation-patent-invalid-13112012.html 2017-01-13T08:35:54.975Z https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-now-approved-in-European-Union-for-treatment-of-type-2-diabetes-14112012.html 2023-03-16T22:45:33.133Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Isis-Pharmaceuticals-form-strategic-alliance-on-RNA-therapeutics-for-cancer-11122012.html 2023-03-16T22:27:53.833Z https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-announces-top-line-results-of-OSKIRA-4-Phase-IIb-study-of-fostamatinib-as-a-monotherapy-for-rheumatoid-arthritis-13122012.html 2023-03-16T22:36:13.527Z https://www.astrazeneca.com/media-centre/press-releases/2012/CRESTOR-US-patent-upheld-by-Court-of-Appeals-for-the-Federal-Circuit-14122012.html 2023-03-16T22:41:07.267Z https://www.astrazeneca.com/media-centre/press-releases/2011.html 2016-11-22T17:02:28.272Z https://www.astrazeneca.com/media-centre/press-releases/2011/us-food-and-drug-administration-extend-review-timeline-for-vand-07012011.html 2017-01-19T13:43:19.199Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-replies-to-the-us-fda-complete-response-letter-for-b-21012011.html 2017-01-19T13:43:36.405Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-plc-fourth-quarter-and-full-year-results-2010-27012011.html 2017-01-19T13:43:48.556Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-approves-nasal-spray-vaccine-Fluenz-for-flu-01022011.html 2017-01-19T13:43:59.966Z https://www.astrazeneca.com/media-centre/press-releases/2011/US-FDA-Assigns-new-PDUFA-date-for-BRILINTA-ticagrelor-tablets-04022011.html 2017-01-19T13:44:18.030Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-halts-phase-iii-trial-of-zibotentan-in-non-metastatic-castrate-resistant-07022011.html 2017-01-19T13:44:37.026Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-and-targacept-initiate-phase-iib-clinical-trial-of-tc-5214-07022011.html 2017-01-19T13:44:53.007Z https://www.astrazeneca.com/media-centre/press-releases/2011/onglyza_-us-label-update-provides-further-evidence-regarding-use-23022011.html 2017-01-19T13:45:07.790Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-to-discontinue-production-of-pulmicort--pmdi--other-07032011.html 2017-01-19T13:45:20.758Z https://www.astrazeneca.com/media-centre/press-releases/2011/Onglyza-is-first-DPP4-Inhibitor-for-Type-2-Diabetes-04032011.html 2017-01-19T13:45:35.264Z https://www.astrazeneca.com/media-centre/press-releases/2011/-fda-accepts-new-drug-application-for-investigational-compound-08032011.html 2017-01-19T13:45:49.337Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-initiates-phase-iii-clinical-programme-evaluating-nk-15032011.html 2017-01-19T13:46:03.053Z https://www.astrazeneca.com/media-centre/press-releases/2011/uk-and-us-governments-reach-agreement-over-astrazeneca-tax-matte-28032011.html 2017-01-19T13:46:17.832Z https://www.astrazeneca.com/media-centre/press-releases/2011/fda-approves-orphan-drug-vandetanib-07042011.html 2017-01-19T13:48:59.815Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-PLC-First-Quarter-Results-2011-28042011.html 2017-07-06T12:56:48.499Z https://www.astrazeneca.com/media-centre/press-releases/2011/health-economics-substudy-of-plato-shows-brilique-to-be-cost-effective-09052011.html 2017-01-19T13:49:27.463Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-signs-agreement-in-japan-with-daiichi-sankyo-to-co-promote-24052011.html 2017-01-19T13:49:40.355Z https://www.astrazeneca.com/media-centre/press-releases/2011/health-canada-approves-brilinta--ticagrelor-tablets-01062011.html 2021-10-22T15:25:34.087Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-extends-its-investment-in-russia-with-new-predictive-science-centre-16062011.html 2017-01-19T13:50:08.174Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-sell-AstraTech-to-DENTSPLY-International-22062011.html 2017-01-19T13:50:21.849Z https://www.astrazeneca.com/media-centre/press-releases/2011/Bristol-Myers-Squibb-and-AstraZeneca-ph3-study-on-DAPAGLIFLOZIN-27062011.html 2017-01-19T13:50:37.816Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-s-nexium-receives-first-regulatory-approval-in-japan-01072011.html 2017-01-19T13:51:08.153Z https://www.astrazeneca.com/media-centre/press-releases/2011/fda-advisory-committee-makes-recommendation-on-investigational-compound-20072011.html 2017-01-19T13:51:20.664Z https://www.astrazeneca.com/media-centre/press-releases/2011/fda-approves-new-medicine-brilinta--ticagrelor--for-use-in-the-us-20072011.html 2017-01-19T13:51:34.492Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-plc-second-quarter-and-half-year-results-2011-28072011.html 2017-01-19T13:51:47.625Z https://www.astrazeneca.com/media-centre/press-releases/2011/positive-agreement-received-for-approval-of-axanum-in-europe-02082011.html 2017-01-19T13:52:01.383Z https://www.astrazeneca.com/media-centre/press-releases/2011/sale-of-astra-tech-to-dentsply-international-complete-31082011.html 2017-01-19T13:52:14.033Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-announces-top-line-results-from-saturn-study-020920111.html 2017-01-19T13:52:26.794Z https://www.astrazeneca.com/media-centre/press-releases/2011/astrazeneca-announces-top-line-results-from-saturn-study-02092011.html 2017-01-19T13:52:52.336Z https://www.astrazeneca.com/media-centre/press-releases/2011/KOMBOGLYZE-saxagliptin-and-metformin-HCl-immediate-release-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-type-2-diabetes-23092011.html 2017-01-19T13:53:06.560Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-announces-first-approval-of-FASLODEX-fulvestrant-in-Japan-26092011.html 2017-01-19T13:59:10.874Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-enters-into-a-settlement-agreement-with-Handa-Pharmaceuticals-regarding-US-SEROQUEL-XR-patent-litigation-29092011.html 2017-01-19T13:58:56.224Z https://www.astrazeneca.com/media-centre/press-releases/2011/BRILIQUE-receives-a-positive-preliminary-medical-benefit-assessment-for-the-majority-of-ACS-patients-in-Germany-as-part-of-new-AMNOG-review-process-04102011.html 2017-01-19T13:58:40.729Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-enters-into-a-settlement-agreement-with-Accord-Healthcare-Inc-and-Intas-Pharmaceuticals-Ltd-regarding-US-SEROQUEL-XR-patent-litigation-05102011.html 2017-01-19T13:58:25.720Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-increases-investment-in-China-with-new-200-million-manufacturing-facility-10102011.html 2017-01-19T13:57:15.656Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-and-Forest-Laboratories-to-initiate-phase-III-clinical-trials-for-ceftazidime-avibactam-to-treat-serious-Gram-negative-bacterial-infections-18102011.html 2017-01-19T13:57:01.312Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-present-new-healthcare-economics-data-demonstrating-cost-effectiveness-of-BRILIQUE-at-ISPOR-EU-21102011.html 2017-07-06T12:56:48.526Z https://www.astrazeneca.com/media-centre/press-releases/2011/US-Food-and-Drug-Administration-extends-action-date-for-dapagliflozin-by-three-months-26102011.html 2017-01-19T13:56:34.470Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-PLC-Third-quarter-and-nine-months-results-2011-27102011.html 2017-07-06T12:56:48.487Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-and-Targacept-announce-first-top-line-Phase-III-results-for-TC-5214-as-an-adjunct-treatment-in-patients-with-major-depressive-disorder-08112011.html 2017-01-19T13:56:07.306Z https://www.astrazeneca.com/media-centre/press-releases/2011/SATURN-demonstrated-effect-of-intensive-statin-treatment-on-reducing-atherosclerosis-15112011.html 2017-01-19T13:55:54.432Z https://www.astrazeneca.com/media-centre/press-releases/2011/CAPRELSA-vandetanib-receives-positive-CHMP-opinion-in-the-European-Union-for-treating-advanced-medullary-thyroid-cancer-18112011.html 2017-01-19T13:55:39.622Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-commits-100-million-MedImmune-Ventures-28112011.html 2017-01-19T13:55:27.075Z https://www.astrazeneca.com/media-centre/press-releases/2011/KOMBOGLYZE-receives-marketing-authorisation-in-the-European-Union-for-adult-patients-with-Type-2-diabetes-29112011.html 2017-01-19T13:55:13.566Z https://www.astrazeneca.com/media-centre/press-releases/2011/Groundbreaking-scientific-collaboration-gives-UK-academia-access-to-compounds-to-advance-medical-research-05122011.html 2017-01-19T13:55:00.834Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-streamline-US-sales-organisation-07122011.html 2017-01-19T13:54:47.537Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-to-acquire-generics-company-to-broaden-patient-access-to-medicines-in-China-08122011.html 2017-01-19T13:54:32.784Z https://www.astrazeneca.com/media-centre/press-releases/2011/G-BA-issues-positive-final-medical-benefit-assessment-for-BRILIQUE-in-Germany-15122011.html 2017-01-19T13:54:20.312Z https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-updates-on-olaparib-and-TC-5214-development-programmes-20122010.html 2017-01-19T13:54:07.467Z https://www.astrazeneca.com/media-centre/press-releases/2010.html 2016-11-22T17:02:41.616Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-Agreements-With-Teva-Pharmaceuticals-Regarding-Nexium-And-Prilosec-US-Patent-Litigations-07012010.html 2017-01-19T12:52:13.821Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-Fourth-Quarter-and-Full-Year-Results-2009-28012010.html 2017-07-06T12:56:48.529Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Approves-New-Indication-for-Crestor-Rosuvastatin-Calcium-09022010.html 2017-01-19T12:52:43.366Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Rigel-Pharmaceuticals-Sign-Worldwide-License-Agreement-for-Late-Stage-Development-Product-Fostamatinib-Disodium-R788-for-the-Treatment-of-Rheumatoid-Arthritis-16022010.html 2017-01-19T12:53:08.092Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-Agreement-With-UK-Tax-Authorities-Over-Transfer-Pricing-23022010.html 2017-01-19T12:54:44.161Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Provides-An-Update-On-The-Status-Of-Its-Arrangements-With-Merck-01032010.html 2017-01-19T12:54:57.308Z https://www.astrazeneca.com/media-centre/press-releases/2010/RECENTIN-did-not-meet-primary-endpoint-in-Horizon-III-study-in-metastatic-colorectal-cancer-08032010.html 2017-01-19T12:55:10.372Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Comments-On-FDA-Joint-Advisory-Committee-Meeting-On-Post-Marketing-Safety-Studies-For-The-Use-Of-LABAs-In-Asthma-11032010.html 2017-01-19T12:55:30.783Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Extends-Branded-Generics-Capability-With-Torrent-Agreement-11032010.html 2017-01-19T12:55:45.502Z https://www.astrazeneca.com/media-centre/press-releases/2010/New-PLATO-Sub-Analysis-of-CABG-Patients-Presented-at-ACC-16032010.html 2017-01-19T12:56:01.401Z https://www.astrazeneca.com/media-centre/press-releases/2010/Jury-Rules-In-Favour-Of-AstraZeneca-In-First-US-Seroquel-Product-Liability-Trial-18032010.html 2017-01-19T12:56:17.032Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Abbott-receive-FDA-complete-response-letter-on-CERTRIAD-new-drug-application-30032010.html 2017-01-19T12:56:29.736Z https://www.astrazeneca.com/media-centre/press-releases/2010/Seroquel-XR-Recommended-For-Approval-In-EU-as-an-Add-On-Treatment-Of-Major-Depressive-Disorder-23042010.html 2017-01-19T12:56:49.347Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Finalises-US-Agreement-On-SEROQUEL-Marketing-27042010.html 2017-01-19T12:57:05.003Z https://www.astrazeneca.com/media-centre/press-releases/2010/Crestor-Gains-New-EU-Indication-to-Prevent-Major-Cardiovascular-Events-in-High-Risk-Patients-27042010.html 2017-01-19T12:57:21.544Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-First-Quarter-Results-2010-29042010.html 2017-07-06T12:56:48.525Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-approved-VIMOVO-for-arthritis-patients-at-risk-of-developing-NSAID-associated-gastric-ulcers-30042010.html 2017-01-19T12:57:53.133Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Reaches-US-Agreement-With-Teva-Pharmaceuticals-Regarding-Entocort-EC-Capsules-18052010.html 2017-01-19T12:58:08.143Z https://www.astrazeneca.com/media-centre/press-releases/2010/Martin-Mackay-to-Lead-AstraZenecas-Research-and-Development-Organisation-26052010.html 2017-01-19T12:58:23.561Z https://www.astrazeneca.com/media-centre/press-releases/2010/NOTICE-Advisory-Committee-Briefing-Materials-for-Motavizumab-BLA-Available-on-US-FDA-Web-Site-28052010.html 2017-01-19T12:58:36.872Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Announces-Results-of-Recentin-HORIZON-II-Phase-III-Trial-in-Metastatic-Colorectal-Cancer-28052010.html 2017-01-19T12:58:52.256Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Receives-FDA-Complete-Response-Letter-for-AXANUM-New-Drug-Application-01062010.html 2017-01-19T12:59:07.817Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-updates-US-product-labels-for-LABA-containing-medications-including-AstraZenecas-SYMBICORT-02062010.html 2017-01-19T12:59:23.855Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Advisory-Committee-Reviews-MedImmunes-Motavizumab-02062010.html 2017-01-19T12:59:41.734Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Submits-Marketing-Authorisation-Application-To-European-Union-For-Cardiovascular-Drug-Axanum-04062010.html 2017-01-19T12:59:58.957Z https://www.astrazeneca.com/media-centre/press-releases/2010/Federal-Court-of-Canada-Rules-on-Applications-for-Generic-Esomep-17062010.html 2017-01-19T13:00:12.978Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-Targacept-Initiate-Phase-3-Clinical-Development-23062010.html 2017-01-19T13:00:27.065Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Resets-its-Decision-Date-For-Motavizumab-25062010.html 2017-01-19T13:00:40.096Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-MMV-Join-Efforts-in-the-Fight-Against-Malaria-28072010.html 2017-01-19T13:00:55.887Z https://www.astrazeneca.com/media-centre/press-releases/2010/CRESTOR-Patent-Upheld-By-US-Court-30072010.html 2017-01-19T13:28:55.736Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-and-MRC-Technology-Form-Strategic-Alliance-05072010.html 2017-01-19T13:29:25.541Z https://www.astrazeneca.com/media-centre/press-releases/2010/Advisory-Committee-Briefing-Materials-For-Brilinta-Ticagrelor-26072010.html 2017-01-19T13:29:58.044Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-Appoints-New-NonExecutive-Director-29072010.html 2021-09-29T08:26:46.608Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Second-Quarter-and-Half-Year-Results-2010-29072010.html 2017-07-06T12:56:48.479Z https://www.astrazeneca.com/media-centre/press-releases/2010/FDA-Advisory-Committee-recommends-US-FDA-approval-of-Brilinta-29072010.html 2017-01-19T13:27:45.611Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Announces-Agreements-in-Principle-in-Seroquel-09082010.html 2017-01-19T13:25:27.517Z https://www.astrazeneca.com/media-centre/press-releases/2010/Genetic-substudy-shows-fewer-major-cardiovascular-events-with-ticagrelor-brilinta-29082010.html 2017-01-19T13:24:40.573Z https://www.astrazeneca.com/media-centre/press-releases/2010/MedImmune-receives-complete-response-letter-on-motavizumab-30082010.html 2017-01-19T13:24:19.792Z https://www.astrazeneca.com/media-centre/press-releases/2010/European-Commission-Issues-Positive-Decision-for-Approval-of-Seroquel-XR-as-an-Add-On-Treatment-of-Major-Depressive-Disorder-02092010.html 2017-01-19T13:23:59.354Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Extends-Review-Timeline-For-BRILINTA-15092010.html 2017-01-19T13:23:40.974Z https://www.astrazeneca.com/media-centre/press-releases/2010/24-Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-Improved-Glycosylated-Hemoglobin-HbA1c-When-Added-to-Glimepiride-in-Adults-with-Type-2-Diabetes-Mellitus-20092010.html 2017-01-19T13:23:12.736Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-and-EU-regulatory-submissions-for-VANDETANIB-in-advanced-medullary-thyroid-cancer-23092010.html 2017-01-19T13:22:44.348Z https://www.astrazeneca.com/media-centre/press-releases/2010/52Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-24092010.html 2017-01-19T13:21:27.696Z https://www.astrazeneca.com/media-centre/press-releases/2010/BRILIQUE-ticagrelor-receives-positive-opinion-from-European-CHMP-for-the-treatment-of-Acute-Coronary-Syndromes-24092010.html 2017-01-19T13:21:14.142Z https://www.astrazeneca.com/media-centre/press-releases/2010/Results-of-Zibotentan-Phase-III-trial-in-castration-resistant-prostate-cancer-27092010.html 2017-01-19T13:21:01.106Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-initiates-phase-III-clinical-development-of-fostamatinib-29092010.html 2017-01-19T13:18:48.115Z https://www.astrazeneca.com/media-centre/press-releases/2010/New-outcomes-study-for-ticagrelor-BRILINTA-01102010.html 2017-01-19T13:18:32.911Z https://www.astrazeneca.com/media-centre/press-releases/2010/Positive-agreement-received-for-approval-of-VIMOVO-in-Europe-11102010.html 2017-01-19T13:18:18.847Z https://www.astrazeneca.com/media-centre/press-releases/2010/European-regulator-backs-nasal-spray-vaccine-FLUENZ-22102010.html 2017-01-19T13:10:58.735Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-initiates-phase-IIB-study-for-AZD9773-CytoFab-25102010.html 2017-01-19T13:10:44.197Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-Third-Quarter-and-Nine-Months-Results-2010-28102010.html 2017-07-06T12:56:48.516Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-announces-copromotion-agreement-with-Daiichi-Sankyo-29102010.html 2017-01-19T13:10:11.073Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-Appeal-Court-affirms-preliminary-injunction-against-Apotex-02112010.html 2017-01-19T13:09:59.017Z https://www.astrazeneca.com/media-centre/press-releases/2010/KOMBIGLYZE-XR-tablets-approved-in-the-US-05112010.html 2017-01-19T13:09:47.180Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-commences-review-of-strategic-options-for-Astra-Tech-19112010.html 2017-01-19T13:09:04.154Z https://www.astrazeneca.com/media-centre/press-releases/2010/US-FDA-Advisory-Committee-Makes-Recommendation-on-New-Drug-Application-for-Vandetanib-in-Advanced-Medullary-Thyroid-Cancer-02122010.html 2017-01-19T13:08:50.269Z https://www.astrazeneca.com/media-centre/press-releases/2010/Public-believe-China-and-India-set-to-become-World-leaders-for-innovation-survey-shows-06122010.html 2017-01-19T13:08:36.739Z https://www.astrazeneca.com/media-centre/press-releases/2010/European-Commission-Approves-Brilique-06122010.html 2017-01-19T13:07:01.797Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-PLC-appoints-new-Non-Executive-Director-17122010.html 2017-01-19T13:06:40.787Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-receives-complete-response-letter-from-US-FDA-for-BRILINTA-ticagrelor-tablets-17122010.html 2017-01-19T13:06:27.908Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-discontinues-motavizumab-RSV-21122010.html 2017-01-19T13:06:15.632Z https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-ends-agreement-with-Abbott-for-Certriad-22122010.html 2017-01-19T13:06:00.758Z https://www.astrazeneca.com/media-centre/press-releases/2009.html 2016-11-22T17:02:50.568Z https://www.astrazeneca.com/media-centre/press-releases/2009/MedImmune-Submits-Marketing-Authorisation-Application-06012009.html 2017-01-19T09:59:08.785Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Fourth-Quarter-and-Full-Year-Results-2008-29012009.html 2017-07-06T12:56:48.509Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZenecas-Partner-POZEN-Informed-By-FDA-That-Gastric-Ulcers-Are-Valid-29062009.html 2017-01-19T10:00:03.058Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZenecas-partner-MAP-pharmaceuticals-Announces-24022009.html 2017-01-19T10:00:15.135Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-To-Participate-In-Tentative-FDA-Psychopharmacologic-Drugs-25022009.html 2017-01-19T10:01:00.451Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Board-Change-27022009.html 2017-01-19T10:01:13.399Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Receives-FDA-Complete-Response-Letter-On-Seroquel-27022009.html 2017-01-19T10:01:36.766Z https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Approves-Symbicort-for-Chronic-Obstructive-Pulmon-02032009.html 2017-01-19T10:01:48.957Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Issues-2008-Annual-Report-04032009.html 2017-01-19T10:02:01.629Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-to-Participate-in-Tentative-FDA-Psychopharmacologic-Drugs-Advisory-Committee-30032009.html 2017-01-19T10:02:16.036Z https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-Saxagliptin-Cardiovascular-Profile-Acceptable-02042009.html 2017-01-19T10:02:45.015Z https://www.astrazeneca.com/media-centre/press-releases/2009/David-Brennan-elected-board-chairman-of-the-Pharmaceutical-03042009.html 2017-01-19T10:02:59.290Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Receives-FDA-Complete-Response-Letter-on-Symbicort-06042009.html 2017-01-19T10:03:15.491Z https://www.astrazeneca.com/media-centre/press-releases/2009/Sale-of-AstraZeneca-OTC-Product-Portfolio-Cleared-06042009.html 2017-01-19T10:03:32.899Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Files-Suit-Against-Apotex-for-a-Declaratory-Judgment-07042009.html 2021-09-29T08:24:57.705Z https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Advisory-Committee-Recommendation-on-Seroquel-XR-09042009.html 2017-01-19T10:03:58.044Z https://www.astrazeneca.com/media-centre/press-releases/2009/Court-Grants-AstraZeneca-Temporary-Restraining-Order-17042009.html 2017-01-19T10:04:15.648Z https://www.astrazeneca.com/media-centre/press-releases/2009/IRESSA-Gefitinib-Recommended-for-Approval-23042009.html 2021-09-29T08:25:47.108Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-Food-and-Drug-Administration-Extends-Review-Timeline-23042009.html 2017-01-19T10:04:44.032Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-First-Quarter-Results-2009-23042009.html 2017-07-06T12:56:48.550Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Announces-Top-Line-Results-From-Pivotal-11052009.html 2017-01-19T10:06:12.492Z https://www.astrazeneca.com/media-centre/press-releases/2009/Court-Grants-AstraZeneca-Preliminary-Injunction-Again-20052009.html 2017-01-19T10:06:46.170Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Regulatory-Update-on-Seroquel-XR-29052009.html 2017-01-19T10:07:12.750Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Merck-and-Co-Inc-Form-Pioneering-Collaboration-01062009.html 2017-01-19T10:07:26.423Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Abbott-Submit-New-Drug-Application-04062009.html 2017-01-19T10:07:39.917Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Abbott-Extend-Relationship-to-Include-04062009.html 2017-01-19T10:07:52.903Z https://www.astrazeneca.com/media-centre/press-releases/2009/Favourable-Vote-from-FDA-Advisory-Committee-on-Seroquel-10062009.html 2017-01-19T10:08:14.039Z https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-saxagliptin-Receives-Positive-Opinion-in-Europe-25062009.html 2017-01-19T10:08:30.795Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Development-Partner-Pozen-Inc-Submits-New-Drugs-30062009.html 2017-01-19T10:08:57.640Z https://www.astrazeneca.com/media-centre/press-releases/2009/IRESSA-Gefitinib-Receives-Marketing-Authorisation-01072009.html 2017-01-19T10:09:13.587Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-to-Advance-AZD3480-in-ADHD-08072009.html 2017-01-19T10:11:45.641Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Terminates-License-Agreement-with-MAP-09072009.html 2017-01-19T10:15:54.500Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Second-Quarter-and-Half-Year-Results-2009-30072009.html 2017-07-06T12:56:48.489Z https://www.astrazeneca.com/media-centre/press-releases/2009/FDA-Approves-ONGLYZA-For-The-Treatment-Of-Type-2-Diabetes-01082009.html 2017-01-19T10:22:10.255Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-And-Astellas-Enter-Agreement-for-CoPromo-04082009.html 2017-01-19T10:22:40.874Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Forest-Laboratories-to-CoDevelop-and-Commercialise-12082009.html 2017-01-19T10:23:06.594Z https://www.astrazeneca.com/media-centre/press-releases/2009/Phase-III-Head-to-Head-Trial-Showed-Ticagrelor-Reduce-30082009.html 2017-01-19T10:24:27.945Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Announces-FDA-Acceptance-of-New-Drug-Application-31082009.html 2017-01-19T10:24:59.490Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Nektar-Sign-Worldwide-Agreement-for-Nektar-21092009.html 2017-01-19T10:25:28.092Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-Court-of-Appeals-Affirms-Summary-Judgment-Decision-25092009.html 2017-01-19T10:25:55.686Z https://www.astrazeneca.com/media-centre/press-releases/2009/Brilinta-Reduced-Cardiovascular-Deaths-and-Heart-Attacks-25092009.html 2017-01-19T10:26:25.712Z https://www.astrazeneca.com/media-centre/press-releases/2009/Seroquel-XR-and-Seroquel-Approved-in-Europe-for-Prevention-29092009.html 2017-01-19T10:26:57.566Z https://www.astrazeneca.com/media-centre/press-releases/2009/ONGLYZA-saxagliptin-Receives-Marketing-Authorisation-05102009.html 2017-01-19T10:28:23.479Z https://www.astrazeneca.com/media-centre/press-releases/2009/Study-Finds-That-ONGLYZA-saxagliptin-When-Added-to-Metformin-05102009.html 2017-01-19T10:28:51.937Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-Food-and-Drug-Administration-Approves-CRESTOR-16102009.html 2017-01-19T10:31:11.524Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Submits-Marketing-Authorisation-Application-16102009.html 2017-01-19T10:40:10.549Z https://www.astrazeneca.com/media-centre/press-releases/2009/Patients-Taking-VIMOVOTM-Showed-Decrease-in-incidence-19102009.html 2017-01-19T10:42:14.780Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-withdraws-regulatory-submissions-for-Zactima-28102009.html 2017-01-19T10:43:13.372Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-PLC-Third-Quarter-2009-29102009.html 2017-07-06T12:56:48.517Z https://www.astrazeneca.com/media-centre/press-releases/2009/Discovery-Research-Leader-Leaves-AstraZeneca-13112009.html 2017-01-19T10:57:38.266Z https://www.astrazeneca.com/media-centre/press-releases/2009/BRILINTA-Demonstrated-Greater-Efficacy-Over-Clopidogrel-16112009.html 2017-01-19T10:57:58.346Z https://www.astrazeneca.com/media-centre/press-releases/2009/Results-from-Two-Phase-II-Trials-Add-to-Understanding-18112009.html 2017-01-19T10:58:19.220Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Submits-US-New-Drug-Application-for-Brilinta-19112009.html 2017-01-19T10:58:38.436Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-and-Targacept-Form-Global-Collaboration-and-Licence-Agreement-03122009.html 2017-01-19T10:58:57.098Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-FDA-Approves-Seroquel-XR-For-AddOn-Treatment-Of-Major-Depressive-Disorder-04122009.html 2017-01-19T10:59:14.893Z https://www.astrazeneca.com/media-centre/press-releases/2009/US-FDA-Approves-Seroquel-For-The-Paediatric-Treatment-04122009.html 2017-01-19T10:59:57.400Z https://www.astrazeneca.com/media-centre/press-releases/2009/Advisory-Committee-Briefing-Materials-For-Crestor-sND-11122009.html 2017-01-19T11:00:25.010Z https://www.astrazeneca.com/media-centre/press-releases/2009/Favourable-Vote-From-FDA-Advisory-Committee-On-Benefit-15122009.html 2017-01-19T11:00:57.050Z https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-To-Acquire-Infection-Research-Company-Novexel-23122009.html 2017-01-19T11:01:18.206Z https://www.astrazeneca.com/media-centre/press-releases/2009/MedImmune-Replies-to-FDA-Complete-Response-Letter-on-Motavizumab-24122009.html 2017-01-19T11:01:44.039Z https://www.astrazeneca.com/media-centre/articles.html 2026-06-15T09:53:05.021Z https://www.astrazeneca.com/media-centre/articles/2026/transforming-cardiovascular-care-burden-heart-failure.html 2026-05-29T14:21:01.972Z https://www.astrazeneca.com/media-centre/articles/2026/obesity-weight-management.html 2026-05-29T14:19:36.784Z https://www.astrazeneca.com/media-centre/articles/2025/advancing-sustainable-respiratory-care-with-the-transition-to-pMDIs-with-near-zero-GWP-propellant.html 2026-06-15T09:50:26.981Z https://www.astrazeneca.com/media-centre/articles/2025/upskillingAI.html 2025-04-17T19:04:35.146Z https://www.astrazeneca.com/media-centre/articles/2025/caresa-a-pioneering-tool-to-model-the-environmental-impact-of-patient-care-pathways.html 2025-05-14T06:44:31.898Z https://www.astrazeneca.com/media-centre/articles/2025/our-commitment-to-improving-lung-health-equity.html 2025-06-06T14:12:19.339Z https://www.astrazeneca.com/media-centre/articles/2025/the-un-at-80-every-human-deserves-a-longer-healthier-future.html 2025-09-24T09:43:40.748Z https://www.astrazeneca.com/media-centre/articles/2025/unveiling-uterine-cancer-burden-equity.html 2025-09-30T17:09:57.113Z https://www.astrazeneca.com/media-centre/articles/2025/empowering-inclusive-lifelong-learning-development.html 2025-11-07T08:30:32.391Z https://www.astrazeneca.com/media-centre/articles/2025/earlier-amyloidosis-diagnosis.html 2025-10-17T16:40:01.305Z https://www.astrazeneca.com/media-centre/articles/2025/COP30-acting-early-on-chronic-disease-can-support-climate-action.html 2025-12-04T11:58:25.045Z https://www.astrazeneca.com/media-centre/articles/2025/statement-on-the-us-uk-agreement-on-pharmaceuticals.html 2025-12-03T12:09:56.301Z https://www.astrazeneca.com/media-centre/articles/2024/coaching-feedforward.html 2024-09-12T09:28:17.488Z https://www.astrazeneca.com/media-centre/articles/2024/wef-annual-meeting.html 2024-05-29T05:56:04.216Z https://www.astrazeneca.com/media-centre/articles/2024/reducing-burden-viral-respiratory-infections-aging-adults.html 2026-04-29T09:54:58.436Z https://www.astrazeneca.com/media-centre/articles/2024/accelerating-transition-renewables-decarbonise-medicines-manufacturing-china.html 2025-05-28T08:24:47.181Z https://www.astrazeneca.com/media-centre/articles/2024/oncology-trailblazers-digital-pathology.html 2024-04-05T16:11:34.508Z https://www.astrazeneca.com/media-centre/articles/2024/upskilling-AI.html 2024-09-12T09:28:17.487Z https://www.astrazeneca.com/media-centre/articles/2024/making-heart-failure-global-health-priority.html 2024-05-14T09:00:11.055Z https://www.astrazeneca.com/media-centre/articles/2024/oncology-trailblazers-building-path-progress.html 2024-06-04T15:19:32.671Z https://www.astrazeneca.com/media-centre/articles/2024/world-environment-day-restoring-protecting-land-future.html 2025-08-28T14:42:06.456Z https://www.astrazeneca.com/media-centre/articles/2024/mitigating-risk-pharmaceuticals-environment.html 2025-05-28T08:24:02.961Z https://www.astrazeneca.com/media-centre/articles/2024/embedding-sustainability-across-r-d-centres.html 2026-08-05T22:16:04.659Z https://www.astrazeneca.com/media-centre/articles/2024/AI-solutions-healthcare-emerging-markets.html 2026-06-15T09:51:41.458Z https://www.astrazeneca.com/media-centre/articles/2024/earlier-amyloidosis-diagnosis.html 2025-10-08T12:59:44.425Z https://www.astrazeneca.com/media-centre/articles/2024/oncology-trailblazers-risk-and-hope-driving-improvements-in-cancer-care.html 2024-09-12T08:31:49.837Z https://www.astrazeneca.com/media-centre/articles/2024/global-operations-digital-ai-wef-lighthouse.html 2024-10-08T09:49:20.431Z https://www.astrazeneca.com/media-centre/articles/2024/transforming-patient-care-partnerships.html 2025-04-24T17:42:24.090Z https://www.astrazeneca.com/media-centre/articles/2024/protecting-restoring-nature-for-a-healthier-future.html 2025-05-28T08:26:42.891Z https://www.astrazeneca.com/media-centre/articles/2024/astrazeneca-in-top-five-in-access-to-medicine-index.html 2026-06-11T13:04:33.346Z https://www.astrazeneca.com/media-centre/articles/2024/electronic-product-information-epi-digitalising-medicine-information-for-patients.html 2026-06-22T09:10:23.494Z https://www.astrazeneca.com/media-centre/articles/2024/strengthening-health-systems-through-the-partnership-for-health-system-sustainability-and-resilience.html 2025-02-05T18:44:11.055Z https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-treating-cancer-personal.html 2025-10-08T13:42:58.350Z https://www.astrazeneca.com/media-centre/articles/2023/putting-health-at-the-heart-of-cop28.html 2025-05-28T08:11:06.534Z https://www.astrazeneca.com/media-centre/articles/2023/astrazeneca-launches-a-healthtech-business-evinova.html 2023-11-20T09:34:35.962Z https://www.astrazeneca.com/media-centre/articles/2023/global-healthcare-leaders-advance-sector-decarbonisation-cop28.html 2026-03-31T09:26:41Z https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-adcs.html 2023-04-18T15:38:04.389Z https://www.astrazeneca.com/media-centre/articles/2023/fostering-culture-lifelong-learning.html 2025-05-28T08:19:20.210Z https://www.astrazeneca.com/media-centre/articles/2023/az-forest-expanding-investment-in-climate-action-and-nature.html 2025-06-26T10:28:23.921Z https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-working-with-time.html 2025-03-26T16:20:47.746Z https://www.astrazeneca.com/media-centre/articles/2023/oncology-trailblazers-moving-mountains-patients.html 2025-08-26T16:13:56.795Z https://www.astrazeneca.com/media-centre/articles/2023/transforming-kidney-health-burden-ckd.html 2026-02-05T01:08:11.669Z https://www.astrazeneca.com/media-centre/articles/2023/decarbonising-respiratory-care.html 2024-01-16T09:43:42.833Z https://www.astrazeneca.com/media-centre/articles/2023/powering-emissions-reductions-clean-heat-renewable-energy.html 2024-03-27T09:55:40.257Z https://www.astrazeneca.com/media-centre/articles/2023/climate-week-un-general-assembly.html 2026-03-31T09:25:00Z https://www.astrazeneca.com/media-centre/articles/2022/celebrating-the-life-and-legacy-of-jose-baselga.html 2022-11-28T16:09:03.907Z https://www.astrazeneca.com/media-centre/articles/2022/neurodiversity-in-workplace.html 2022-07-22T13:26:33.778Z https://www.astrazeneca.com/media-centre/articles/2022/supporting-early-talent-inclusive-diverse-future-workforce.html 2025-05-28T08:22:35.180Z https://www.astrazeneca.com/media-centre/articles/2022/raising-awareness-attr.html 2024-08-28T16:26:40.319Z https://www.astrazeneca.com/media-centre/articles/2022/oncology-trailblazers-breast-cancer.html 2022-12-09T18:27:47.894Z https://www.astrazeneca.com/media-centre/articles/2022/accessibility-workplace.html 2023-01-06T06:47:58.761Z https://www.astrazeneca.com/media-centre/articles/cancer-care-africa.html 2025-10-06T12:56:19.614Z https://www.astrazeneca.com/media-centre/articles/accelerating-transition-electric-vehicles.html 2025-07-11T13:22:08.347Z https://www.astrazeneca.com/media-centre/articles/data-driven-approaches-to-accelerate-clinical-trial-diversity.html 2024-10-29T10:53:47.217Z https://www.astrazeneca.com/media-centre/articles/transforming-respiratory-care.html 2024-09-04T15:46:31.611Z https://www.astrazeneca.com/media-centre/articles/breast-cancer-grant-programme.html 2025-09-24T10:02:37.089Z https://www.astrazeneca.com/media-centre/articles/astrazeneca-at-esc.html 2025-08-28T10:22:21.256Z https://www.astrazeneca.com/media-centre/articles/astrazeneca-calor-obesity-study.html 2026-06-03T10:24:01.288Z https://www.astrazeneca.com/media-centre/articles/pioneering-new-possibilities-for-the-rare-disease-community.html 2026-03-12T16:01:14Z https://www.astrazeneca.com/media-centre/medical-releases.html 2024-03-11T06:30:41.053Z https://www.astrazeneca.com/media-centre/medical-releases/Arthritis-and-Rheumatology-publishes-positive-Phase-II-data-on-anifrolumab-in-lupus-14112016.html 2023-03-15T22:37:37.792Z https://www.astrazeneca.com/media-centre/medical-releases/durvalumab-monotherapy-demonstrates-efficacy-in-urothelial-bladder-cancer.html 2023-03-15T22:57:37.482Z https://www.astrazeneca.com/media-centre/medical-releases/astrazenecas-combination-of-durvalumab-with-tremelimumab-shows-clinical-activity-in-non-small-cell-lung-cancer-irrespective-of-pd-l1-status-cancer-0120160.html 2023-03-15T22:48:57.382Z https://www.astrazeneca.com/media-centre/medical-releases/durvalumab-shows-promising-preliminary-early-data-in-lung-and-head-and-neck-cancers-10102016.html 2023-03-16T21:22:00.865Z https://www.astrazeneca.com/media-centre/medical-releases/euclid-trial-results-for-brilinta-brilique-presented-at-the-american.html 2023-03-16T21:23:24.722Z https://www.astrazeneca.com/media-centre/medical-releases/Early-data-demonstrate-clinical-activity-of-acalabrutinib-in-difficult-to-treat-chronic-lymphocytic-leukaemia-05122016.html 2023-03-16T21:22:31.628Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-supports-the-publication-of-the-2017-gold-strategy-for-improving-copd-diagnosis-management-and-prevention-09122016.html 2023-03-15T22:50:27.477Z https://www.astrazeneca.com/media-centre/medical-releases/US-FDA-approves-Symbicort-budesonide-formoterol-for-the-treatment-of-asthma-in-paediatric-patients-300120170.html 2023-03-16T22:15:04.815Z https://www.astrazeneca.com/media-centre/medical-releases/lynparza--olaparib--maintenance-treatment-offers-sustained-quality-of-life-alongside-improved-progression-free-survival-in-women-with-brca-mutated-ovarian-cancer-02072017.html 2023-03-16T21:54:21.793Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-tagrisso-osimertinib-data-in-patients-with-egfr-t790m-mutation-positive-lung-cancer-and-central-nervous-system-metastases-06062017.html 2023-03-15T22:48:04.723Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-supports-long-term-efficacy-of-ticagrelor-in-patients-up-to-five-years-following-a-heart-attack-06092017.html 2023-03-16T21:59:33.048Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-new-evidence-on-symbicort-budesonide-formoterol-in-copd-patients-at-risk-of-exacerbation.html 2023-03-15T22:46:53.029Z https://www.astrazeneca.com/media-centre/medical-releases/forxiga-depict-1-trial-demonstrates-improved-glycaemic-control-without-increasing-hypoglycaemia-14092017.html 2023-03-16T21:49:49.028Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-and-chi-meds-savolitinib-shows-encouraging-clinical-activity-in-2nd-line-egfr-mutation-positive-lung-cancer-with-met-amplification-171017.html 2023-03-15T22:39:03.362Z https://www.astrazeneca.com/media-centre/medical-releases/zs-9-sodium-zirconium-cyclosilicate-phase-iii-long-term-safety-and-efficacy-data-presented-at-asn-kidney-week-201702112017.html 2023-03-16T22:15:37.149Z https://www.astrazeneca.com/media-centre/medical-releases/faslodex-fulvestrant-receives-eu-approval-for-the-treatment-of-hormone-receptor-positive-advanced-breast-cancer-in-combination-with-palbociclib-14112017.html 2023-03-16T21:47:03.164Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-show-benefit-of-tagrisso-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-and-central-nervous-system-metastases-20112017.html 2023-03-16T21:58:12.501Z https://www.astrazeneca.com/media-centre/medical-releases/new-england-journal-of-medicine-publishes-results-of-phase-iii-flaura-trial-in-the-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-20112017.html 2023-03-16T22:00:01.730Z https://www.astrazeneca.com/media-centre/medical-releases/risk-of-repeat-heart-attack-twice-as-likely-from-occlusions-in-arteries-that-did-not-cause-initial-event.html 2023-03-16T22:11:29.581Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-enrols-first-patient-in-new-brilinta-ticagrelor-stroke-trial-23012018.html 2023-03-15T22:42:51.754Z https://www.astrazeneca.com/media-centre/medical-releases/brilinta-meets-primary-endpoint-in-phase-iii-thrombolysis-trial.html 2023-03-15T22:51:13.631Z https://www.astrazeneca.com/media-centre/medical-releases/brilinta-ticagrelor-associated-with-a-reduction-in-risk-for-cardiovascular-events-versus-clopidogrel-in-heart-attack-survivors-with-moderate-kidney-disease-090418.html 2023-03-15T22:54:55.943Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-presents-imfinzi-durvalumab-plus-tremelimumab-combination-data-at-aacr-annual-meeting-170418.html 2023-03-15T22:46:10.017Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-and-medimmune-present-phase-ii-data-for-medi0382-at-ada-2018-demonstrating-significant-improvements-in-glycaemic-control-and-weight-loss-in-patients-with-type-2-diabetes.html 2023-03-15T22:39:54.147Z https://www.astrazeneca.com/media-centre/medical-releases/farxiga-in-combination-with-onglyza-demonstrates-similar-glycaemic-control-with-additional-benefits-vs-insulin-glargine-in-patients-with-type-2-diabetes25062018.html 2023-03-16T21:39:57.162Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-expands-heart-failure-research-with-new-phase-iii-deliver-trial-of-forxiga-in-patients-with-and-without-type-2-diabetes23082018.html 2023-03-15T22:44:24.408Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-from-real-world-evidence-indicates-need-for-better-secondary-prevention-to-reduce-long-term-ischaemic-risk-in-heart-attack-survivors-29082018.html 2023-03-16T21:56:43.134Z https://www.astrazeneca.com/media-centre/medical-releases/european-respiratory-journal-publishes-phase-iii-telos-trial-for-pt009-dual-combination-therapy-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-16092018.html 2023-03-16T21:23:58.159Z https://www.astrazeneca.com/media-centre/medical-releases/first-patients-enrolled-in-phase-iiib-ponente-trial-evaluating-the-elimination-of-oral-corticosteroids-with-fasenra-in-severe-eosinophilic-asthma-18092018.html 2023-03-16T21:49:05.230Z https://www.astrazeneca.com/media-centre/medical-releases/new-pegasus-timi-54-sub-analyses-provide-direction-on-selecting-patients-most-likely-to-benefit-from-long-term-treatment-with-brilinta-ticagrelor.html 2023-03-16T22:01:53.866Z https://www.astrazeneca.com/media-centre/medical-releases/imfinzi-demonstrates-clinical-activity-in-stage-iv-1st-line-non-small-cell-lung-cancer-in-phase-iii-mystic-trial-13122018.html 2023-03-16T21:50:43.307Z https://www.astrazeneca.com/media-centre/medical-releases/phase-iii-treat-trial-provides-evidence-on-the-use-of-brilinta-in-high-risk-patients-treated-with-pharmacological-thrombolysis18032019.html 2023-03-16T22:06:43.847Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-supports-new-global-recommendations-on-asthma-care12042019.html 2023-03-15T22:50:05.355Z https://www.astrazeneca.com/media-centre/medical-releases/phase-iii-combination-trial-of-bydureon-and-forxiga-shows-signif.html 2023-03-16T22:06:08.546Z https://www.astrazeneca.com/media-centre/medical-releases/socrates-trial-results-for-brilinta-brilique-presented-at-europe.html 2023-03-16T22:12:25.365Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-two-new-phase-iiib-trials-for-forxiga-in-c.html 2023-03-15T22:41:25.617Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-receives-approval-in-the-eu-for-qtern--saxagliptin-a.html 2023-03-15T22:48:31.032Z https://www.astrazeneca.com/media-centre/medical-releases/positive-chmp-opinion-in-eu-for-saxa-dapa--saxagliptin-and-dapag.html 2023-03-16T22:10:27.802Z https://www.astrazeneca.com/media-centre/medical-releases/acalabrutinib-recommended-for-orphan-drug-designation-in-Europe-for-three-indications.html 2023-03-15T22:34:44.985Z https://www.astrazeneca.com/media-centre/medical-releases/Tagrisso-osimertinib-shows-clinical-activity-in-patients-with-leptomeningeal-disease-from-lung-cancer.html 2023-03-16T22:14:01.552Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-further-evidence-for-the-potential-of-AZD9291-in-first-line-and-pre-treated-non-small-cell-lung-cancer.html 2023-03-15T22:45:36.186Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-advances-in-oncology-research-at-ECC-2015-with-data-on-AZD9291-durvalumab-and-LYNPARZA-olaparib.html 2023-03-15T22:45:00.945Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-presents-positive-Tagrisso-osimertinib-follow-up-data-in-lung-cancer-at-ELCC-2016.html 2023-03-15T22:47:22.592Z https://www.astrazeneca.com/media-centre/medical-releases/Lynparza-olaparib-latest-data-suggest-potential-overall-survival-advantage-in-patients-with-platinum-sensitive-ovarian-cancer.html 2023-03-16T21:54:06.597Z https://www.astrazeneca.com/media-centre/medical-releases/AstraZeneca-to-present-anifrolumab-lupus-data-at-Annual-European-Congress-of-Rheumatology-EULAR-2016.html 2023-03-15T22:50:49.917Z https://www.astrazeneca.com/media-centre/medical-releases/farxiga-heart-failure-research-broadened-with-new-phase-iii-determine-trials.html 2023-03-16T21:39:34.316Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-two-lancet-oncology-publications-of-phase-i-dose-expansion-results-of-trastuzumab-deruxtecan-in-her2-positive-metastatic-breast-and-gastric-cancer.html 2023-03-15T22:40:53.468Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-enters-strategic-collaboration-with-transgene-to-develop-innovative-oncolytic-virus-immunotherapies30042019.html 2023-03-15T22:43:45.106Z https://www.astrazeneca.com/media-centre/medical-releases/fasenra-reduces-oral-corticosteroid-use-and-maintains-long-term-efficacy-and-safety-profile-in-severe-eosinophilic-asthma.html 2023-03-16T21:46:21.386Z https://www.astrazeneca.com/media-centre/medical-releases/farxiga-study-showed-reduced-progression-of-kidney-disease-or-renal-death-in-patients-with-type-2-diabetes10062019.html 2023-03-16T21:45:38.243Z https://www.astrazeneca.com/media-centre/medical-releases/archive.html 2024-11-01T15:02:59.309Z https://www.astrazeneca.com/media-centre/medical-releases/positive-results-from-two-roxadustat-phase-iii-trials-in-china-for-the-treatment-of-anaemia-published-in-the-new-england-journal-of-medicine-24072019.html 2019-07-24T21:23:41.234Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-show-symbicort-used-as-an-anti-inflammatory-reliever-in-mild-to-moderate-asthma-is-more-effective-at-preventing-severe-asthma-attacks--27082019.html 2023-03-16T21:59:03.993Z https://www.astrazeneca.com/media-centre/medical-releases/forxiga-reduced-the-risk-of-a-composite-of-cardiovascular-death-or-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-both-with-and-without-kidney-disease-31082019.html 2023-03-16T21:50:13.466Z https://www.astrazeneca.com/media-centre/medical-releases/new-analysis-of-fasenra-phase-iii-galathea-and-terranova-copd-trials-identifies-factors-associated-with-exacerbation-rate-reductions.html 2023-03-16T21:55:43.990Z https://www.astrazeneca.com/media-centre/medical-releases/brilinta-monotherapy-in-high-bleeding-risk-patients-who-underwent-pci-had-reduced-risk-of-clinically-relevant-bleeding-than-with-dual-antiplatelet-therapy-in-the-twilight-trial.html 2023-03-15T22:51:49.180Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-from-the-phase-iii-dapa-hf-trial-showed-farxiga-dapagliflozin-reduced-the-worsening-of-heart-failure-or-cv-death-in-hfref-patients-with-and-without-ckd.html 2023-03-16T21:57:36.278Z https://www.astrazeneca.com/media-centre/medical-releases/subgroup-analysis-of-twilight-trial-patients-with-nste-acs.html 2023-03-16T22:13:37.868Z https://www.astrazeneca.com/media-centre/medical-releases/consistent-effects-of-farxiga-in-heart-failure-patients-with-reduced-ejection-fraction-shown-in-new-analyses-from-landmark-phase-iii-dapa-hf-trial.html 2023-03-15T22:57:08.643Z https://www.astrazeneca.com/media-centre/medical-releases/three-clinical-trials-announced-for-fasenra-in-eosinophil-driven-skin-diseases.html 2023-03-16T22:14:25.991Z https://www.astrazeneca.com/media-centre/medical-releases/lokelma-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html 2023-03-16T21:53:47.065Z https://www.astrazeneca.com/media-centre/medical-releases/lokelma-label-update-approved-in-eu-for-patients-with-hyperkalaemia-on-stable-haemodialysis.html 2023-03-16T21:52:58.860Z https://www.astrazeneca.com/media-centre/medical-releases/anifrolumab-showed-early-and-sustained-treatment-benefit-for-patients-with-systemic-lupus-erythematosus-in-the-tulip-clinical-trial-programme.html 2023-03-15T22:36:59.481Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-licenses-preclinical-porcupine-inhibitor-rxc006-for-idiopathic-pulmonary-fibrosis.html 2020-08-04T06:17:53.559Z https://www.astrazeneca.com/media-centre/medical-releases/fasenra-significantly-reduced-exacerbation-rate-for-severe-eosinophilic-asthma-patients-in-phase-iiib-andhi-trial.html 2023-03-16T21:46:44.311Z https://www.astrazeneca.com/media-centre/medical-releases/Anifrolumab-reduces-disease-flares-in-patients-with-systemic-lupus-erythematosus-while-allowing-oral-corticosteroid-tapering.html 2023-03-15T22:36:27.161Z https://www.astrazeneca.com/media-centre/medical-releases/brilinta-reduced-subsequent-disabling-stroke-or-death-in-patients-who-had-an-acute-ischaemic-stroke-or-transient-ischaemic-attack-in-phase-iii-thales-trial-sub-analysis.html 2023-03-15T22:52:19.243Z https://www.astrazeneca.com/media-centre/medical-releases/farxiga-showed-cardiovascular-and-renal-benefit-in-patients-with-chronic-kidney-disease-irrespective-of-cardiovascular-disease-status.html 2023-03-16T21:45:09.747Z https://www.astrazeneca.com/media-centre/medical-releases/brilinta-reduced-the-composite-of-stroke-and-death-in-patients-with-head-and-neck-artery-atherosclerosis.html 2023-03-15T22:54:21.555Z https://www.astrazeneca.com/media-centre/medical-releases/lokelma-label-update-approved-in-china-for-patients-with-hyperka.html 2023-03-16T21:52:24.523Z https://www.astrazeneca.com/media-centre/medical-releases/first-patients-dosed-in-phase-iii-trials-evaluating-fasenra.html 2023-03-16T21:48:19.204Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-show-overuse-of-reliever-medication-in-asthma-is-responsible-for-250k-tonnes-of-greenhouse-gas-emissions-every-year-in-the-uk.html 2023-03-16T21:58:41.128Z https://www.astrazeneca.com/media-centre/medical-releases/first-patients-dosed-in-three-dermatology-trials-evaluating-fasenra-in-bullous-pemphigoid-atopic-dermatitis-and-chronic-spontaneous-urticaria.html 2023-03-16T21:48:45.316Z https://www.astrazeneca.com/media-centre/medical-releases/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients.html 2023-03-16T22:04:52.348Z https://www.astrazeneca.com/media-centre/medical-releases/new-fasenra-data-from-the-meltemi-extension-trial-confirm-long-term-safety-and-efficacy-in-severe-eosinophilic-asthma-for-up-to-5-years.html 2023-03-16T22:00:50.307Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-at-heart-failure-2021-showcases-astrazenecas-leading-and-diverse-heart-failure-portfolio.html 2021-06-29T08:04:38.586Z https://www.astrazeneca.com/media-centre/medical-releases/astrazenecas-investigational-mpo-inhibitor-azd4831-shows-promise-in-patients-with-heart-failure-and-a-preserved-ejection-fraction.html 2023-03-15T22:49:32.076Z https://www.astrazeneca.com/media-centre/medical-releases/bydureon-bcise-exenatide-extended-release-approved-in-the-us-for-the-treatment-of-type-2-diabetes-in-paediatric-patients-ages-10-years-and-older.html 2023-03-15T22:55:38.922Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-at-esc-congress-2021-showcase-astrazenecas-leading-cardiovascular-renal-and-metabolic-portfolio.html 2023-03-16T21:56:12.996Z https://www.astrazeneca.com/media-centre/medical-releases/new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-comorbid-nasal-polyps.html 2023-03-16T22:05:18.447Z https://www.astrazeneca.com/media-centre/medical-releases/new-fasenra-data-from-the-ponente-trial-show-sustained-robust-oral-corticosteroid-reductions.html 2021-10-26T10:03:06.950Z https://www.astrazeneca.com/media-centre/medical-releases/carbon-studies-showed-uncontrolled-asthma-is-associated-with-an-increased-carbon-footprint-of-asthma-care.html 2023-03-15T22:56:32.267Z https://www.astrazeneca.com/media-centre/medical-releases/saphnelo-consistently-reduces-systemic-lupus-erythematosus-disease-activity-regardless-of-disease-duration-and-prior-treatment.html 2021-11-01T13:51:03.905Z https://www.astrazeneca.com/media-centre/medical-releases/new-sub-analyses-further-support-consistency-of-farxigas-cardiorenal-and-mortality-benefits-in-treating-chronic-kidney-disease.html 2023-03-16T22:02:25.305Z https://www.astrazeneca.com/media-centre/medical-releases/fasenra-granted-orphan-drug-and-fast-track-designations-in-the-us-for-eosinophilic-gastritis-and-eosinophilic-gastroenteritis.html 2023-03-16T21:46:00.300Z https://www.astrazeneca.com/media-centre/medical-releases/lokelma-granted-fast-track-designation-in-the-us-to-reduce-cardiovascular-outcomes-in-patients-on-chronic-haemodialysis-with-hyperkalaemia.html 2023-03-16T21:50:58.781Z https://www.astrazeneca.com/media-centre/medical-releases/eplontersen-granted-orphan-drug-designation-in-the-us-for-transthyretin-amyloidosis.html 2023-03-16T21:22:53.906Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-further-reinforce-efficacy-of-tezspire-in-a-broad-population-of-severe-asthma-patients.html 2022-02-25T11:53:00.309Z https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html 2023-03-16T21:24:35.379Z https://www.astrazeneca.com/media-centre/medical-releases/sabina-programme-demonstrates-saba-reliever-overuse-is-a-global-issue-in-asthma-management.html 2023-03-16T22:11:59.226Z https://www.astrazeneca.com/media-centre/medical-releases/new-nirsevimab-data-analyses-reinforce-efficacy-rsv.html 2023-03-16T22:01:30.810Z https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-omicron-variants-ba4-ba5-according-new-study-university-oxford.html 2023-05-18T14:48:05.605Z https://www.astrazeneca.com/media-centre/medical-releases/first-patients-dosed-in-iris-phase-iii-trial-evaluating-saphnelo-in-lupus-nephritis.html 2023-03-16T21:47:55.787Z https://www.astrazeneca.com/media-centre/medical-releases/bydureon-bcise-exenatide-prolonged-release-approved-in-the-eu-for-paediatric-patients-with-type-2-diabetes.html 2022-06-07T19:11:03.014Z https://www.astrazeneca.com/media-centre/medical-releases/propel-phase-iii-trial-positive-results-of-lynparza-plus-abiraterone.html 2023-03-16T22:11:09.585Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-shares-data-at-easl-and-esmo-world-gi-for-imfinzi-combinations-in-patients-with-liver-and-biliary-tract-cancers.html 2022-07-01T07:29:36.891Z https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html 2023-03-16T22:20:25.560Z https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-73-effective-at-preventing-omicron-related-infections-after-fourth-dose-according-to-real-world-evidence-study-in-thailand.html 2023-03-16T22:19:47.609Z https://www.astrazeneca.com/media-centre/medical-releases/poseidon-phase-iii-post-hoc-exploratory-analyses-presented-at-wclc-2022.html 2023-03-16T22:07:05.999Z https://www.astrazeneca.com/media-centre/medical-releases/new-analyses-in-real-world-setting-support-the-effectiveness-of-fasenra-in-severe-eosinophilic-asthma.html 2023-03-16T21:54:55.044Z https://www.astrazeneca.com/media-centre/medical-releases/new-tezspire-data-at-ers-international-congress-2022-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients.html 2023-03-16T22:05:37.235Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-advancing-clinical-practice-in-heart-failure-with-unprecedented-data-and-number-of-simultaneous-publications-of-deliver-phase-iii-results.html 2022-09-08T04:43:05.573Z https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-highly-effective-at-preventing-covid-19-severe-outcomes-and-death.html 2023-03-16T22:20:08.696Z https://www.astrazeneca.com/media-centre/medical-releases/new-beyfortus-data-reinforce-efficacy-against-infant-rsv-hospitalisations.html 2023-05-12T03:55:42.792Z https://www.astrazeneca.com/media-centre/medical-releases/farxiga-demonstrated-consistent-benefit-regardless-of-heart-failure-duration-and-across-the-full-spectrum-of-cardiorenal-disease.html 2023-05-22T11:51:31.713Z https://www.astrazeneca.com/media-centre/medical-releases/new-astrazeneca-data-presented-at-ats-2023-strengthen-the-body-of-evidence-supporting-early-intervention-with-breztri-in-copd.html 2023-05-22T11:47:14.093Z https://www.astrazeneca.com/media-centre/medical-releases/real-world-evidence-highlights-the-urgent-need-to-act-on-the-growing-global-burden-of-chronic-kidney-disease.html 2023-06-17T09:39:27.206Z https://www.astrazeneca.com/media-centre/medical-releases/real-world-evidence-study-shows-the-significant-impact-of-hyperkalaemia-on-cardiorenal-patient-outcomes.html 2023-06-17T09:40:18.935Z https://www.astrazeneca.com/media-centre/medical-releases/eplontersen-phase-iii-results-published-in-jama.html 2023-09-28T15:43:55.624Z https://www.astrazeneca.com/media-centre/medical-releases/large-real-world-evidence-studies-reveal-disproportionate-burden-of-covid-19-on-the-immunocompromised.html 2023-10-13T05:31:12.575Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-celebrates-science-in-pictures.html 2023-11-23T10:11:54.902Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-establishes-new-world-class-functional-genomics-laboratory-with-medical-research-council-and-the-milner-therapeutics-institute-at-the-university-of-cambridge.html 2023-11-27T09:12:06.557Z https://www.astrazeneca.com/media-centre/medical-releases/mandara-phase-iii-data-published-new-england-journal-medicine-show-remission-achievable-goal-eosinophilic-granulomatosis-polyangiitis-egpa-fasenra.html 2024-02-23T17:44:33.067Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-initiation-tharros-phase-iii-clinical-trial-investigating-potential-breztri-improve-cardiopulmonary-outcomes-people-with-copd.html 2024-03-13T08:10:36.707Z https://www.astrazeneca.com/media-centre/medical-releases/saphnelo-demonstrates-higher-rates-of-remission-in-patients-with-systemic-lupus-erythematosus-compared-to-standard-therapy-alone-over-4-year-period.html 2024-03-20T23:37:39.597Z https://www.astrazeneca.com/media-centre/medical-releases/results-miracle-phase-iii-trial-show-treatment-fasenra-statistically-reduction-74-annual-exacerbation-rate-patients-asia-severe-eosinophilic-asthma.html 2024-04-10T04:48:16.669Z https://www.astrazeneca.com/media-centre/medical-releases/real-world-evidence-eccmid-2024-further-substantiate-continued-significant-disproportionate-risk-severe-covid-19-facing-immunocompromised-individuals.html 2024-04-26T06:07:16.486Z https://www.astrazeneca.com/media-centre/medical-releases/new-data-presented-at-ats-2024-show-the-potential-of-tezepelumab-to-play-a-role-in-the-future-treatment-of-chronic-obstructive-pulmonary-disease.html 2024-05-19T21:15:17.049Z https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html 2024-05-28T17:47:33.550Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-unveils-latest-research-at-esc-congress-2024-showcasing-strength-of-its-cardiovascular-renal-and-metabolism-portfolio-and-pipeline.html 2024-08-23T17:28:33.561Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-new-ai-technology-milton-predicts-more-than-1000-diseases-before-diagnosis.html 2024-09-10T16:33:45.221Z https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html 2024-09-19T04:34:48.148Z https://www.astrazeneca.com/media-centre/medical-releases/new-long-term-alpha-phase-iii-trial-data-published-in-blood-show-voydeya-as-add-on-to-ultomiris-or-soliris-maintained-clinical-improvements-for-the-subset-of-people-with-pnh-experiencing-clinically-significant-extravascular-haemolysis.html 2025-01-03T20:04:00.450Z https://www.astrazeneca.com/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html 2025-06-14T16:04:03.561Z https://www.astrazeneca.com/media-centre/medical-releases/statistically-significant-natron-phase-iii-trial-results-for-hypereosinophilic-syndrome-show-fasenra-delayed-time-to-first-flare-or-worsening-of-disease.html 2025-11-07T13:59:45.351Z https://www.astrazeneca.com/media-centre/medical-releases/dna-research-uncovers-22-genes-that-could-put-people-at-risk-of-long-term-health-conditions-following-common-viral-infection.html 2026-01-28T15:50:19.919Z https://www.astrazeneca.com/media-centre/medical-releases/imfinzi-regimen-reduced-early-disease-recurrence-among-high-risk-non-muscle-invasive-bladder-cancer-patients-in-potomac-phase-iii-trial-exploratory-analyses.html 2026-05-14T16:06:40.077Z https://www.astrazeneca.com/media-centre/image-and-broadcast-library.html 2026-07-17T13:53:29.268Z https://www.astrazeneca.com/media-centre/archive.html 2024-12-02T09:13:41.690Z https://www.astrazeneca.com/media-centre/social-media-community-guidelines.html 2024-02-15T11:34:57.028Z https://www.astrazeneca.com/media-centre/contacts.html 2026-05-11T11:03:22.322Z https://www.astrazeneca.com/media-centre/pdf.html 2024-09-05T12:39:20.063Z https://www.astrazeneca.com/sustainability.html 2026-06-03T15:37:41.558Z https://www.astrazeneca.com/sustainability/climate-change.html 2026-06-03T15:56:16.186Z https://www.astrazeneca.com/sustainability/climate-change/renewable-energy.html 2026-06-25T08:27:02.285Z https://www.astrazeneca.com/sustainability/climate-change/product-sustainability.html 2026-06-03T15:57:08.638Z https://www.astrazeneca.com/sustainability/climate-change/az-forest.html 2026-06-03T15:57:25.745Z https://www.astrazeneca.com/sustainability/climate-change/accelerating-transition-electric-vehicles.html 2026-06-03T15:58:03.456Z https://www.astrazeneca.com/sustainability/climate-change/creating-culture-sustainability-across-labs.html 2026-06-03T21:11:37.859Z https://www.astrazeneca.com/sustainability/partnerships-and-alliances.html 2026-05-06T19:05:33.108Z https://www.astrazeneca.com/sustainability/resources.html 2026-06-25T08:32:56.777Z https://www.astrazeneca.com/sustainability/resources/policies-and-standards.html 2026-06-03T15:58:38.926Z https://www.astrazeneca.com/sustainability/resources/double-materiality-assessment.html 2026-06-03T15:58:59.118Z https://www.astrazeneca.com/sustainability/resources/archive.html 2026-06-03T15:59:16.628Z https://www.astrazeneca.com/sustainability/resources/our-impact.html 2026-06-03T15:59:58.098Z https://www.astrazeneca.com/sustainability/resources/sustainability-governance.html 2026-06-03T16:00:17.347Z https://www.astrazeneca.com/sustainability/health-systems-resilience.html 2026-06-03T15:49:43.635Z https://www.astrazeneca.com/sustainability/health-systems-resilience/PHSSR.html 2026-06-03T16:00:38.412Z https://www.astrazeneca.com/sustainability/nature.html 2026-06-22T09:11:56.852Z https://www.astrazeneca.com/sustainability/nature/waste-circularity.html 2026-06-03T16:01:04.667Z https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment.html 2026-06-19T13:39:37.785Z https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment/dashboard-archive.html 2026-06-03T16:01:45.688Z https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment/EcoPharmacoVigilance-Dashboard.html 2026-06-24T13:40:54.215Z https://www.astrazeneca.com/sustainability/nature/water-stewardship.html 2026-06-22T09:05:46.246Z https://www.astrazeneca.com/sustainability/ethics-compliance.html 2026-05-06T23:09:57.917Z https://www.astrazeneca.com/sustainability/ethics-compliance/data-and-ai-ethics.html 2026-06-03T16:02:27.240Z https://www.astrazeneca.com/sustainability/ethics-compliance/our-commitment-to-clinical-trial-transparency.html 2026-06-03T16:02:44.112Z https://www.astrazeneca.com/sustainability/ethics-compliance/astrazeneca-and-global-transparency.html 2026-07-06T14:57:08.825Z https://www.astrazeneca.com/sustainability/ethics-compliance/animals-in-research.html 2026-06-03T16:03:19.764Z https://www.astrazeneca.com/sustainability/ethics-compliance/bioethics.html 2026-06-03T16:03:41.208Z https://www.astrazeneca.com/sustainability/health-equity.html 2026-06-03T15:49:02.204Z https://www.astrazeneca.com/sustainability/health-equity/healthcare-delivery.html 2026-06-03T16:04:11.272Z https://www.astrazeneca.com/sustainability/health-equity/science.html 2026-06-03T16:04:26.916Z https://www.astrazeneca.com/sustainability/health-equity/healthy-heart-africa.html 2026-06-03T16:04:42.498Z https://www.astrazeneca.com/sustainability/health-equity/community-investment.html 2026-06-03T16:04:59.329Z https://www.astrazeneca.com/sustainability/workforce-safety-and-health.html 2026-06-25T17:31:07.841Z https://www.astrazeneca.com/sustainability/sustainable-science.html 2026-07-24T22:49:43.044Z https://www.astrazeneca.com/investor-relations.html 2026-07-31T16:12:56.209Z https://www.astrazeneca.com/investor-relations/meet-the-management-at-esmo-2025.html 2025-10-21T14:20:19.900Z https://www.astrazeneca.com/investor-relations/h1-and-q2-2024-results-event.html 2025-06-12T11:23:15.688Z https://www.astrazeneca.com/investor-relations/tools.html 2026-06-19T11:56:31.186Z https://www.astrazeneca.com/investor-relations/tools/historic-lookup.html 2026-05-28T13:41:13.338Z https://www.astrazeneca.com/investor-relations/tools/sp-center.html 2026-06-19T11:55:09.512Z https://www.astrazeneca.com/investor-relations/tools/sp-calculator.html 2026-05-28T13:40:47.357Z https://www.astrazeneca.com/investor-relations/tools/dividend-center.html 2026-06-19T11:55:02.916Z https://www.astrazeneca.com/investor-relations/tools/sec-filing.html 2026-05-28T13:38:44.753Z https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-esmo-2024.html 2024-09-16T21:14:13.493Z https://www.astrazeneca.com/investor-relations/meet-the-management-lung-cancer-and-qcs.html 2024-09-10T12:48:08.217Z https://www.astrazeneca.com/investor-relations/astrazeneca-health-equity-investor-event.html 2024-11-15T16:59:37.991Z https://www.astrazeneca.com/investor-relations/9m-and-q3-2024-results-event.html 2025-06-12T11:18:57.648Z https://www.astrazeneca.com/investor-relations/meet-the-management-weight-management-virtual-event.html 2024-11-05T14:36:53.520Z https://www.astrazeneca.com/investor-relations/full-year-and-q4-2024-results-event.html 2025-06-12T11:22:35.069Z https://www.astrazeneca.com/investor-relations/q1-2025-results-event.html 2025-06-12T11:17:45.129Z https://www.astrazeneca.com/investor-relations/sustainability-2024-highlights-summary-call.html 2025-05-29T13:15:38.655Z https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-asco-2025.html 2025-06-03T04:45:37.512Z https://www.astrazeneca.com/investor-relations/h1-and-q2-2025-results-event.html 2025-07-29T16:22:22.643Z https://www.astrazeneca.com/investor-relations/meet-the-management-at-esc-2025.html 2025-09-01T10:10:32.530Z https://www.astrazeneca.com/investor-relations/9m-and-q3-2025-results-event.html 2025-11-17T12:38:46.272Z https://www.astrazeneca.com/investor-relations/full-year-and-q4-2025-results-event.html 2026-02-10T16:05:24.497Z https://www.astrazeneca.com/investor-relations/q1-2026-results-event.html 2026-04-29T17:39:57.165Z https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-asco-2026.html 2026-06-02T02:15:40.960Z https://www.astrazeneca.com/investor-relations/meet-the-management-at-ada-2026.html 2026-06-09T01:44:39.512Z https://www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html 2024-05-28T11:39:10.001Z https://www.astrazeneca.com/investor-relations/resources.html 2026-06-05T09:54:02.446Z https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements.html 2026-06-05T09:14:28.148Z https://www.astrazeneca.com/investor-relations/results-and-presentations.html 2026-07-31T16:13:40.723Z https://www.astrazeneca.com/investor-relations/results-and-presentations/archive.html 2024-12-24T12:59:26.281Z https://www.astrazeneca.com/investor-relations/annual-reports.html 2026-03-19T09:55:20Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015.html 2024-12-03T11:04:44.151Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/cautionary-statement.html 2023-11-02T10:02:57.574Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/reader-information.html 2023-03-22T22:45:17.974Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016.html 2023-03-22T22:41:40.984Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/contact-information.html 2025-11-11T22:24:33.279Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/annual-report-and-cautionary-statement.html 2023-03-14T22:29:17.816Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2017.html 2018-04-13T09:36:51.904Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2018.html 2025-06-09T15:44:53.555Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2019.html 2025-06-11T10:23:25.965Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2020.html 2025-06-11T14:57:58.872Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2021.html 2025-06-11T15:02:40.107Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2022.html 2025-06-11T15:18:20.356Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2023.html 2026-02-18T18:02:47.755Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2024.html 2025-06-11T15:56:10.712Z https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2025.html 2026-04-13T12:57:20.306Z https://www.astrazeneca.com/investor-relations/corporate-governance.html 2026-04-30T08:34:29.373Z https://www.astrazeneca.com/investor-relations/shareholder-information.html 2026-07-31T16:14:11.992Z https://www.astrazeneca.com/investor-relations/shareholder-information/contact-us-agm.html 2025-09-23T08:54:46Z https://www.astrazeneca.com/investor-relations/dividend-policy.html 2026-07-29T14:25:31.361Z https://www.astrazeneca.com/investor-relations/key-facts.html 2026-07-26T14:09:11.957Z https://www.astrazeneca.com/investor-relations/faqs.html 2026-08-03T09:46:07.945Z https://www.astrazeneca.com/investor-relations/debt-investors.html 2026-07-24T14:01:36.771Z https://www.astrazeneca.com/investor-relations/debt-investors/emtn-programme.html 2026-06-10T08:08:29.557Z https://www.astrazeneca.com/investor-relations/events.html 2026-07-31T16:12:02.396Z https://www.astrazeneca.com/investor-relations/astrazeneca-adr-programme.html 2025-11-02T22:50:40.071Z https://www.astrazeneca.com/investor-relations/jp-morgan-42nd-annual-healthcare-conference.html 2024-01-10T16:57:21.754Z https://www.astrazeneca.com/investor-relations/sustainability-2023-highlights-summary-call.html 2024-03-27T08:26:26.181Z https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-asco-2024.html 2024-06-04T12:26:58.047Z https://www.astrazeneca.com/investor-relations/contacts-information.html 2026-06-19T15:14:35.338Z https://www.astrazeneca.com/investor-relations/sustainability-highlights-call-2026.html 2026-07-06T17:44:18.241Z https://www.astrazeneca.com/investor-relations/h1-and-q2-2026-results-event.html 2026-07-27T15:21:31.016Z https://www.astrazeneca.com/investor-relations/meet-the-management-event-at-ers-2026.html 2026-07-31T14:49:38.442Z https://www.astrazeneca.com/partnering.html 2026-02-24T15:38:42.937Z https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research-partner-portal.html 2026-01-22T19:54:22.428Z https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research-partner-portal/training-centre.html 2026-07-31T10:13:18.283Z https://www.astrazeneca.com/partnering/our-partnering-teams.html 2026-04-28T21:09:28.570Z https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html 2026-04-29T16:24:02.935Z https://www.astrazeneca.com/partnering/why-partner-with-astrazeneca.html 2026-03-23T09:29:05Z https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research.html 2026-07-24T15:45:05.509Z https://www.astrazeneca.com/partnering/Externally-sponsored-scientific-research-training-centre.html 2023-08-02T14:39:09.829Z https://www.astrazeneca.com/partnering/external-funding.html 2023-08-01T04:52:05.771Z https://www.astrazeneca.com/partnering/a-catalyst-network.html 2025-12-19T19:30:35.059Z https://www.astrazeneca.com/partnering/az-suppliers.html 2025-09-23T09:18:08.668Z https://www.astrazeneca.com/partnering/az-suppliers/supplier-contact-form.html 2025-01-30T16:22:28.892Z https://www.astrazeneca.com/partnering/supplier-sustainability-hub.html 2026-08-04T12:46:32.712Z https://www.astrazeneca.com/partnering/sustainable-procurement.html 2026-04-29T04:16:37.636Z https://www.astrazeneca.com/terms-and-conditions.html 2026-07-23T09:37:16.493Z https://www.astrazeneca.com/what-science-can-do.html 2026-05-13T15:31:31.961Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/high-proteinuria-chronic-kidney-disease.html 2026-05-14T18:57:03.071Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/understanding-links-between-genetics-and-biology-to-advance-drug-discovery.html 2026-05-14T21:23:01.034Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/new-era-multi-omic-data-analysis-oncology.html 2026-05-14T19:30:05.669Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/endothelin-1.html 2026-05-14T19:51:47.706Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/strategic-treatment-combinations-cancer.html 2026-05-14T19:03:35.678Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/the-unmet-need-in-dyslipidaemia.html 2026-03-30T09:33:53Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/unpacking-raas-pathway-role-aldosterone.html 2026-05-14T20:45:14.172Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/transforming-astrazenecas-rd-productivity.html 2023-05-19T13:09:53.901Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/pioneers-in-asthma-where-is-the-science-leading-us.html 2026-05-14T21:51:49.862Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/Hitting-the-bullseye-finding-better-targets-for-drug-development.html 2023-10-16T12:33:14.905Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/nash-a-new-approach-brings-new-hope.html 2026-05-15T12:31:13.391Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/modelling-chronic-kidney-disease-in-3d.html 2026-05-14T19:56:41.996Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/novel-genetic-targets-for-fatty-liver-disease.html 2023-10-13T09:55:29.647Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/exploring-the-genome-to-find-novel-targets-for-chronic-diseases.html 2026-05-14T21:05:16.162Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/research-idiopathic-pulmonary-fibrosis.html 2026-05-14T22:24:41.384Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/precision-medicine-approach-immunology-targeted-biology.html 2026-05-14T22:28:51.804Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/navigating-genetics-diabetes-resistance.html 2026-05-14T22:27:14.968Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/tumour-microenvironment.html 2026-05-14T22:09:33.320Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/premalignantdisease.html 2026-05-14T18:44:39.933Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/impacts-severe-infection-respiratory-viruses.html 2026-05-14T22:00:35.824Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/bronchiectasis-research.html 2026-05-14T21:55:15.597Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/creating-better-health-outcomes-holistic-approach-weight-management.html 2024-11-07T16:37:24.635Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/rethinking-prevention-of-recurrent-c-diff-infections.html 2025-11-17T09:32:36.013Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/multifaceted-mechanisms-and-approaches-in-weight-management.html 2026-03-30T09:39:35Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/hcc-patient-charter-collective-action-transform-care.html 2026-05-14T20:22:04.655Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/hope-and-innovation-in-bladder-cancer.html 2026-05-26T14:34:23.246Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/ebv-genomics-chronic-disease-variants-study.html 2026-05-14T20:10:50.175Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/linking-genomics-proteomics-health-transform-drug-discovery.html 2026-05-14T16:56:31.469Z https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/advancing-science-in-uncontrolled-hypertension.html 2026-05-08T16:32:16.442Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/targeting-progression-of-liver-damage-in-nash.html 2023-03-10T06:03:12.162Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/transforming-treatment-for-billions-of-people-living-with-chronic-diseases.html 2026-05-14T20:54:12.666Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/MRC-collaboration-cell-oligonucleotide-therapies.html 2026-07-14T09:29:02.522Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/advances-epigenetics-oncology.html 2026-05-14T20:55:30.002Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/novel-gene-editing-efficient-route-gene-therapies.html 2026-05-14T20:48:10.886Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/Accelerating-innovation-to-transform-cancer-care.html 2026-05-14T18:50:32.526Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/exploring-new-frontiers-in-immuno-oncology.html 2026-05-14T22:49:05.785Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/liquid-biopsy-ctdna.html 2026-05-14T21:08:13.566Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/developing-cell-based-therapies-to-put-cancer-cures-within-reach.html 2026-05-14T19:09:40.578Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/precision-medicine-NASH.html 2026-07-14T09:29:02.522Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/developing-the-next-generation-of-drug-delivery-technologies.html 2026-07-14T09:29:02.522Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/cell-lineage-targeted-regeneration-research.html 2026-05-14T22:02:38.109Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/t-cell-receptor-therapies.html 2025-09-19T11:48:20.940Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/immunotherapy-cancer-treatment-bispecific-antibodies-and-immune-cell-engagers.html 2026-05-14T16:42:24.508Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/engineering-novel-cancer-treatments.html 2026-05-14T18:53:53.646Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/regulatory-success-cell-therapy.html 2026-05-14T17:00:55.111Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/multispecific-antibodies-redefining-medicine.html 2026-05-14T21:00:19.862Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/advancing-beyond-the-genome.html 2026-05-14T20:52:34.833Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/transforming-care-for-serious-bacterial-infections.html 2026-05-14T20:41:58.273Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/immunology-cell-therapy.html 2026-05-14T20:20:26.488Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/our-oncology-r-and-d-strategy.html 2026-05-14T20:16:08.534Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/turning-natures-messengers-medicines-innovation-peptide-discovery-development.html 2026-05-14T16:45:59.205Z https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/genetic-targeting-dilated-cardiomyopathy.html 2026-05-14T16:18:04.772Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/innovative-analytics-bridging-the-gap-between-science-and-patient.html 2023-03-10T07:41:23.711Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/Streamlining-clinical-trials-through-digital-solutions.html 2026-05-14T22:30:23.532Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/haematology-research-blood-cancer-care.html 2026-03-30T09:32:35Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/clinical-innovation-digital-health-solutions-transforming-trials.html 2026-05-14T19:43:22.726Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/clinical-innovation-driving-sustainable-clinical-trials.html 2026-08-05T22:16:04.657Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/diagnosis-monitoring-respiratory-diseases.html 2026-05-14T19:24:14.218Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/oncology-partnerships.html 2026-05-14T19:22:00.151Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/rare-disease-research.html 2024-02-22T11:40:19.507Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/new-era-rare-neurological-disease.html 2026-05-14T21:02:11.479Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/advancing-gene-editing-with-epscas9-technology.html 2026-05-14T20:56:49.145Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/leading-cardiovascular-renal-metabolism-innovation.html 2025-03-26T13:39:54.738Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/investing-in-clinical-trials.html 2026-05-14T20:46:24.883Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/data-visualisation-turning-science-into-stories.html 2025-06-25T12:59:12.009Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/holistic-approaches-for-oncology-clinical-development.html 2026-05-14T16:38:01.024Z https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/advance-mrd-testing-in-blood-cancer-treatments.html 2026-07-17T09:00:55.757Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/smart-factories-delivering-more-for-patients-worldwide.html 2026-05-14T22:52:49.940Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/discover-me-south-africa-enabling-diversity-discovery-science.html 2026-05-14T21:43:02.810Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/precision-medicine-history.html 2026-05-14T22:19:56.567Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/matching-drug-disease-omic-signatures-drug-repurposing.html 2026-05-14T22:16:45.488Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/Kidney-disease-research-organoids.html 2026-05-14T22:04:33.213Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/mapping-immunological-landscape-cancer.html 2026-05-14T21:06:22.582Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/developing-global-supply-network-fit-future.html 2026-05-14T21:36:47.397Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/translational-science.html 2023-12-15T16:02:06.454Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/science-and-innovation-for-cancer-chronic-and-rare-disease.html 2025-03-12T22:35:25.179Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/every-breath-counts-local-efforts-impact-global-asthma-care.html 2026-05-04T06:45:23.952Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/aiming-to-revolutionise-gi-cancer-care.html 2026-05-14T20:44:06.052Z https://www.astrazeneca.com/what-science-can-do/topics/technologies/multiple-myeloma-lymphoma-leukemia-treatment-advances.html 2025-09-05T12:48:57.095Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/how-data-and-ai-are-helping-unlock-the-secrets-of-disease.html 2023-03-10T09:30:17.427Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/democratising-data-from-no-to-know.html 2023-03-10T09:30:59.229Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/uniting-human-and-machine-intelligence-for-drug-discovery.html 2023-10-16T12:26:08.767Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/computational-pathology-potential-transform-cancer-diagnostics.html 2026-03-30T09:40:30Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/neural-networks-strengthen-drug-discovery-approaches.html 2024-07-02T23:18:02.120Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/unlocking-potential-data-ai-driven-drug-discovery-development.html 2023-12-05T11:30:32.877Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/connected-medicines-innovations-data-science-ai.html 2024-08-22T12:53:59.575Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/generative-ai-drug-discovery-development.html 2025-05-28T08:17:09.599Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/biologics-discovery.html 2024-11-07T14:03:47.649Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/mapdiff-edge-set-attention-ai-protein-design-breakthroughs.html 2026-03-30T09:28:21Z https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/unlocking-future-drug-discovery-through-AI-advances.html 2026-03-30T09:31:05Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/driving-sustainability-in-healthcare.html 2024-10-17T14:25:04.536Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/sustainable-drug-discovery-using-green-chemistry.html 2024-10-17T14:24:44.797Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/biocatalysis-perform-sustainable-chemical-reactions.html 2024-10-17T14:22:41.565Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/medicine-and-a-lower-carbon-future.html 2025-01-14T12:59:14.557Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/personal-growth-can-transform-societies.html 2025-05-28T08:22:35.179Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/improving-global-health-through-climate-action-and-equity.html 2025-03-12T22:34:30.303Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/building-more-resilient-more-sustainable-health-systems.html 2025-03-12T22:36:51.299Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/collaboration-for-sustainable-healthcare-transformation.html 2025-03-12T22:36:18.806Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/cardiovascular-and-renal-disease-climate-change-and-a-more-resilient-future.html 2025-05-28T08:22:35.180Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/sustainable-genomics-research.html 2026-03-30T09:18:13Z https://www.astrazeneca.com/what-science-can-do/topics/sustainability/creating-culture-sustainability-across-labs.html 2026-04-27T22:29:42.546Z https://www.astrazeneca.com/what-science-can-do/topics/covid-19/viral-variants-and-immunocompromised.html 2024-08-14T11:45:44.538Z https://www.astrazeneca.com/what-science-can-do/topics/covid-19/burden-of-disease.html 2026-04-29T09:54:58.433Z https://www.astrazeneca.com/what-science-can-do/stories-of-impact.html 2025-12-09T20:37:01.498Z https://www.astrazeneca.com/what-science-can-do/stories-of-impact/early-diagnosis-and-treatment-to-transform-care.html 2025-04-10T08:53:21.112Z https://www.astrazeneca.com/what-science-can-do/stories-of-impact/studying-the-worlds-genetic-diversity-to-achieve-better-global-health.html 2025-12-09T18:53:45.426Z https://www.astrazeneca.com/our-company.html 2026-04-15T09:47:46Z https://www.astrazeneca.com/our-company/our-locations/cambridge.html 2026-01-29T15:45:25.800Z https://www.astrazeneca.com/our-company/our-locations/cambridge/Community-in-Cambridge.html 2024-07-24T06:39:39.552Z https://www.astrazeneca.com/our-company/our-locations/gothenburg.html 2026-05-22T08:41:17.291Z https://www.astrazeneca.com/our-company/our-locations/gaithersburg.html 2026-06-04T09:39:33.321Z https://www.astrazeneca.com/our-company/leadership.html 2026-07-24T15:13:27.154Z https://www.astrazeneca.com/our-company/leadership/susan-galbraith.html 2026-03-19T21:46:11Z https://www.astrazeneca.com/our-company/Contact-us.html 2025-10-21T19:47:31.530Z https://www.astrazeneca.com/our-company/history.html 2025-07-21T21:29:40.516Z https://www.astrazeneca.com/country-sites.html 2022-05-30T08:01:29.659Z https://www.astrazeneca.com/country-sites/serbia.html 2025-06-06T08:00:57.053Z https://www.astrazeneca.com/country-sites/vietnam.html 2024-08-22T10:59:44.301Z https://www.astrazeneca.com/country-sites/vietnam/legal-notice-and-terms-of-use.html 2021-05-12T08:18:05.243Z https://www.astrazeneca.com/country-sites/slovenia.html 2026-06-22T14:26:55.733Z https://www.astrazeneca.com/country-sites/uruguay.html 2019-08-29T13:37:58.007Z https://www.astrazeneca.com/country-sites/israel.html 2024-06-06T17:50:12.204Z https://www.astrazeneca.com/country-sites/indonesia.html 2026-03-04T17:02:37Z https://www.astrazeneca.com/country-sites/thailand.html 2026-04-29T09:54:58.432Z https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-nov.html 2021-11-01T12:00:56.438Z https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-nov-th.html 2021-11-05T11:15:09.156Z https://www.astrazeneca.com/country-sites/thailand/press-releases.html 2026-06-12T14:44:46.640Z https://www.astrazeneca.com/country-sites/thailand/press-releases/thai20210428.html 2022-06-01T10:56:03.061Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccines-made-by-siam-bioscience-pass-quality-testing-in-europe-and-us-first-batch-delivery-is-near.html 2022-06-01T10:57:11.650Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-commences-new-covid-19-vaccine-supply-chain-in-thailand.html 2022-06-01T10:58:08.076Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-deliver-six-million-covid-19-vaccine-doses-in-thailand.html 2022-06-01T10:58:45.545Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-53-million-doses-of-covid-19-vaccine-to-thailand-during-july.html 2022-06-01T11:20:16.708Z https://www.astrazeneca.com/country-sites/thailand/press-releases/travelling-with-covid-19-vaccine-astrazeneca-made-in-thailand.html 2021-10-11T12:42:00.249Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-ceo-met-with-prime-minister-prayut-chan-o-cha-about-the-delivery-of-the-vaccine-against-covid-19-to-thailand-th.html 2022-06-01T11:01:53.665Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-5-3-million-doses-of-covid-19-vaccine-to--t.html 2022-06-01T11:04:32.166Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-supply-thailand-with-an-additional-60-million-cov.html 2022-06-01T11:05:09.721Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-manufactured-in-thailand-authorised-for-world-health-organization-emergency-use.html 2022-06-01T11:05:48.912Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-manufactured-in-thailand-authorised-for-world-health-organization-emergency-use-thai.html 2022-06-01T11:38:39.681Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-a-leading-science-led-biopharmaceutical-company.html 2022-06-01T11:00:24.768Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-a-leading-science-led-biopharmaceutical-company-thai.html 2022-06-01T11:01:14.752Z https://www.astrazeneca.com/country-sites/thailand/press-releases/girls-take-over.html 2022-06-01T11:40:01.826Z https://www.astrazeneca.com/country-sites/thailand/press-releases/girls-take-over-thai.html 2022-06-01T11:41:23.118Z https://www.astrazeneca.com/country-sites/thailand/press-releases/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html 2021-11-18T11:55:32.746Z https://www.astrazeneca.com/country-sites/thailand/press-releases/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention1.html 2022-06-01T11:42:37.556Z https://www.astrazeneca.com/country-sites/thailand/press-releases/thailand-becoming-better-protected-from-non-communicable-diseases-as-over-14-million-young-people.html 2022-06-01T11:45:28.575Z https://www.astrazeneca.com/country-sites/thailand/press-releases/thailand-becoming-better-protected-from-non-communicable-diseases-as-over-14-million-young-people1.html 2022-06-01T11:46:32.847Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-formerly-azd7442-long-acting-antibody-combination-authorised-for-emergency.html 2022-06-01T11:47:41.294Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-formerly-azd7442-long-acting-antibody-combination-authorised-for-emergency-thailand.html 2022-06-01T11:49:02.575Z https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-significantly-boosted-antibody-levels-against-omicron.html 2021-12-23T13:01:49.991Z https://www.astrazeneca.com/country-sites/thailand/press-releases/th-vaxzevria-significantly-boosted-antibody-levels-against-omicron.html 2021-12-23T13:01:19.004Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-completes-delivery-of-61-million-covid-19-vaccine-doses-to-thailand.html 2021-12-30T08:50:47.207Z https://www.astrazeneca.com/country-sites/thailand/press-releases/th-astrazeneca-completes-delivery-of-61-million-covid-19-vaccine-doses-to-thailand.html 2021-12-30T08:50:24.583Z https://www.astrazeneca.com/country-sites/thailand/press-releases/new-vaxzevria-data-further-support-its-use-as-third-dose-booster-english.html 2022-01-14T13:06:56.974Z https://www.astrazeneca.com/country-sites/thailand/press-releases/new-vaxzevria-data-further-support-its-use-as-third-dose-booster-thai.html 2022-01-14T13:06:37.624Z https://www.astrazeneca.com/country-sites/thailand/press-releases/the-thoracic-society-of-thailand-under-royal-patronage--in-partn.html 2022-01-26T05:46:28.101Z https://www.astrazeneca.com/country-sites/thailand/press-releases/the-thoracic-society-of-thailand-under-royal-patronage--in-partn-thai.html 2022-01-26T05:46:53.663Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-certified-as-top-employer-2022-in-thailand.html 2022-01-28T09:04:46.386Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-certified-as-top-employer-2022-in-thailand-thai.html 2022-01-28T09:05:34.881Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-antibody-combination-evusheld-tixagevimab-co-packaged-with-cilgavimab-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html 2022-08-26T08:36:32.926Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-certified-as-top-employer-2022-in-thailand-thai1.html 2022-08-26T08:33:07.135Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-eng.html 2022-08-26T08:34:47.323Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-thai.html 2022-08-26T08:31:01.179Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-evusheld-long-acting-antibody-combination-approved-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19-in-a-broad-population.html 2022-08-26T08:29:56.736Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-evusheld-long-acting-antibody-combination-approved-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19-in-a-broad-population1.html 2022-08-26T08:28:13.741Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations.html 2022-04-22T09:42:19.062Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-shelf-life-extended-in-thailand.html 2022-04-08T06:04:03.943Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-and-mrna-vaccines-provide-equivalent-protection-against-covid-19-hospitalisation-and-deaths.html 2022-04-28T07:15:49.247Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-and-mrna-vaccines-provide-equivalent-protection-against-covid-19-hospitalisation-and-deaths1.html 2022-04-28T07:20:47.380Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1.html 2022-04-22T09:48:37.732Z https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-approved-in-the-eu-as-third-dose-booster-against-covid-19.html 2022-05-23T11:54:16.985Z https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-approved-in-the-eu-as-third-dose-booster-against-covid-191.html 2022-05-24T05:48:24.067Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-covid-19-vaccine-shelf-life-extended-in-thailand1.html 2022-04-08T06:07:24.131Z https://www.astrazeneca.com/country-sites/thailand/press-releases/banphaeo-general-hospital-collaborates-with-depa-astrazeneca-thailand-in-launching-dont-wait-get-checked-campaign-embraces-ai-to-detect-lung-cancer-in-early-stage1.html 2022-04-20T11:51:40.031Z https://www.astrazeneca.com/country-sites/thailand/press-releases/banphaeo-general-hospital-collaborates-with-depa-astrazeneca-thailand-in-launching-dont-wait-get-checked-campaign-embraces-ai-to-detect-lung-cancer-in-early-stage.html 2022-04-20T11:45:27.445Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-prevented-COVID-19.html 2022-08-26T07:58:29.755Z https://www.astrazeneca.com/country-sites/thailand/press-releases/evusheld-significantly-prevented-COVID-19-TH.html 2022-08-26T07:58:59.910Z https://www.astrazeneca.com/country-sites/thailand/press-releases/YHP-World-No-Tobacco-Day-2022_Press-release-EN_Final_website.html 2023-02-22T06:23:37.881Z https://www.astrazeneca.com/country-sites/thailand/press-releases/YHP-World-No-Tobacco-Day-2022_Press-release-TH_Final_website.html 2022-06-21T08:43:28.700Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-supply-thailand-with-257500-doses-of-its-covid-19-long-acting-antibody-combination-azd7442.html 2022-07-08T08:00:45.795Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-to-supply-thailand-with-257500-doses-of-its-covid-19-long-acting-antibody-combination-azd7442-TH.html 2022-07-11T09:19:43.515Z https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-provides-equally-effective-protection-against-hospitalisation-and-deaths-compared-with-mrna-vaccines.html 2022-07-18T11:20:56.003Z https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-provides-equally-effective-protection-against-hospitalisation-and-deaths-compared-with-mrna-vaccines-th.html 2022-07-18T11:21:06.641Z https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-73-effective-at-preventing-omicron-related-infections-after-fourth-dose-according-to-real-world-evidence-study-in-thailand.html 2022-07-22T09:33:29.672Z https://www.astrazeneca.com/country-sites/thailand/press-releases/vaxzevria-73-effective-at-preventing-omicron-related-infections-after-fourth-dose-according-to-real-world-evidence-study-in-thailand-th.html 2022-07-25T05:59:44.590Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-long-acting-antibody-laab-combination-administered-to-first-group-of-patients-in-thailand-to-protect-against-covid-19-th.html 2022-08-26T10:43:11.616Z https://www.astrazeneca.com/country-sites/thailand/press-releases/azd7442-long-acting-antibody-combination-approved-for-prevention-and-treatment-of-covid-19-in-japan-EN.html 2022-09-05T08:56:24.053Z https://www.astrazeneca.com/country-sites/thailand/press-releases/azd7442-long-acting-antibody-combination-approved-for-prevention-and-treatment-of-covid-19-in-japan-TH.html 2022-09-05T08:56:45.976Z https://www.astrazeneca.com/country-sites/thailand/press-releases/boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron-equivalent-to-mrna-covid-19-vaccines.html 2022-09-13T09:26:34.590Z https://www.astrazeneca.com/country-sites/thailand/press-releases/boosting-with-astrazenecas-vaccine-provides-high-protection-against-omicron-equivalent-to-mrna-covid-19-vaccines-th.html 2022-10-31T11:46:53.250Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-azd7442-long-acting-antibody-combination-approved-in-the-eu-for-the-treatment-of-covid-19.html 2022-09-27T12:07:58.420Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-announces-azd7442-long-acting-antibody-combination-approved-in-the-eu-for-the-treatment-of-covid-19-th.html 2022-10-31T11:54:46.197Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-additional-41575-units-of-COVID-19-long-acting-antibody-LAAB-to-thailand.html 2022-10-06T06:27:59.560Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-delivers-additional-41575-units-of-COVID-19-long-acting-antibody-LAAB-to-thailand-TH.html 2022-10-31T11:49:58.815Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-plan-international-celebrate-international-day-of-the-girl-supporting-gender-equality-and-girls-rights-advocacy-through-the-girls-belong-here-campaign.html 2022-10-18T05:36:32.127Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-plan-international-celebrate-international-day-of-the-girl-supporting-gender-equality-and-girls-rights-advocacy-through-the-girls-belong-here-campaign-TH.html 2022-10-31T11:58:39.114Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-launches-its-making-health-happen-campaign-in-thailand-to-build-a-healthy-future-for-people-society-and-the-planet.html 2023-04-20T05:09:02.348Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-launches-its-making-health-happen-campaign-in-thailand-to-build-a-healthy-future-for-people-society-and-the-planet-TH.html 2022-10-31T11:35:29.093Z https://www.astrazeneca.com/country-sites/thailand/press-releases/department-of-medicine-national-cancer-institute-in-collaboration-with-astrazeneca-create-video-clips-to-educate-and-enhance-understanding-about-cancer-under-the-new-normal-same-cancer-campaign.html 2022-11-01T07:16:06.151Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-long-acting-antibody-laab-combination-granted-conditional-marketing-approval-for-the-treatment-of-covid-19-in-thailand.html 2022-11-10T05:33:50.196Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazenecas-long-acting-antibody-laab-combination-granted-conditional-marketing-approval-for-the-treatment-of-covid-19-in-thailand-th.html 2022-11-10T05:34:34.100Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-two-aces-2022-awards.html 2022-11-25T12:21:04.695Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-two-aces-2022-awards-th.html 2022-11-25T12:20:27.664Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-sends-campaign-prepare-immunity-for-every-special.html 2022-12-21T06:00:39.471Z https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-astrazeneca-highly-effective-at-preventing-covid-19-severe-outcomes-and-death-according-to-new-real-world-evidence-study-in-thailand.html 2022-12-15T12:18:36.454Z https://www.astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-astrazeneca-highly-effective-at-preventing-covid-19-severe-outcomes-and-death-according-to-new-real-world-evidence-study-in-thailand-TH.html 2022-12-15T12:26:24.168Z https://www.astrazeneca.com/country-sites/thailand/press-releases/healthy-lung-in-health-region-11-th.html 2022-12-28T09:35:13.135Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-award-2023-for-the-third-year-in-a-row-reaffirming-its-position-as-a-great-place-to-work.html 2023-01-23T05:52:27.168Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-award-2023-for-the-third-year-in-a-row-reaffirming-its-position-as-a-great-place-to-work-th.html 2023-02-10T00:06:01.758Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-launch-campaign-parker-panda-and-dr-bunny-th.html 2023-02-10T05:44:06.015Z https://www.astrazeneca.com/country-sites/thailand/press-releases/the-effects-of-chronic-pm25-crisis-result-in-gene-mutations-causing-lung-cancer-near-body-menace-that-should-not-be-overlooked-th.html 2023-03-01T04:28:22.921Z https://www.astrazeneca.com/country-sites/thailand/press-releases/international-womens-day-article-2023-th.html 2023-03-09T05:10:28.210Z https://www.astrazeneca.com/country-sites/thailand/press-releases/LAAB-enhancing-immunity-for-the-elderly-th.html 2023-03-15T05:36:25.829Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-announces-partnership-with-phyathai-2-hospital-introduces-ai-to-enhance-the-diagnosis-of-early-stage-lung-cancer.html 2023-03-22T20:23:45.877Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-announces-partnership-with-phyathai-2-hospital-introduces-ai-to-enhance-the-diagnosis-of-early-stage-lung-cancer-th.html 2023-03-22T20:23:30.478Z https://www.astrazeneca.com/country-sites/thailand/press-releases/asthma-close-matter-that-should-not-be-overlooked.html 2023-04-28T16:15:29.073Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-suggest-factors-that-women-should-not-overlook-on-international-ovarian-cancer-day.html 2023-05-08T05:39:13.843Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-appoints-roman-ramos-as-country-president.html 2023-05-23T03:49:25.927Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-appoints-roman-ramos-as-country-president-th.html 2023-05-23T03:49:17.221Z https://www.astrazeneca.com/country-sites/thailand/press-releases/az-x-phyathai2the-art-of-x-ray-TH.html 2023-06-02T05:09:04.209Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-trains-young-peer-educators-for-the-fourth-consecutive-year-as-support-for-the-young-health-programme-in-thailand.html 2023-06-20T04:54:35.997Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-trains-young-peer-educators-for-the-fourth-consecutive-year-as-support-for-the-young-health-programme-in-thailand-TH.html 2023-06-20T10:13:28.353Z https://www.astrazeneca.com/country-sites/thailand/press-releases/common-seasonal-diseases-in-children-TH.html 2023-06-21T12:00:50.542Z https://www.astrazeneca.com/country-sites/thailand/press-releases/leading-organizations-in-thailand-join-the-discussion-inclusion-and-inclusion-in-the-workplace-on-the-occasion-of-lgbt-pride-mont-th.html 2023-06-30T05:22:39.148Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-revealing-the-results-of-a-survey-of-at-risk-populations-in-thailand-more-than-60-still-affected-in-life-from-covid-19.html 2023-07-04T11:35:57.852Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-commitment-dealing-health-crises-non-communicable-diseases-ncds-killer-people-worldwide.html 2023-07-28T19:21:00.190Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-collaboration-songkhla-nakarin-hospital-developed-innovative-asthma-smart-kiosk-project-enhance-efficiency-asthma-care.html 2023-09-01T04:18:23.603Z https://www.astrazeneca.com/country-sites/thailand/press-releases/why-does-rsv-have-to-be-vigilant-respiratory-infections-caused-by-viruses-childrens-villains-that-parents-must-be-prepared-to-deal-with.html 2023-09-06T05:23:24.919Z https://www.astrazeneca.com/country-sites/thailand/press-releases/asthma-smart-kiosk-healthy-lung-smart-care-healthy-lung-smart-care.html 2023-09-25T05:41:34.733Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-plan-international-thailand-organized-the-event-2023-young-health-program-ncd-seminar-promote-thai-youth-to-stay-away-from-chronic-non-communicable-diseases.html 2023-09-29T06:54:30.335Z https://www.astrazeneca.com/country-sites/thailand/press-releases/matters-of-the-heart-not-far-away-astrazeneca-together-with-samitivej-hospital-organized-the-event-healthy-heart-can-start-it-now-on-world-heart-day-2023.html 2023-10-03T08:35:00.596Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-cooperates-with-bangkok-metropolitan-administration-on-the-dont-wait-get-checked-enhances-the-diagnosis-of-early-stage-lung-cancer-through-ai-innovations.html 2023-10-09T06:58:36.384Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-cooperates-with-bangkok-metropolitan-administration-on-the-dont-wait-get-checked-enhances-the-diagnosis-of-early-stage-lung-cancer-through-ai-innovations-TH.html 2023-10-10T05:12:05.937Z https://www.astrazeneca.com/country-sites/thailand/press-releases/depa-partners-with-astrazeneca-thailand-to-boost-digital-healthcare-innovation-for-thai-public-health-system-and-improved-quality-of-life.html 2023-10-19T05:10:56.395Z https://www.astrazeneca.com/country-sites/thailand/press-releases/depa-partners-with-astrazeneca-thailand-to-boost-digital-healthcare-innovation-for-thai-public-health-system-and-improved-quality-of-life-TH.html 2023-10-19T05:35:48.732Z https://www.astrazeneca.com/country-sites/thailand/press-releases/rethink-pink-we-care-event-TH.html 2023-10-19T04:38:02.152Z https://www.astrazeneca.com/country-sites/thailand/press-releases/extra-protection-for-ics-and-high-risk-TH.html 2023-10-27T04:25:33.254Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-collaborates-with-plan-international-and-4-other-world-class-organisations-in-continuing-girls-take-over-activity-to-mark-the-international-day-of-the-girl-child.html 2023-11-07T08:18:12.169Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-collaborates-with-plan-international-and-4-other-world-class-organisations-in-continuing-girls-take-over-activity-to-mark-the-international-day-of-the-girl-child-TH.html 2023-11-07T08:19:38.481Z https://www.astrazeneca.com/country-sites/thailand/press-releases/az-laa-policy-maker-interview.html 2023-11-29T12:08:55.356Z https://www.astrazeneca.com/country-sites/thailand/press-releases/az-siriraj-genomics-mou.html 2023-12-22T20:55:30.748Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-thailand-collaboration-bangkok-cancer-hospital-wattanosoth-launches-pilot-collaboration-alleviate-gap-reduce-cancer-mortality-rate.html 2024-11-04T22:01:35.577Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-thailand-collaboration-bangkok-cancer-hospital-wattanosoth-launches-pilot-collaboration-alleviate-gap-reduce-cancer-mortality-rate-EN.html 2024-11-04T21:56:53.565Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-2024-fourth-consecutive-year-demonstrating-achievement-organisational-leadership-personnel-excellence.html 2024-11-04T21:56:12.578Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-wins-top-employer-2024-fourth-consecutive-year-demonstrating-achievement-organisational-leadership-personnel-excellence-TH.html 2024-11-04T22:01:01.858Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-joins-hands-with-buddhachinaraj-phitsanulok-hospital-advance-proactive-healthcaintroducing-asthma-smart-kiosk-innovation-pioneer-enhanced-lung-disease-management.html 2024-11-04T22:03:35.266Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astraZeneca-joins-hands-with-buddhachinaraj-phitsanulok-hospital-advance-proactive-healthcaintroducing-asthma-smart-kiosk-innovation-pioneer-enhanced-lung-disease-management-TH.html 2024-11-04T22:04:12.654Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-joins-forces-with-bnh-hospital-to-enhance-respiratory-health-among-the-thai-population-pioneering-innovations-in-precise-severe-asthma-care-and-immunisation-against-respiratory-syncytial-virus-rsv.html 2024-11-04T21:55:45.787Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-joins-forces-with-bnh-hospital-to-enhance-respiratory-health-among-the-thai-population-pioneering-innovations-in-precise-severe-asthma-care-and-immunisation-against-respiratory-syncytial-virus-rsv-TH.html 2024-11-04T22:00:22.445Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-strengthened-its-commitment-with-the-thai-government-to-collaborate-on-tackling-ncds-in-thailand.html 2024-11-04T21:55:11.810Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-strengthened-its-commitment-with-the-thai-government-to-collaborate-on-tackling-ncds-in-thailand-TH.html 2024-11-04T21:59:48.524Z https://www.astrazeneca.com/country-sites/thailand/press-releases/mdkku-astrazeneca-and-depa-thailand-join-forces-to-utilise-ai-for-early-detection-of-heart-failure-and-lung-cancer.html 2024-11-04T21:54:19.867Z https://www.astrazeneca.com/country-sites/thailand/press-releases/mdkku-astrazeneca-and-depa-thailand-join-forces-to-utilise-ai-for-early-detection-of-heart-failure-and-lung-cancer-TH.html 2024-11-04T21:59:09.171Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-empowers-young-female-leaders-at-annual-girlstakeover-event.html 2024-10-30T15:16:16.321Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-empowers-young-female-leaders-at-annual-girlstakeover-event-TH.html 2024-10-30T15:21:07.137Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-launches-ncd-certification-programme-to-enhance-chronic-disease-care.html 2024-10-30T19:58:12.086Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-launches-ncd-certification-programme-to-enhance-chronic-disease-care-TH.html 2024-10-30T19:58:26.712Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-siriraj-genomics-join-forces-for-the-third-annual-rethink-pink-we-care-event-empowering-thai-women-against-breast-cancer.html 2024-10-30T19:55:55.353Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-and-siriraj-genomics-join-forces-for-the-third-annual-rethink-pink-we-care-event-empowering-thai-women-against-breast-cancer-TH.html 2024-10-30T20:02:16.082Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-awarded-most-innovative-company-by-british-chamber-of-commerce-thailand-TH.html 2024-12-02T09:30:27.039Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-awarded-most-innovative-company-by-british-chamber-of-commerce-thailand.html 2024-12-02T09:25:30.557Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-honored-with-thai-swedish-chambers-company-of-the-year-advancing-healthcare-for-thai-people-through-transformative-contributions-and-medical-innovations.html 2024-12-02T10:05:12.253Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-honored-with-thai-swedish-chambers-company-of-the-year-advancing-healthcare-for-thai-people-through-transformative-contributions-and-medical-innovations-TH.html 2024-12-02T10:07:34.696Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-expands-pioneering-ai-screening-project-enhance-early-disease-detection.html 2024-12-27T07:07:34.135Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-expands-pioneering-ai-screening-project-enhance-early-disease-detection-th.html 2025-02-24T09:40:44.376Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-prapokklao-hospital-chanthaburi-sign-mou-elevate-centre-excellence-cancer.html 2024-12-27T07:16:25.321Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-prapokklao-hospital-chanthaburi-sign-mou-elevate-centre-excellence-cancer-th.html 2024-12-27T07:23:13.276Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-signs-memorandum-understanding.html 2024-12-27T11:35:05.648Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-signs-memorandum-understanding-th.html 2024-12-27T11:39:07.482Z https://www.astrazeneca.com/country-sites/thailand/press-releases/the-born-a-fighter-campaign-supports-and-educates-neurofibromatosis-nf-warriors-celebrating-the-7th-event-on-nf1-awareness-day-in-thailand.html 2025-02-06T17:42:41.834Z https://www.astrazeneca.com/country-sites/thailand/press-releases/the-born-a-fighter-campaign-supports-and-educates-neurofibromatosis-nf-warriors-celebrating-the-7th-event-on-nf1-awareness-day-in-thailand-th.html 2025-02-06T17:47:41.744Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-recognised-top-employer-celebrating-five-consecutive-years-excellence.html 2025-02-24T12:10:53.356Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-recognised-top-employer-celebrating-five-consecutive-years-excellence-TH.html 2025-02-24T12:16:31.387Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-reveals-success-in-using-ai-to-screen-lung-cancer-from-x-ray-images-enhancing-sustainable-health-security.html 2025-04-23T10:03:42.333Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-reveals-success-in-using-ai-to-screen-lung-cancer-from-x-ray-images-enhancing-sustainable-health-security-TH.html 2025-04-23T10:01:58.979Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-faculty-pharmaceutical-sciences-chulalongkorn-university-signed-mou-announce-collaboration-enhancing-potential-pharmaceutical-personnel-TH.html 2025-06-18T22:03:58.682Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-faculty-pharmaceutical-sciences-chulalongkorn-university-signed-mou-announce-collaboration-enhancing-potential-pharmaceutical-personnel.html 2025-06-18T22:04:49.174Z https://www.astrazeneca.com/country-sites/thailand/press-releases/hat-joins-forces-ministry-public-health-astrazeneca-thailand-unveiling-collaborative-excellence-heart-failure-management-initiative-th.html 2025-06-18T22:27:21.586Z https://www.astrazeneca.com/country-sites/thailand/press-releases/hat-joins-forces-ministry-public-health-astrazeneca-thailand-unveiling-collaborative-excellence-heart-failure-management-initiative.html 2025-06-18T22:30:05.234Z https://www.astrazeneca.com/country-sites/thailand/press-releases/lampang-cancer-hospital-and-astrazeneca-sign-mou-to-advance-cancer-treatment-and-improve-survival-outcomes-th.html 2025-08-04T18:41:55.602Z https://www.astrazeneca.com/country-sites/thailand/press-releases/lampang-cancer-hospital-and-astrazeneca-sign-mou-to-advance-cancer-treatment-and-improve-survival-outcomes.html 2025-08-04T18:49:07.278Z https://www.astrazeneca.com/country-sites/thailand/press-releases/department-of-disease-control-the-kidney-foundation-astrazeneca-partners-launch-first-national-collaborative-excellence-for-chronic-kidney-disease-screening-th.html 2025-09-03T20:46:21.939Z https://www.astrazeneca.com/country-sites/thailand/press-releases/department-of-disease-control-the-kidney-foundation-astrazeneca-partners-launch-first-national-collaborative-excellence-for-chronic-kidney-disease-screening.html 2025-09-03T21:09:14.885Z https://www.astrazeneca.com/country-sites/thailand/press-releases/ieat-and-astrazeneca-proactively-conduct-lung-screenings-visiting-gc-and-scg-plants-for-ai-assisted-x-rays-to-drive-early-detection.html 2026-04-16T05:43:55Z https://www.astrazeneca.com/country-sites/thailand/press-releases/ieat-and-astrazeneca-proactively-conduct-lung-screenings-visiting-gc-and-scg-plants-for-ai-assisted-x-rays-to-drive-early-detection-th.html 2026-04-16T05:47:44Z https://www.astrazeneca.com/country-sites/thailand/press-releases/project-idea-2026-faq.html 2026-07-02T09:16:58.684Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-appoints-john-serry-as-country-president.html 2026-07-13T05:01:08.384Z https://www.astrazeneca.com/country-sites/thailand/press-releases/astrazeneca-thailand-appoints-john-serry-as-country-president-TH.html 2026-07-13T05:24:59.873Z https://www.astrazeneca.com/country-sites/thailand/press-releases/ministry-of-public-health-unites-all-sectors-to-advance-lung-health-in-thailand-en.html 2026-07-27T10:53:00.523Z https://www.astrazeneca.com/country-sites/thailand/press-releases/ministry-of-public-health-unites-all-sectors-to-advance-lung-health-in-thailand-TH.html 2026-07-27T10:51:51.750Z https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-en.html 2021-10-06T10:35:40.847Z https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-th.html 2021-11-01T11:05:07.036Z https://www.astrazeneca.com/country-sites/georgia.html 2025-03-17T12:18:34.341Z https://www.astrazeneca.com/country-sites/croatia.html 2026-07-22T12:20:22.786Z https://www.astrazeneca.com/country-sites/austria.html 2022-05-30T08:01:29.659Z https://www.astrazeneca.com/country-sites/egypt.html 2026-06-11T06:49:18.917Z https://www.astrazeneca.com/country-sites/egypt/az-egypt-statement-30052018.html 2018-05-30T15:34:31.530Z https://www.astrazeneca.com/country-sites/greece.html 2026-07-23T09:22:41.074Z https://www.astrazeneca.com/country-sites/gulf.html 2023-11-07T05:04:18.564Z https://www.astrazeneca.com/country-sites/ireland.html 2026-06-05T14:09:46.547Z https://www.astrazeneca.com/country-sites/taiwan.html 2026-05-12T10:15:52.548Z https://www.astrazeneca.com/country-sites/taiwan/23032020.html 2020-03-25T08:34:01.728Z https://www.astrazeneca.com/country-sites/the-philippines.html 2026-01-20T06:00:51.912Z https://www.astrazeneca.com/country-sites/saudi-arabia.html 2025-03-20T09:47:56.209Z https://www.astrazeneca.com/country-sites/singapore.html 2026-06-17T05:15:22.343Z https://www.astrazeneca.com/country-sites/singapore/press-releases.html 2024-03-13T04:01:48.424Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-and-oncoshot-establish-strategic-partnership-to-bett0.html 2021-09-24T09:28:29.386Z https://www.astrazeneca.com/country-sites/singapore/press-releases/diabetics--guide-to-fasting-during-ramadan-launched-by-diabetes-.html 2021-09-24T13:05:30.772Z https://www.astrazeneca.com/country-sites/singapore/press-releases/leaders-from-mcdonald-s--astrazeneca--nomura--and-dell-advocate-.html 2021-09-24T10:24:56.327Z https://www.astrazeneca.com/country-sites/singapore/press-releases/sgh-and-astrazeneca-unveil-promising-intervention-to-improve-ast.html 2021-09-24T10:33:56.487Z https://www.astrazeneca.com/country-sites/singapore/press-releases/unlikely-partners-join-hands-as-part-of-sweden--s-pore-initiativ.html 2021-09-24T13:04:21.899Z https://www.astrazeneca.com/country-sites/singapore/press-releases/the-big-read--enough-is-enough--just-what-does-it-take-to-break-.html 2021-09-24T13:12:57.627Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-and-lucence-collaborate-in-south-east-asia.html 2021-11-12T08:00:00.114Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-singapore-signs-mou-with-tech-partners-on-innovation-projects.html 2021-12-03T09:08:28.965Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazenecas-antibody-drug-for-covid-19-treatment-to-arrive-in-spore-by-end-of-the-year.html 2021-12-14T07:34:16.025Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-signs-mou-to-empower-the-breast-cancer-community-in-singapore.html 2022-09-15T04:15:22.398Z https://www.astrazeneca.com/country-sites/singapore/press-releases/singhealth-polyclinics-launches-primary-care-research-institute.html 2023-08-31T15:49:38.783Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-manufacture-adcs-in-singapore.html 2024-05-28T06:05:10.612Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html 2024-11-07T06:41:36.091Z https://www.astrazeneca.com/country-sites/singapore/press-releases/national-university-health-system-sahlgrenska-university-hospital-and-industry-partners-astrazeneca-and-ericsson-establish-global-health-innovation-network.html 2024-11-22T04:58:24.058Z https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazenecas-flumist-trivalent-singapores-first-intranasal-influenza-vaccine-now-available-for-influenza-protection.html 2025-11-19T08:44:26.466Z https://www.astrazeneca.com/country-sites/estonia.html 2026-05-12T06:46:00.770Z https://www.astrazeneca.com/country-sites/latvia.html 2026-05-12T07:02:51.786Z https://www.astrazeneca.com/country-sites/lithuania.html 2025-06-12T19:39:47.089Z https://www.astrazeneca.com/country-sites/near-east-and-maghreb.html 2025-10-16T14:13:16.932Z https://www.astrazeneca.com/country-sites/african-cluster.html 2026-07-13T11:30:23.498Z https://www.astrazeneca.com/legal-notice-and-terms-of-use.html 2025-11-18T04:28:07Z https://www.astrazeneca.com/legal-notice-and-terms-of-use/id.html 2021-09-27T14:25:00.721Z https://www.astrazeneca.com/global.html 2015-08-18T10:07:53.662Z https://www.astrazeneca.com/global/en.html 2015-09-03T11:33:45.833Z https://www.astrazeneca.com/global/en/AstraZeneca-Websites.html 2026-05-06T08:13:58.826Z https://www.astrazeneca.com/global/en/annualreport.html 2016-03-08T11:55:51.440Z https://www.astrazeneca.com/global/en/Resources.html 2026-04-29T09:54:58.435Z https://www.astrazeneca.com/global/en/sitemap.html 2026-04-29T09:54:58.437Z https://www.astrazeneca.com/search_results.html 2020-06-24T17:53:40.259Z